



US010130701B2

(12) **United States Patent**
Bickerton et al.

(10) **Patent No.:** **US 10,130,701 B2**
(45) **Date of Patent:** **Nov. 20, 2018**

(54) **CORONAVIRUS**

OTHER PUBLICATIONS

(71) **Applicant:** **THE PIRBRIGHT INSTITUTE,**
Pirbright, Woking (GB)

(72) **Inventors:** **Erica Bickerton,** Woking (GB); **Sarah Keep,** Woking (GB); **Paul Britton,** Woking (GB)

(73) **Assignee:** **THE PIRBRIGHT INSTITUTE,**
Woking, Pirbright (GB)

(*) **Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) **Appl. No.:** **15/328,179**

(22) **PCT Filed:** **Jul. 23, 2015**

(86) **PCT No.:** **PCT/GB2015/052124**

§ 371 (c)(1),

(2) **Date:** **Jan. 23, 2017**

(87) **PCT Pub. No.:** **WO2016/012793**

PCT Pub. Date: **Jan. 28, 2016**

(65) **Prior Publication Data**

US 2017/0216427 A1 Aug. 3, 2017

(30) **Foreign Application Priority Data**

Jul. 23, 2014 (GB) 1413020.7

(51) **Int. Cl.**

A61K 39/215 (2006.01)

C12N 7/00 (2006.01)

C12N 9/12 (2006.01)

A61K 39/00 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 39/215** (2013.01); **C12N 7/00**

(2013.01); **C12N 9/127** (2013.01); **C12Y**

207/07048 (2013.01); **A61K 2039/5254**

(2013.01); **A61K 2039/54** (2013.01); **C12N**

2770/20021 (2013.01); **C12N 2770/20022**

(2013.01); **C12N 2770/20034** (2013.01); **C12N**

2770/20051 (2013.01); **C12N 2770/20062**

(2013.01)

(58) **Field of Classification Search**

CPC **A61K 39/215**

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

7,452,542 B2 * 11/2008 Denison C07K 14/005
424/221.1

FOREIGN PATENT DOCUMENTS

WO WO-2004/092360 A2 10/2004

WO WO-2005/049814 A2 6/2005

WO WO-2007/078203 A1 7/2007

WO WO-2011/004146 A1 1/2011

Sperry Journal of Virology, 2005, vol. 79, No. 6, pp. 3391-3400.*
Altschul et al., Basic local alignment search tool. *J. Mol. Biol.* 215:
403-10 (1990).

Ammayappan et al., Identification of sequence changes responsible for the attenuation of avian infectious bronchitis virus strain Arkansas DPI, *Arch. Virol.*, 154(3):495-9 (2009).

Anonymous: "EM_STD:KF377577", Oct. 30, 2013.

Armesto et al., A recombinant avian infectious bronchitis virus expressing a heterologous spike gene belonging to the 4/91 serotype, *PLoS One*, 6(8):e24352 (2011).

Armesto et al., The replicase gene of avian coronavirus infectious bronchitis virus is a determinant of pathogenicity, *PLoS One*, 4(10):e7384 (2009).

Armesto et al., Transient dominant selection for the modification and generation of recombinant infectious bronchitis coronaviruses, *Methods Mol. Biol.*, 454:255-73 (2008).

Ausubel et al., *Short Protocols in Molecular Biology*, 4th edition, Chapter 18 (1999).

Britton et al., Generation of a recombinant avian coronavirus infectious bronchitis virus using transient dominant selection, *J. Virol. Methods*, 123(2):203-11 (2005).

Britton et al., Modification of the avian coronavirus infectious bronchitis virus for vaccine development, *Bioeng. Bugs.*, 3(2):114-9 (2012).

Casais et al., Recombinant avian infectious bronchitis virus expressing a heterologous spike gene demonstrates that the spike protein is a determinant of cell tropism, *J. Virol.*, 77(16):9084-9 (2003).

Casais et al., Reverse genetics system for the avian coronavirus infectious bronchitis virus, *J. Virol.*, 75(24):12359-69 (2001).

Devereux et al., A comprehensive set of sequence analysis programmes for the VAX. *Nucl. Acids Res.* 12: 387-95 (1984).

Cavanagh et al., Manipulation of the infectious bronchitis coronavirus genome for vaccine development and analysis of the accessory proteins, *Vaccine*, 25(30):5558-62 (2007).

International Preliminary Report on Patentability, International Application No. PCT/GB2015/052124, dated Jan. 24, 2017.

International Search Report and Written Opinion, International Application No. PCT/GB2015/052124, dated Oct. 9, 2015.

Larkin et al., Clustal W and Clustal X version 2.0, *Bioinformatics*, 23(21):2947-8 (2007).

Menachery et al., Attenuation and restoration of severe acute respiratory syndrome coronavirus mutant lacking 2'-O-methyltransferase activity, *J. Virol.*, 88(8):4251-64 (2014).

Tatusova et al., BLAST 2 Sequences, a new tool for comparing protein and nucleotide sequences, *FEMS Microbiol. Lett.*, 174(2):247-50 (1999).

(Continued)

Primary Examiner — Bao Q Li

(74) *Attorney, Agent, or Firm* — Marshall, Gerstein & Borun LLP

(57)

ABSTRACT

The present invention provides a live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a mutation in one or more of non-structural protein(s) (nsp-10, nsp-14, nsp-15 or nsp-16. The coronavirus may be used as a vaccine for treating and/or preventing a disease, such as infectious bronchitis, in a subject.

25 Claims, 15 Drawing Sheets

Specification includes a Sequence Listing.

(56)

References Cited

OTHER PUBLICATIONS

Wang et al., Attenuation of porcine reproductive and respiratory syndrome virus strain MN184 using chimeric construction with vaccine sequence, *Virology*, 371(2):418-29 (2008).

Wei et al., Development and characterization of a recombinant infectious bronchitis virus expressing the ectodomain region of S1 gene of H120 strain, *Appl. Microbiol. Biotechnol.*, 98(4):1727-35 (2014).

* cited by examiner

FIGURE 1




FIGURE 2





FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8





FIGURE 9

A



B





Fig. 10



			*	20	*	40	*	60	*	80		
M41	Nsp14	:	GIGLFKICNKEFSGVHPAYAVTTKALAATTKYNDELAALNVVEAGSEITYKHILISLLGFNLSVNVVEGCHNMFITRDEATK									
Mod	Nsp14	:	GIGLFKICNKEFSGVHPAYAVTTKALAATTKYNDELAALNVVEAGSEITYKHILISLLGFNLSVNVVEGCHNMFITRDEATK									
			*	100	*	120	*	140	*	160		
M41	Nsp14	:	NVRGHWVGFQVEATHACGTINIGTNLPFQVGFTGADFFVVIPEGLVDTSIGNNFEFVNSKAPPGEQFNHLBALFKSAKPWRV									
Mod	Nsp14	:	NVRGHWVGFQVEATHACGTINIGTNLPFQVGFTGADFFVVIPEGLVDTSIGNNFEFVNSKAPPGEQFNHLBALFKSAKPWRV									
			*	180	*	200	*	220	*	240		
M41	Nsp14	:	VREPRIVOMLADNLCNVSDCVVFVWCHGLELITTLRYFVKIGKQDQVCSGCSRATTNSHTQAYACNKHICLGDFVYNPLLA									
Mod	Nsp14	:	VREPRIVOMLADNLCNVSDCVVFVWCHGLELITTLRYFVKIGKQDQVCSGCSRATTNSHTQAYACNKHICLGDFVYNPLLA									
			*	260	*	280	*	300	*	320		
M41	Nsp14	:	DIQQWGYSENLOFNHDLHCNVHGHARVASADATMTRCLATINNAFCQDVNMGLTYPHIANEDEVNSSCRYLQRMYLNAQCVL									
Mod	Nsp14	:	DIQQWGYSENLOFNHDLHCNVHGHARVASADATMTRCLATINNAFCQDVNMGLTYPHIANEDEVNSSCRYLQRMYLNAQCVL									
			*	340	*	360	*	380	*	400		
M41	Nsp14	:	ALKVNVVYDIGNPKGIKCYRRGDLNFRFYDKNPVFNVKQFEYDYINQHKIKFADGLCMFWNCNVDLCYPNSITVCRYDITR									
Mod	Nsp14	:	ALKVNVVYDIGNPKGIKCYRRGDLNFRFYDKNPVFNVKQFEYDYINQHKIKFADGLCMFWNCNVDLCYPNSITCRYDITR									
			*	420	*	440	*	460	*	480		
M41	Nsp14	:	LSVFNLPGCNGGSLYVNHAEHTPKFDRTSFRNLKAMPFFFYDSSPCETIQLDGVAQDLVSLATKDCITRCNIGGAVCKK									
Mod	Nsp14	:	LSVFNLPGCNGGSLYVNHAEHTPKFDRTSFRNLKAMPFFFYDSSPCETIQLDGVAQDLVSLATKDCITRCNIGGAVCKK									
			*	500	*	520						
M41	Nsp14	:	HAQMYADEFVTSYNAAVTAGFTFWYTNNEFNPNLWKSFSALQ									
Mod	Nsp14	:	HAQMYADEFVTSYNAAVTAGFTFWYTNNEFNPNLWKSFSALQ									

Fig. 10 (cont.)

Nsp15

	*	20	*	40	*	60	*	80
M41 Nsp15:	SIDNLA YNNYKGGHYDAIAGEMPTIVTGGKVFVIDQGVKAVFTNOTILPTSVAFELYAKTNIRTLPNNRIILKGLGVDT							
Mod Nsp15:	SIDNLA YNNYKGGHYDAIAGEMPTIVTGGKVFVIDQGVKAVFTNOTILPTSVAFELYAKTNIRTLPNNRIILKGLGVDT							

	*	100	*	120	*	140	*	160
M41 Nsp15:	NGFVINDYTNQTFLYRNIVKVCAYTDIEPNGLIVLYDDRYGDIQSFLAADMVAVLVSTQC YKRYSYVEIPSNLLVQNGIPL							
Mod Nsp15:	NGFVINDYTNQTFLYRNIVKVCAYTDIEPNGLIVLYDDRYGDIQSFLAADMVAVLVSTQC YKRYSYVEIPSNLLVQNGIPL							

	*	180	*	200	*	220	*	240
M41 Nsp15:	KDGANLYVYKEVNGAFVTLPTNTQGRSYETTFEPSSIWERDEFLMSESEFEKYGKELGLQHILYGEVDKPOLGGLHTV							
Mod Nsp15:	KDGANLYVYKEVNGAFVTLPTNTQGRSYETTFEPSSIWERDEFLMSESEFEKYGKELGLQHILYGEVDKPOLGGLHTV							

	*	260	*	280	*	300	*	320
M41 Nsp15:	IGKCRLLRANKLNAKSVINSDDVMQNYFVLADNGSYKQVCTVVDLLLDFFLELLRNILKEYGINKSKVVTVSIDYHSIN							
Mod Nsp15:	IGKCRLLRANKLNAKSVINSDDVMQNYFVLADNGSYKQVCTVVDLLLDFFLELLRNILKEYGINKSKVVTVSIDYHSIN							

	*
M41 Nsp15:	FMWFEEDGLIKTCYPOLO
Mod Nsp15:	FMWFEEDGLIKTCYPOLO

Fig. 10 (cont.)

Nsp16

* 20 * 40 * 60 * 80
 M41 Nsp16: SAWTCGYNMPELYKVNQNCVMEPCNIPNYIGVGIALPESGILNNVAKYITQLCOYLSKTTMCVPHNMRVMHFAGASDKGVAPGS
 Mod Nsp16: SAWTCGYNMPELYKVNQNCVMEPCNIPNYIGVGIALPESGILNNVAKYITQLCOYLSKTTMCVPHNMRVMHFAGASDKGVAPGS
 * 100 * 120 * 140 * 180
 M41 Nsp16: TVLKQGLPEGTHLVNDIVDYVSDAHVSVLSDCNKYKTEHKFDLVISIMYTTUNDSEKRRKHEGVIANNGNDVFTYLSSEFL
 Mod Nsp16: TVLKQGLPEGTHLVNDIVDYVSDAHVSVLSDCNKYKTEHKFDLVISIMYTTUNDSEKRRKHEGVIANNGNDVFTYLSSEFL
 * 180 * 200 * 220 * 240
 M41 Nsp16: NNIALGGSFAVKVTETSSWHEVLYDIAQDCANWTFCTAVNASSEAFI GVNILGASEKVRVSGKTLHANYIFERNCHYI
 Mod Nsp16: NNIALGGSFAVKVTETSSWHEVLYDIAQDCANWTFCTAVNASSEAFI GVNILGASEKVRVSGKTLHANYIFERNCHYI
 * 260 * 280 * 300
 M41 Nsp16: QTSAYSIFDVAKFDLRLLKATPVVNLKTEQKTDLVFNLKCGKILLVRDVGNTSFTSDSFVCTM
 Mod Nsp16: QTSAYSIFDVAKFDLRLLKATPVVNLKTEQKTDLVFNLKCGKILLVRDVGNTSFTSDSFVCTM




Fig. 11A**Fig. 11B**

Fig. 11C

CORONAVIRUS

FIELD OF THE INVENTION

The present invention relates to an attenuated coronavirus comprising a variant replicase gene, which causes the virus to have reduced pathogenicity. The present invention also relates to the use of such a coronavirus in a vaccine to prevent and/or treat a disease.

BACKGROUND TO THE INVENTION

Avian infectious bronchitis virus (IBV), the aetiological agent of infectious bronchitis (IB), is a highly infectious and contagious pathogen of domestic fowl that replicates primarily in the respiratory tract but also in epithelial cells of the gut, kidney and oviduct. IBV is a member of the Order Nidovirales, Family Coronaviridae, Subfamily Coronavirinae and Genus *Gammacoronavirus*; genetically very similar coronaviruses cause disease in turkeys, guinea fowl and pheasants.

Clinical signs of IB include sneezing, tracheal rales, nasal discharge and wheezing. Meat-type birds have reduced weight gain, whilst egg-laying birds lay fewer eggs and produce poor quality eggs. The respiratory infection predisposes chickens to secondary bacterial infections which can be fatal in chicks. The virus can also cause permanent damage to the oviduct, especially in chicks, leading to reduced egg production and quality; and kidney, sometimes leading to kidney disease which can be fatal.

IBV has been reported to be responsible for more economic loss to the poultry industry than any other infectious disease. Although live attenuated vaccines and inactivated vaccines are universally used in the control of IBV, the protection gained by use of vaccination can be lost either due to vaccine breakdown or the introduction of a new IBV serotype that is not related to the vaccine used, posing a risk to the poultry industry.

Further, there is a need in the industry to develop vaccines which are suitable for use in ovo, in order to improve the efficiency and cost-effectiveness of vaccination programmes. A major challenge associated with in ovo vaccination is that the virus must be capable of replicating in the presence of maternally-derived antibodies against the virus, without being pathogenic to the embryo. Current IBV vaccines are derived following multiple passage in embryonated eggs, this results in viruses with reduced pathogenicity for chickens, so that they can be used as live attenuated vaccines. However such viruses almost always show an increased virulence to embryos and therefore cannot be used for in ovo vaccination as they cause reduced hatchability. A 70% reduction in hatchability is seen in some cases.

Attenuation following multiple passage in embryonated eggs also suffers from other disadvantages. It is an empirical method, as attenuation of the viruses is random and will differ every time the virus is passaged, so passage of the same virus through a different series of eggs for attenuation purposes will lead to a different set of mutations leading to attenuation. There are also efficacy problems associated with the process: some mutations will affect the replication of the virus and some of the mutations may make the virus too attenuated. Mutations can also occur in the S gene which may also affect immunogenicity so that the desired immune response is affected and the potential vaccine may not protect against the required serotype. In addition there are problems associated with reversion to virulence and stability of vaccines.

It is important that new and safer vaccines are developed for the control of IBV. Thus there is a need for IBV vaccines which are not associated with these issues, in particular vaccines which may be used for in ovo vaccination.

SUMMARY OF ASPECTS OF THE INVENTION

The present inventors have used a reverse genetics approach in order to rationally attenuate IBV. This approach is much more controllable than random attenuation following multiple passages in embryonated eggs because the position of each mutation is known and its effect on the virus, i.e. the reason for attenuation, can be derived.

Using their reverse genetics approach, the present inventors have identified various mutations which cause the virus to have reduced levels of pathogenicity. The levels of pathogenicity may be reduced such that when the virus is administered to an embryonated egg, it is capable of replicating without being pathogenic to the embryo. Such viruses may be suitable for in ovo vaccination, which is a significant advantage and has improvement over attenuated IBV vaccines produced following multiple passage in embryonated eggs.

Thus in a first aspect, the present invention provides a live, attenuated coronavirus comprising a variant replicase gene encoding polypeptides comprising a mutation in one or more of non-structural protein(s) (nsp)-10, nsp-14, nsp-15 or nsp-16.

The variant replicase gene may encode a protein comprising one or more amino acid mutations selected from the list of:

- Pro to Leu at position 85 of SEQ ID NO: 6;
- Val to Leu at position 393 of SEQ ID NO: 7;
- Leu to Ile at position 183 of SEQ ID NO: 8;
- Val to Ile at position 209 of SEQ ID NO: 9.

The replicase gene may encode a protein comprising the amino acid mutation Pro to Leu at position 85 of SEQ ID NO: 6.

The replicase gene may encode a protein comprising the amino acid mutations Val to Leu at position 393 of SEQ ID NO: 7; Leu to Ile at position 183 of SEQ ID NO: 8; and Val to Ile at position 209 of SEQ ID NO: 9.

The replicase gene may encode a protein comprising the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6; Val to Leu at position 393 of SEQ ID NO: 7; Leu to Ile at position 183 of SEQ ID NO: 8; and Val to Ile at position 209 of SEQ ID NO: 9.

The replicase gene may comprise one or more nucleotide substitutions selected from the list of:

- C to T at nucleotide position 12137;
 - G to C at nucleotide position 18114;
 - T to A at nucleotide position 19047; and
 - G to A at nucleotide position 20139;
- compared to the sequence shown as SEQ ID NO: 1.

The coronavirus may be an infectious bronchitis virus (IBV).

The coronavirus may be IBV M41.

The coronavirus may comprise an S protein at least part of which is from an IBV serotype other than M41.

For example, the S1 subunit or the entire S protein may be from an IBV serotype other than M41.

The coronavirus according to the first aspect of the invention has reduced pathogenicity compared to a coronavirus expressing a corresponding wild-type replicase, such that when the virus is administered to an embryonated egg, it is capable of replicating without being pathogenic to the embryo.

In a second aspect, the present invention provides a variant replicase gene as defined in connection with the first aspect of the invention.

In a third aspect, the present invention provides a protein encoded by a variant coronavirus replicase gene according to the second aspect of the invention.

In a fourth aspect, the present invention provides a plasmid comprising a replicase gene according to the second aspect of the invention.

In a fifth aspect, the present invention provides a method for making the coronavirus according to the first aspect of the invention which comprises the following steps:

- (i) transfecting a plasmid according to the fourth aspect of the invention into a host cell;
- (ii) infecting the host cell with a recombining virus comprising the genome of a coronavirus strain with a replicase gene;
- (iii) allowing homologous recombination to occur between the replicase gene sequences in the plasmid and the corresponding sequences in the recombining virus genome to produce a modified replicase gene; and
- (iv) selecting for recombining virus comprising the modified replicase gene.

The recombining virus may be a vaccinia virus.

The method may also include the step:

- (v) recovering recombinant coronavirus comprising the modified replicase gene from the DNA from the recombining virus from step (iv).

In a sixth aspect, the present invention provides a cell capable of producing a coronavirus according to the first aspect of the invention.

In a seventh aspect, the present invention provides a vaccine comprising a coronavirus according to the first aspect of the invention and a pharmaceutically acceptable carrier.

In an eighth aspect, the present invention provides a method for treating and/or preventing a disease in a subject which comprises the step of administering a vaccine according to the seventh aspect of the invention to the subject.

Further aspects of the invention provide:

the vaccine according to the seventh aspect of the invention for use in treating and/or preventing a disease in a subject.

use of a coronavirus according to the first aspect of the invention in the manufacture of a vaccine for treating and/or preventing a disease in a subject.

The disease may be infectious bronchitis (IB).

The method of administration of the vaccine may be selected from the group consisting of; eye drop administration, intranasal administration, drinking water administration, post-hatch injection and in ovo injection.

Vaccination may be by in ova vaccination.

The present invention also provides a method for producing a vaccine according to the seventh aspect of the invention, which comprises the step of infecting a cell according to the sixth aspect of the invention with a coronavirus according to the first aspect of the invention.

DESCRIPTION OF THE FIGURES

FIG. 1—Growth kinetics of M41-R-6 and M41-R-12 compared to M41-CK (M41 EP4) on CK cells

FIG. 2—Clinical signs, snicking and wheezing, associated with M41-R-6 and M41-R-12 compared to M41-CK (M41 EP4) and Beau-R (Bars show mock, Beau-R, M41-R 6, M41-R 12, M41-CK EP4 from left to right of each timepoint).

FIG. 3—Ciliary activity of the viruses in tracheal rings isolated from tracheas taken from infected chicks. 100% ciliary activity indicates no effect by the virus; apathogenic, 0% activity indicates complete loss of ciliary activity, complete ciliostasis, indicating the virus is pathogenic (Bars show mock, Beau-R, M41-R 6, M41-R 12, M41-CK EP4 from left to right of each timepoint).

FIG. 4—Clinical signs, snicking, associated with M41R-nsp10rep and M41R-nsp14,15,16rep compared to M41-R-12 and M41-CK (M41 EP5) (Bars show mock, M41-R12; M41R-nsp10rep; M41R-nsp14,15,16rep and M41-CK EP5 from left to right of each timepoint).

FIG. 5—Ciliary activity of M41R-nsp10rep and M41R-nsp14,15,16rep compared to M41-R-12 and M41-CK in tracheal rings isolated from tracheas taken from infected chicks (Bars show mock; M41-R12; M41R-nsp10rep; M41R-nsp14,15,16rep and M41-CK EP5 from left to right of each timepoint).

FIG. 6—Clinical signs, snicking, associated with M41R-nsp10, 15rep, M41R-nsp10, 14, 15rep, M41R-nsp10, 14, 16rep, M41R-nsp10, 15, 16rep and M41-K compared to M41-CK (Bars show mock, M41R-nsp10,15rep1; M41R-nsp10,14,16rep4; M41R-nsp10,15,16rep8; M41R-nsp10,14, 15rep10; M41-K6 and M41-CK EP4 from left to right of each timepoint).

FIG. 7—Clinical signs, wheezing, associated with M41R-nsp10, 15rep, M41R-nsp10, 14, 15rep, M41R-nsp10, 14, 16rep, M41R-nsp10, 15, 16rep and M41-K compared to M41-CK (Bars show mock, M41R-nsp10,15rep1; M41R-nsp10,14,16rep4; M41R-nsp10,15,16rep8; M41R-nsp10,14, 15rep10; M41-K6 and M41-CK EP4 from left to right of each timepoint).

FIG. 8—Ciliary activity of M41R-nsp10, 15rep, M41R-nsp10, 14, 15rep, M41R-nsp10, 14, 16rep, M41R-nsp10, 15, 16rep and M41-K compared to M41-CK in tracheal rings isolated from tracheas taken from infected chicks (Bars show mock, M41R-nsp10,15rep1; M41R-nsp10,14,16rep4; M41R-nsp10,15,16rep8; M41R-nsp10,14,15rep10; M41-K6 and M41-CK EP4 from left to right of each timepoint).

FIG. 9—Growth kinetics of rIBVs compared to M41-CK on CK cells. FIG. 9A shows the results for M41-R and M41-K. FIG. 9B shows the results for M41-nsp10 rep; M41R-nsp14, 15, 16 rep; M41R-nsp10, 15 rep; M41R-nsp10, 15, 16 rep; M41R-nsp10, 14, 15 rep; and M41R-nsp10, 14, 16.

FIG. 10—Position of amino acid mutations in mutated nsp10, nsp14, nsp15 and nsp16 sequences.

FIG. 11—A) Snicking; B) Respiratory symptoms (wheezing and rales combined) and C) Ciliary activity of rIBV M41R-nsp 10,14 rep and rIBV M41R-nsp 10,16 rep compared to M41-CK (Bars show mock, M41R-nsp10,14rep; M41R-nsp10,16rep and M41-K from left to right of each timepoint).

DETAILED DESCRIPTION

The present invention provides a coronavirus comprising a variant replicase gene which, when expressed in the coronavirus, causes the virus to have reduced pathogenicity compared to a corresponding coronavirus which comprises the wild-type replicase gene.

Coronavirus

Gammacoronavirus is a genus of animal virus belonging to the family Coronaviridae. Coronaviruses are enveloped viruses with a positive-sense single-stranded RNA genome and a helical symmetry.

The genomic size of coronaviruses ranges from approximately 27 to 32 kilobases, which is the longest size for any known RNA virus.

Coronaviruses primarily infect the upper respiratory or gastrointestinal tract of mammals and birds. Five to six different currently known strains of coronaviruses infect humans. The most publicized human coronavirus, SARS-CoV which causes severe acute respiratory syndrome (SARS), has a unique pathogenesis because it causes both upper and lower respiratory tract infections and can also cause gastroenteritis. Middle East respiratory syndrome coronavirus (MERS-CoV) also causes a lower respiratory tract infection in humans. Coronaviruses are believed to cause a significant percentage of all common colds in human adults.

Coronaviruses also cause a range of diseases in livestock animals and domesticated pets, some of which can be serious and are a threat to the farming industry. Economically significant coronaviruses of livestock animals include infectious bronchitis virus (IBV) which mainly causes respiratory disease in chickens and seriously affects the poultry industry worldwide; porcine coronavirus (transmissible gastroenteritis, TGE) and bovine coronavirus, which both result in diarrhoea in young animals. Feline coronavirus has two forms, feline enteric coronavirus is a pathogen of minor clinical significance, but spontaneous mutation of this virus can result in feline infectious peritonitis (FIP), a disease associated with high mortality.

There are also two types of canine coronavirus (CCoV), one that causes mild gastrointestinal disease and one that has been found to cause respiratory disease. Mouse hepatitis virus (MHV) is a coronavirus that causes an epidemic murine illness with high mortality, especially among colonies of laboratory mice.

Coronaviruses are divided into four groups, as shown below:

Alpha

- Canine coronavirus (CCoV)
- Feline coronavirus (FeCoV)
- Human coronavirus 229E (HCoV-229E)
- Porcine epidemic diarrhoea virus (PEDV)
- Transmissible gastroenteritis virus (TGEV)
- Human Coronavirus NL63 (NL or New Haven)

Beta

- Bovine coronavirus (BCoV)
- Canine respiratory coronavirus (CRCoV)—Common in SE Asia and Micronesia
- Human coronavirus OC43 (HCoV-OC43)
- Mouse hepatitis virus (MHV)
- Porcine haemagglutinating encephalomyelitis virus (HEV)
- Rat coronavirus (Roy). Rat Coronavirus is quite prevalent in Eastern Australia where, as of March/April 2008, it has been found among native and feral rodent colonies.
- (No common name as of yet) (HCoV-HKU1)
- Severe acute respiratory syndrome coronavirus (SARS-CoV)
- Middle East respiratory syndrome coronavirus (MERS-CoV)

Gamma

- Infectious bronchitis virus (IBV)
- Turkey coronavirus (Bluecomb disease virus)
- Pheasant coronavirus
- Guinea fowl coronavirus

Delta

- Bulbul coronavirus (BuCoV)
- Thrush coronavirus (ThCoV)
- Munia coronavirus (MuCoV)
- Porcine coronavirus (PorCoV) HKU15

The variant replicase gene of the coronavirus of the present invention may be derived from an alphacoronavirus such as TGEV; a betacoronavirus such as MHV; or a *gammacoronavirus* such as IBV.

As used herein the term “derived from” means that the replicase gene comprises substantially the same nucleotide sequence as the wild-type replicase gene of the relevant coronavirus. For example, the variant replicase gene of the present invention may have up to 80%, 85%, 90%, 95%, 98% or 99% identity with the wild type replicase sequence. The variant coronavirus replicase gene encodes a protein comprising a mutation in one or more of non-structural protein (nsp)-10, nsp-14, nsp-15 or nsp-16 when compared to the wild-type sequence of the non-structural protein.

IBV

Avian infectious bronchitis (IB) is an acute and highly contagious respiratory disease of chickens which causes significant economic losses. The disease is characterized by respiratory signs including gasping, coughing, sneezing, tracheal rales, and nasal discharge. In young chickens, severe respiratory distress may occur. In layers, respiratory distress, nephritis, decrease in egg production, and loss of internal egg quality and egg shell quality are common.

In broilers, coughing and rattling are common clinical signs, rapidly spreading in all the birds of the premises. Morbidity is 100% in non-vaccinated flocks. Mortality varies depending on age, virus strain, and secondary infections but may be up to 60% in non-vaccinated flocks.

The first IBV serotype to be identified was Massachusetts, but in the United States several serotypes, including Arkansas and Delaware, are currently circulating, in addition to the originally identified Massachusetts type.

The IBV strain Beaudette was derived following at least 150 passages in chick embryos. IBV Beaudette is no longer pathogenic for hatched chickens but rapidly kills embryos.

H120 is a commercial live attenuated IBV Massachusetts serotype vaccine strain, attenuated by approximately 120 passages in embryonated chicken eggs. H52 is another Massachusetts vaccine, and represents an earlier and slightly more pathogenic passage virus (passage 52) during the development of H120. Vaccines based on H120 are commonly used.

IB QX is a virulent field isolate of IBV. It is sometimes known as “Chinese QX” as it was originally isolated following outbreaks of disease in the Qingdao region in China in the mid 1990s. Since that time the virus has crept towards Europe. From 2004, severe egg production issues have been identified with a very similar virus in parts of Western Europe, predominantly in the Netherlands, but also reported from Germany, France, Belgium, Denmark and in the UK.

The virus isolated from the Dutch cases was identified by the Dutch Research Institute at Deventer as a new strain that they called D388. The Chinese connection came from further tests which showed that the virus was 99% similar to the Chinese QX viruses. A live attenuated QX-like IBV vaccine strain has now been developed.

IBV is an enveloped virus that replicates in the cell cytoplasm and contains a non-segmented, single-stranded, positive sense RNA genome. IBV has a 27.6 kb RNA genome and like all coronaviruses contains the four structural proteins; spike glycoprotein (S), small membrane pro-

tein (E), integral membrane protein (M) and nucleocapsid protein (N) which interacts with the genomic RNA.

The genome is organised in the following manner: 5'UTR—polymerase (replicase) gene—structural protein genes (S-E-M-N)—UTR 3'; where the UTR are untranslated regions (each ~500 nucleotides in IBV).

The lipid envelope contains three membrane proteins: S, M and E. The IBV S protein is a type I glycoprotein which oligomerizes in the endoplasmic reticulum and is assembled into homotrimer inserted in the virion membrane via the transmembrane domain and is associated through non-covalent interactions with the M protein. Following incorporation into coronavirus particles, the S protein is responsible for binding to the target cell receptor and fusion of the viral and cellular membranes. The S glycoprotein consists of four domains: a signal sequence that is cleaved during synthesis; the ectodomain, which is present on the outside of the virion particle; the transmembrane region responsible for anchoring the S protein into the lipid bilayer of the virion particle; and the cytoplasmic tail.

All coronaviruses also encode a set of accessory protein genes of unknown function that are not required for replication in vitro, but may play a role in pathogenesis. IBV

encodes two accessory genes, genes 3 and 5, which both express two accessory proteins 3a, 3b and 5a, 5b, respectively.

The variant replicase gene of the coronavirus of the present invention may be derived from an IBV. For example the IBV may be IBV Beaudette, H120, H52, IB QX, D388 or M41.

The IBV may be IBV M41. M41 is a prototypic Massachusetts serotype that was isolated in the USA in 1941. It is an isolate used in many labs throughout the world as a pathogenic lab stain and can be obtained from ATCC (VR-21™). Attenuated variants are also used by several vaccine producers as IBV vaccines against Massachusetts serotypes causing problems in the field. The present inventors chose to use this strain as they had worked for many years on this virus, and because the sequence of the complete virus genome is available. The M41 isolate, M41-CK, used by the present inventors was adapted to grow in primary chick kidney (CK) cells and was therefore deemed amenable for recovery as an infectious virus from a cDNA of the complete genome. It is representative of a pathogenic IBV and therefore can be analysed for mutations that cause either loss or reduction in pathogenicity.

The genome sequence of IBV M41-CK is provided as SEQ ID NO: 1.

IBV M41-CK Sequence

SEQ ID NO: 1

```

ACTTAAGATAGATATTAATATATATCTATCACACTAGCCTTGCGCTAGATTCCAACCTTA
ACAAAACGGACTTAAATACCTACAGCTGGTCTCATAGGTGTTCATTGCAGTGCACTTT
AGTGCCCTGGATGGACCTGGCCACCTGTCAGGTTTTTGTATTAAATCTTATTGTTGC
TGGTATCACTGCTTGTGTTTGCCTGTCTCACTTTATACATCCGTTGCTTGGGCTACCTAG
TATCCAGCGTCTACGGGCGCGTGGCTGGTTCGAGTGCAGAAACCTCTGGTTTCATCTA
GCGGTAGGCGGGTGTGTGAAGTAGCACTTCAGACGTACCGGTTCTGTTGTGTGAAATAC
GGGGTCACCTCCCCCACATACCTCTAAGGGCTTTTGAGCCTAGCGTTGGGCTACGTTCT
CGCATAAGGTGCGGTATACGACGTTTGTAGGGGTAGTGCCAAACAACCCCTGAGGTGAC
AGGTTCTGGTGGTGTGTTAGTGAGCAGACATACAATAGACAGTGACAACATGGCTTCAAGC
CTAAACAGGGAGTATCTCGAACTAAGGGATGTCATTGTTGTATCCAAAGAGATTGCT
GAACAACCTTTGTGACGCTTTGTTTTCTATACGTCACACAACCCCTAAGGATTACGCTGAT
GCTTTTGAGTTAGGCAGAAGTTGATCGTAATCTGCAGACTGGGAAACAGTTCAAATTT
GAACTGTGTGTGCTCTTCTCTTGAAGGGAGTTGACAAAATAACACCTGGCGTCCCA
GCAAAAGTCTTAAAGCCACTTCTAAGTTGGCAGATTAGAAGACATCTTGTGTGTCTCT
CCCTTTGCAAGAAAATATCGTGAACCTTTGAAGACAGCATGCCAGTGGTCTCTTACTGTA
GAAACACTGGATGCTCGTGCAAACTCTTGATGAAATTTTGACCCTACTGAAATACTT
TGGCTTCAGGTGGCAGCAAAATCCAAGTTTCGGCTATGGCGATGCGCAGGCTTGTGGA
GAAGTAAGTCAAAAGTCATGGATGCTTTGGGCTCAAATATGAGTGCTCTTTCCAGATT
TTTAAACAACAAATAGTCAGAATTTTCAAAAGCGCTGGCTATTTTGAATGTGAGT
GAATTACCACAGCGTATTGCAGCACTTAAGATGGCTTTTGCTAAGTGTGCCAAGTCCATT
ACTGTTGTGGTTATGGAGAGACTCTAGTTGTTAGAGAGTTCGAGGAAGTGTCTTGGCA
AGCATTAAATGGTGTGTTGCAAAATCTTTGAAGAACTCCAAATGGTTTCATGGGTGCT
AAAATTTTCACTACACTGCTTCTTTAGGAGGCTGCAGTGAATAATGTGGATAACATA
CCAAATGCACCGAGAGGCACTAAAGGGTTTGAAGTCGTTGGTAATGCCAAAGGTACACAA

```

-continued

GTGTTGTGCGTGGCATGGGAAATGACTTAACACTGGTTGAGCAAAAAGCTGAAATTGCT
GTGGAGTCAGAAGGTTGGTCTGCAATTTGGGTGGACATCTTTGCTATGCTTTAAGAGT
GGTGATCGCTTTTACGCGGCACCTCTTTCAGGAAATTTGCATTGCATGATGTGCATTGT
TGTGAGCGTGTGTCTGCTTTCTGATGGTGTAAACCCGAGATAAATGATGGACTTATT
CTTGACGCAATCTACTCTTCTTTTAGTGTGCGAGAACTTGTGGCAGCCATTAAGGGGT
GAACCATTTAAGTTTCTGGGTATAAATTTGTGTATGCAAGGATGCAGCAGTTTCTTTT
ACATTAGCGAAGGCTGCTACTATTGCAGATGTTTTGAAGCTGTTCAATCAGCGCGTGTG
AAAGTAGAAGATGTTTGGTCTTCACTTACTGAAAAGTCTTTGAATTCTGGAGGCTTGCA
TATGGAAGAGTGCCTAATCTGAAGAATTTGTTAAGACTGTTTTTGAAGGCTCAAATG
GCGATTGTGATTTTAGCGACAGTGTGGAGAGGGCATTGGCATCTTGTTCGCAAGTC
ATCTATAAAGTAGGTGGTCTTTTACTAAAGTTGTTGACTTTTGTGAAAAATATTGAAA
GGTTTTTGTGCACAGTTGAAAAGAGCTAAGCTCATTGTCACTGAAACCCCTCTGTGTTTTG
AAAGGAGTTGCACAGCATTGTTTTCAACTATTGCTGGATGCAATACAGTTTATGTATAAA
AGTTTTAAGAAGTGTGCACTTGGTAGAATCCATGGAGACTTGCTCTTCTGGAAGGAGGT
GTGCACAAAAATTATCAAGAGGGCGATGAAATTTGGTTGAGGGCATTGATAGTATTGAT
GTTGAAGATCTGGGTGTTGTTCAAGAAAAATTGATTGATTTTGATGTTTGTGATAATGTG
ACACTTCCAGAGAACCAACCCGGTCATATGGTTCAAATCGAGGATGACGGAAGAACTAC
ATGTTCTTCCGCTTCAAAAAGGATGAGAACATTTATTATACCAATGTCACAGCTTGGT
GCTATTAAATGTGGTTTGCAAAGCAGGCGGTAAACTGTCACCTTTGGAGAACTACTGTG
CAAGAAATACCACCACCTGATGTTGTGTTTATTAAGGTTAGCATTGAGTGTGTGGTGAA
CCATGGAATACAATCTTCAAAAAGGCTTATAAGGAGCCATTGAAGTAGAGACAGACCTC
ACAGTTGAACAATTGCTCTCTGTGGTCTATGAGAAAATGTGTGATGATCTCAAGCTGTTT
CCGAGGCTCCAGAACCACCACCTTTGAGAATGTCACACTTGTGATAAGAATGGTAAA
GATTTGGATTGCATAAAATCATGCCATCTGATCTATCGTGATTATGAGAGCGATGATGAC
ATCGAGGAAGAAGATGCAGAAGAATGTGACACGGATTGAGGTGATGCTGAGGAGTGTGAC
ACTAATTGAGAATGTGAAGAAGAAGATGAGGATACTAAAGTGTGGCTCTTATACAAGAC
CCGGCAAGTAACAAATATCCTCTGCCTCTTGATGATGATTATAGCGTCTACAATGGATGT
ATTGTTTATAAGGACGCTCTCGATGTTGTGAATTTACCATCTGGTGAAGAAACCTTTGTT
GTCAATAACTGCTTTGAAGGGGCTGTTAAAGCTCTTCCGAGAAAGTTATTGATGTTCTA
GGTGACTGGGGTGAGGCTGTTGATGCGCAAGAACAATTGTGTCAACAAGAATCAACTCGG
GTCATATCTGAGAAATCAGTTGAGGGTTTTACTGGTAGTTGTGATGCAATGGCTGAACAA
GCTATTGTTGAAGAGCAGGAATAGTACCTGTTGTTGAACAAAGTCAGGATGTAGTTGTT
TTTACACCTGCAGACCTAGAAGTTGTTAAAGAAACAGCAGAAGAGGTTGATGAGTTTATT
CTCATTTCTGCTGTCCCTAAAGAAGAAGTTGTGTCTCAGGAGAAAGAGGACCCACAGTT
GAGCAAGAGCCTACCTAGTTGTTAAAGCACAACGTGAGAAGAAGGCTAAAAGTTCAA
GTTAAACCAGCTACATGTGAAAAACCAATTTTGGAGTACAAAACATGTGTGGGTGAT
TTGGCTGTTGTAATTGCCAAAGCATTGGATGAGTTTAAAGAGTTCTGCATTGTAAACGCT
GCAAATGAGCACATGTCGCATGGTGGTGGCGTTGCAAAGGCAATTGCAGACTTTTGTGGA
CCGGACTTTGTTGAATATTGCGCGGACTATGTTAAGAAACATGGTCCACAGCAAAACTT
GTCACACCTTCATTGTTAAAGGCATTCAATGTGTGAATAATGTTGTAGGACCTCGCCAT
GGAGACAGCAACTTGGGTGAGAAGCTTGTGCTGCTTACAAGAGTGTCTTGTAGGTGGA

GTGGTTAACTATGTTGTGCCAGTTCTCTCATCAGGGATTTTGGTGTAGATTTAAAAATA
TCAATAGATGCTATGCGCGAAGCTTTTAAAGGTTGTGCCATACGCGTTCTTTTATTTCT
CTGAGTCAAGAACACATCGATTATTTTCGATGCAACTGTAGCAGAAGACAATTTATCTT
ACGGAGGATGGTGTAAATACCGCTCTGTTGTTTAAACCTGGTGATTCTTTGGGTCAA
TTTGACAGGTTTTTGCAAGAAATAAGGTAGTCTTTTCGGCTGATGATGTTGAGGATAAA
GAAATCCTCTTTATACCCACAACCTGACAAGACTATTCTTGAATATTATGGTTTAGATGCG
CAAAAGTATGTAACATATTGCAAACGCTTGCGCAGARATGGGATGTTCAATATAGAGAC
AATTTTGTATATTAGAGTGGCGTGACGAAATTGCTGGATTAGTTCAGCAATAGTTCTC
CTTCAAGCTGTCAAATTAGATTTAAAGGTTTCTTGCAAGAAGCATGGGCTAACTGTTG
GGTGAGATCCTACAGACTTTGTTGCTGTTGTTATGCAAGTTGCAATGCTAAAGTAGGT
GATTTTTCAGATGCTAATTGGCTTTTGCCCAATTTAGCAGAACATTTTGACGCAGATTAC
ACAAATGCACTTCTTAAGAAGTGTGTGTCGTGCAATTGTGGTGTAAAGTTATGAACTT
AGGGGTCTTGAAGCCTGTATTGAGCCAGTTGAGCACCTAATCTTCTACATTTTAAACG
CAATATTCAAATTGCCCAACCTGTGGTGCAAGTAGTACGGATGAAGTAATAGAAGCTTCA
TTACCGTACTTATTGCTTTTGTCTACTGATGGTCTGCTACAGTTGATTGTGATGAAAT
GCTGTAGGACTGTTGTTTTCATTGGCTCTACTAATAGTGGCCATTGTTATACACAAGCC
GATGGTAAGGCTTTTGACAATCTTGCTAAGGATAGAAAATTTGGAAGGAAGTCGCCTTAC
ATTACAGCAATGTATACACGTTTTTCTCTTAGGAGTGAAAATCCCTACTTGTGTTGAA
CATAGTAAGGTAAGCTAAAGTAGTAAAGAAGATGTTTCTAACCTTGCTACTAGTTCT
AAAGCCAGTTTTGACGATCTTACTGACTTTGAACACTGGTATGATAGCAACATCTATGAG
AGTCTTAAAGTGACAGGAGACCTGATAATCTTGATGAATATGTGTCATTTACGACAAAG
GAAGATTCTAAGTTGCCACTGACACTTAAAGTTAGAGGTATCAAATCAGTTGTTGACTTT
AGGTCTAAGGATGGTTTTACTTATAAGTTAACACCTGATACTGATGAAAATTCAAAAACA
CCAGTCTACTACCCAGTCTTGATTCTATTAGTCTTAGGGCAATATGGGTTGAAGGCAGT
GCTAATTTTGTGTTGGGCATCCAAATTATTATAGTAAGTCTCTCCGAATTCACGTTT
TGGGAAAATGCCGAGAGCTTTGTTAAATGGGTTATAAAATTGATGGTGTAACATATGGGC
CTTTGGCTGCAGAACACCTTAATAAACCTAATTTGAGAGAAATTTTAACATTGCTAAG
AAAGCTATTGTTGGATCTAGTGTGTTACTACGCAGTGTGGTAAAATACTAGTTAAAGCA
GCTACATACGTTGCCGATAAAGTAGGTGATGGTGTAGTTCGCAATATTACAGATAGAATT
AAGGGTCTTTGTGATTACACGTGGCCATTTGAAAAGAAAATGTCCCTACAATTTCTA
AAGACACTGTGTTCTTTTCTTTTATTCTTAAAGGCTAGTGCTAAGAGTTAGTTTCT
AGCTATAAGATTGTGTTATGTAAGGTGGTGTGCTACCTTACTTATAGTGTGGTTTATA
TACACAAGTAATCCAGTAGTGTGTTACTGGAATACGTGTGCTAGACTTCCTATTTGAAGGT
TCTTTATGTGGTCTTATAATGACTACGGTAAAGATTCTTTTGATGTGTACGGTATTGT
GCAGGTGATTTTACTTGTGCTGTGTTTACATGATAGAGATTCACCTCATCTGTACAAA
CATGCTTATAGCGTAGAACAAATTTATAAGGATGCAGCTTCTGGCATTAACTTTAATTGG
AATTGGCTTTATTTGGTCTTTCTAATATTATTGTTAAGCCAGTGGCAGGTTTTGTTATT
ATTTGTTATTGTGTTAAGTATTGTTGATTGAGTTCAACTGTGTTGCAAACTGGTGTAGGT
TTTCTAGATTGGTTGTAAAAACAGTTTTTACCCATTTTAATTTTATGGGAGCGGGATTT
TATTTCTGGCTCTTTTACAAGATATACGTACAAGTGCATCATATATTGTACTGTAAGGAT

- continued

GTAACATGTGAAGTGTGCAAGAGAGTTGCACGCAGCAACAGGCAAGAGGTTAGCGTTGTA
GTTGGTGGACGCAAGCAAATAGTGCATGTTTACACTAATTCTGGCTATAACTTTTGTAAAG
AGACATAATTGGTATTGTAGAAATTGTGATGATTATGGTCACCAAAATACATTTATGTCC
CCTGAAGTTGCTGGCGAGCTTTCTGAAAAGCTTAAGCGCCATGTTAAACCTACAGCATAT
GCTTACCACGTTGTGTATGAGGCATGCGTGGTTGATGATTTTGTTAATTTAAAAATAAAG
GCTGCAATTGCTGGTAAGGATAATGCATCTTCTGCTGTTAAGTGTTCAGTGTACAGAT
TTTTTAAAGAAAGCTGTTTTCTTAAGGAGGCATTGAAATGTGAACAAATATCTAATGAT
GGTTTTATAGTGTGTAATACACAGAGTGCAGCATGCACTAGAGGAAGCAAAGAATGCAGCC
GTCTATTATGCGCAATATCTGTGTAAGCCAATACTTATACTTGACCAGGCACCTTATGAG
CAATTAATAGTAGAGCCTGTGCTAAGAGTGTATAGATAAAGTGTGTAGCATTTTGTCT
AATATAATATCTGTAGATACTGCAGCTTTAAATTATAAGGCAGGCACACTTCGTGATGCT
CTGCTTTCTATTACTAAAGACGAAGAAGCCGTAGATATGGCTATCTTCTGCCACAATCAT
GAAGTGGAATACACTGGTGACGGTTTTACTAATGTGATACCGTCATATGGTATGGACACT
GATAAGTTGACACCTCGTGATAGAGGGTTTTTGATAAATGCAGATGCTTCTATTGCTAAT
TTAAGAGTCAAAAATGCTCCTCCGGTAGTATGGAAGTTTTCTGATCTTATTAATTGTCT
GACAGTTGCCCTAAATATTTAATTTAGCTACTGTCAAGTCAGGAGGTCGTTTCTTTATA
ACAAAGTCTGTGCTAAACAAGTTATTTCTTGTCATACCCAGAACTGTTGGTAGAGAAA
AAGGCAGGTGGTGTATTATAAACACTTTTAAATGGTTTATGAGTGTTTTAAATGGCTT
TTTGCTTTTTATATACTTTTTACAGCATGTTGTTGGGTTACTACTATATGGAGATGAAT
AAAAGTTTTGTTACCCCATGTATGATGTAACTCCACACTGCATGTTGAAGGGTTCAA
GTTATAGACAAAGGTGTTATTAGAGAGATTGTGTGAGAAGATAATTGTTTCTCTAATAAG
TTTGTTAATTTTGACGCCTTTTGGGGTAAATCATATGAAAATAATAAAACTGTCCAATT
GTTACAGTTGTTATAGATGGTGACGGGACAGTAGCTGTTGGTGTTCCTGGTTTTGTATCA
TGGGTTATGGATGGTGTATGTTTGTGCATATGACACAGACTGATCGTAGACCTTGGTAC
ATTCTACCTGGTTTAAATAGAGAAATTGTTGGTTACACTCAGGATTCAATTATCACTGAG
GGTAGTTTTTATACATCTATAGCATTATTTCTGCTAGATGTTTATATTTAACAGCCAGC
AATACACCTCAATTGTATTGTTTTAATGGCGACAATGATGCACCTGGAGCCTTACCATTT
GGTAGTATTATTCCTCATAGAGTATACTTCCAACCTAATGGTGTAGGCTTATAGTTCCA
CAACAAACTGTCATACACCCTACATAGTGAAGTTTGTTCAGACAGCTATTGTAGAGGT
AGTGATGTGAGTATACATAACCAGGTTACTGTGTGTCACTAGACTCCCAATGGGTTTTG
TTAATGATGAATACATTAGTAAACCTGGCGTTTTCTGTGGTTCTACTGTTAGAGAACTT
ATGTTAATATGGTTAGTACATTCTTACTGGTGTCAACCCTAATATTTATATTAGCTA
GCAACTATGTTTTAATACTAGTTGTTATTGTGTTAATTTTGCAATGGTTATAAGTTT
CAAGGTGTTTTTAAAGCTTATGCGACCATTGTGTTTACAATAATGTAGTTTGGGTTATT
AATGCATTGTTTTGTGTGTACATAGTTATAATAGTGTTTAGCTGTTATATTATTAGTA
CTCTATTGCTATGCATCATGGTTACAAGTCGCAATACTGCTATAATAATGCATTGTTGG
CTTGTTTTTACCTTTGGTTTAAATAGTACCCACATGGTTGGCTTGTGCTATCTGGGATTT
ATTCTTTATATGTACACACCGTTGGTTTTCTGGTGTACGGTACTACTAAAAATACTCGT
AAGTTGTATGATGGCAACGAGTTTGTGGTAATTATGACCTTGCTGCGAAGAGCACTTTT
GTTATTCGTGGTACTGAATTTGTTAAGCTTACGAATGAGATAGGTGATAAATTTGAAGCC
TATCTTCTCGGTATGCTAGACTTAAATACTATTAGGCACTGGTAGTGAGCAAGATTAC

TTGCAAGCTTGTGCGTCATGGTTAGCTTATGCTTTGGACCAATATAGAAATAGTGGTGTT
GAGGTTGTTTATACCCACCGCTTACTCTATTGGTGTTAGTAGACTACACGCTGGTTTT
AAAAAAGTAGTTTCTCCTAGTAGTGCTGTTGAGAAGTCATTGTTAGTGCTCTTATAGA
GGCAATAATCTTAATGGACTGTGGCTGGGTGATTCTATTTACTGCCCACGCCATGTGTTA
GGTAAGTTTAGTGGTGACCAGTGGGGTGACGTACTAAACCTTGCTAATAATCATGAGTTT
GAAGTTGTAAGTCAAAATGGTGTTACTTTGAATGTTGTCAGCAGGCGGCTTAAAGGAGCA
GTTTTAATTTTACAAACTGCAGTTGCCAATGCTGAACTCCTAAGTATAAGTTTGTAA
GCTAATTGTGGTGATAGTTTCACTATAGCTTGTTCTTATGGTGGTACAGTTATAGGACTT
TACCTGTCACTATGCGTTCTAATGGTACTATTAGAGCATCTTCTTAGCAGGAGCCTGT
GGCTCAGTTGGTTTTAATATAGAAAAGGGTAGTTAATTTCTTTTATATGCACCATCTT
GAGTTACCTAATGCATTACACACTGGAAGTACCTAATGGGTGAGTTTTATGGTGGTTAT
GTAGATGAAGAGGTGCGCAAAGAGTGCCACCAGATAATCTAGTTACTAACAATATTGTA
GCATGGCTCTATGGGGCAATTATTAGTGTTAAAGAAAGTAGTTTTTACAACTTAAATGG
TTGGAGAGTACTACTGTTTCTATTGAAGATTACAATAGGTGGGCTAGTGATAATGGTTTT
ACTCCATTTTCCACTAGTACTGCTATTACTAAATTAAGTGCTATAACTGGGGTTGATGTT
TGTAAGTCCCTCGCACTATTATGGTAAAAAGTGCTCAATGGGGTAGTGATCCCATTTTA
GGACAATATAATTTGAAGACGAATTGACACCAGAATCTGTATTTAATCAAGTTGGTGGT
GTTAGGTTACAGTCTTCTTTTGAAGAAAGCTACATCTTGGTTTGGAGTAGATGTGTA
TTAGCTTGCTTCTTGTGTTGTGTGCTATTGTCTTATTACGGCAGTGCCACTTAAG
TTTTATGTACATGCAGCTGTTATTTGTTGATGGCTGTGCTCTTATTTCTTTTACTGTT
AAACATGTTATGGCATAACATGGACACTTTCCTATTGCCTACATTGATTACAGTTATTATT
GGAGTTTGCTGTAAGTCCCTTTCATATACAATACTCTAATTAGTCAAGTTGTTATTTTC
TTAAGCCAATGGTATGATCCTGTAGTCTTTGATACTATGGTACCATGGATGTTATTGCCA
TTAGTGTTGTACACTGCTTTTAAAGTGTTACAAGGCTGCTATATGAATCTTTCAACT
TCTTTGTTAATGCTGTATCAGTTTATGAAGTTAGGTTTGTATTATACCTCTTGAAAC
ACTCTTACTGCATATACAGAAGGTAATTGGGAGTTATTCTTTGAGTTGGTTCACACTATT
GTGTTGGCTAATGTTAGTAGTAATCCTTAATTGGTTAATTGTTTTAAGTGCTAAG
TGGATTTTATATTATGCAATGCAACATACTTAAATAATTATGTGTTAATGGCAGTCATG
GTTAATGGCATAGGCTGGCTTGCACCTGTACTTTGGATTGTATTGGTGGGTTAATAAA
GTTTTTGGTTTAACTTAGGTAAATACAATTTTAAAGTTTCAGTAGATCAATATAGGTAT
ATGTGTTTGCATAAGGTAAATCCACCTAAAAGTGTTGGGAGGCTTTTACTACAAATATA
CTTATACAAGGAATTGGAGGCGATCGTGTGTTGCCTATAGCTACAGTGCAATCTAAATTG
AGTGATGTAAAGTGTAACAAGTGTGTTTAAATGCAGCTTTTGACTAAGCTTAATGTTGAA
GCAAATTCAAAAATGCATGCTTATCTTGTGAGTTACACAATAAAATCCTCGCATCTGAT
GATGTTGGAGAGTGATGGATAATTATTGGGTATGCTTATAACACTATTTGTATAGAT
TCTACTATTGATTTTGGGTGAGTATTGTGATGATATACTTAAGAGGTCAACTGTATTACAA
TCGGTTACTCAAGAGTTTTTCGCACATACCTCGTATGCTGAATATGAAAGAGCTAAGAGT
ATTTATGAAAAGGTTTTAGCCGATTCTAAAAATGGTGGTGTAAACAGCAAGAGCTTGCT
GCATATCGTAAAGCTGCCAATATTGCAAAGTCAGTTTTTGATAGAGACTTGGCTGTTCAA
AAGAAGTTAGATAGCATGGCAGAACGTGCTATGACAACAATGTATAAAGAGGCGCGTGTA

-continued

ACTGATAGAAGAGCAAAATTAGTTTCATCATACATGCACTACTTTTTTCAATGCTTAAAG
AAAAATAGATTCTGAGAAGCTTAATGTCCTTATTGACCAGGCGAATAGTGGTGTGTACCC
CTAGCAACTGTTCCAAATTGTTGTAGTAATAAGCTTACCCTGTTATACCAGACCCAGAG
ACGTGGGTCAAGTGTGTGGAGGGTGTGCATGTTACATATTCAACAGTTGTTTGGAAATATA
GACTGTGTACTGATGCCGATGGCACAGAGTTACACCCCACTTCTACAGGTAGTGGATTG
ACTTACTGTATAAGTGGTGATAATATAGCATGGCCTTTAAAGGTTAACTTGACTAGGAAT
GGGCATAATAAGGTTGATGTTGCCTTGCAAAATAATGAGCTTATGCCTCACGGTGTAAG
ACAAAGGCTTGCGTAGCAGGTGTAGATCAAGCACATTGTAGCGTTGAGTCTAAATGTTAT
TATACAAGTATTAGTGGCAGTTCAGTTGTAGCTGCTATTACCTCTTCAAATCCTAATCTG
AAAGTAGCCTCTTTTTGAATGAGGCAGGTAATCAGATTTATGTAGACTTAGACCGAGCA
TGTAATTTGGTATGAAAGTGGGTGATAAGGTTGAAGTTGTTTACCTGTATTTTATAAAA
AATACGAGGTCTATTGTAAGAGGTATGGTACTTGGTGTATATCTAATGTTGTGTGTTA
CAATCTAAAGGTCATGAGACAGAGGAAGTGGATGCTGTAGGCATTCTCTCACTTTGTTCT
TTTGCACTAGATCCTGCGGATACATATTGTAATATGTGGCAGCAGGTAATCAACCTTTA
GGTAACTGTGTTAAATGTTGACAGTACATAATGGTAGTGGTTTGCAATAACATCAAAG
CCAAGTCCAACCTCCGGATCAGGATTCTTATGGAGGAGCTTCTGTGTCTTTATTGTAGA
GCACATATAGCACACCCCTGGCGAGCAGGAAATTTAGATGGACGCTGTCAATTTAAAGGT
TCTTTTGTGCAAAATACCTACTACGGAGAAAGATCCTGTTGGATTCTGTCTACGTAAACAAG
GTTTGCAGTGTGTTGTCAGTGTGGATTGGTTATGGATGTCAGTGTGATTCACTTAGACAA
CCTAAACCTTCTGTTCACTGAGTGTGCTGTTGCATCTGGTTTGTATAAGAATTATTTAAAC
GGGTACGGGGTAGCAGTGAAGCTCGGCTGATACCCCTAGCTAATGGATGTGACCCCGATG
TTGTAAAGCGAGCCTTTGATGTTTGTAAATAAGGAATCAGCCGGTATGTTTCAAATTTGA
AGCGTAACTGTGCAGATTCCAAGAAGTACGTGATACTGAAGATGGAATCTTGAGTATT
GTGATTCTTATTTTGTGGTTAAACAAACCACTCCTAGTAATTATGAACATGAGAAAGCTT
GTTATGAAGACTTAAAGTCAGAAGTAACAGCTGATCATGATTTCTTTGTGTTCAATAAGA
ACATTTATAATATTAGTAGGCAGAGGCTTACTAAGTATACTATGATGGATTTTGTCTATG
CTTTGCGGCACCTTTGACCCAAAGGATTGCGAAGTCTTAAAGAAATACTTGTCATTATG
GTTGTATAGAAGATTATCACCTAAGTGGTTTGAAGAGAATAAGGATTGGTACGACCCAA
TAGAAAACCCATAATATTATGCCATGTTGGCTAAATGGGACCTATTGTACGAGGTGCTT
TATTGAATGCTATTGAGTTCGGAACCTCATGGTTGAAAAAGGTTATGTTGGTGTATTATA
CACTTGATAACCAAGATCTTAATGGCAAATTTTATGATTTTGGTGATTTTCAGAAGACAG
CGCCTGGTGCTGGTGTCTGTTTTTGATACGTATTATCTTACATGATGCCCATCATAG
CCATGACTGATGCGTTGGCACCTGAGAGGTATTTTGAATATGATGTGCATAAGGTTATA
AATCTTATGATCTCCTCAAGTATGATTATACTGAGGAGAAACAAGATTTGTTTCAGAAGT
ACTTTAAGTATTGGGATCAAGAGTATCACCTAACTGTGCGACTGTAGTGTGACAGGT
GTTTGATACATTGTGCAAACTTCAACATCTTGTCTTACACTGTACCGCAGACTTCTT
TCGGTAATTTGTGTAGAAAGGTTTTTGTGTGATGGTGTAACATTTATAGCTACTTGTGGCT
ATCATTCTAAGGAACCTTGGTGTATTATGAATCAAGATAACACCATGTCATTTTCAAAA
TGGGTTTGAAGTGAACCTCATGGAGTTTGTGGAGATCGTGGCTTGTAGTGGGACATGCA
ATAAATTAGTGGATCTTAGAACGTCTTGTCTTAGTGTGCTTTAGCGTCTGGTATTA
CTCATCAAACGGTAAACAGGTCACTTTAACAAGGATTTCTACGATTTTGCAGAGAAGG

CTGGTATGTTTAAAGGAAGGTTCTTCTATACCACTTAAACATTTCTTCTACCCACAGACTG
GTAATGCTGCTATAAACGATTATGATTATTATCGTTATAACAGGCCTACCATGTTTGATA
TACGTCAACTTTTATTTTGTGTTAGAGTGAAGTCTTAAATATTTTGAATGTTATGAAGGCG
GCTGTATACCGCAAGCCAAGTTGTAGTTAACAATTTAGATAAGAGTGCAGGTATCCGT
TCAATAAGTTTGGAAAGGCCCGTCTCTATTATGAAATGAGTCTAGAGGAGCAGGACCAAC
TCTTTGAGAGTACAAGAAGAACGTCCTGCCTACTATAACTCAGATGAATTTAAATATG
CCATATCCGCGAAAAATAGAGCGCGTACAGTGGCAGGTGTCTATCCTTTCTACTATGA
CTAATAGGCAGTTTCATCAGAAGATTCTTAAGTCTATAGTCAACACTAGAAACGCTCCTG
TAGTTATTGGAACAACCAAGTTTTATGGCGGTTGGGATAACATGTTGAGAAACCTTATTC
AGGGTGTGGAAGACCCGATTCTTATGGGTTGGGATTATCCAAAGTGTGATAGAGCAATGC
CTAATTTGTTGCGTATAGCAGCATCTTTAGTACTCGCTCGTAAACACACTAATTGTTGTA
CTTGCTGTAACGCGTTTATAGGTTGTATAATGAATGCGCTCAGGTTTTATCTGAACTG
TCTTAGCTACAGGTGGTATATATGTGAAACCTGGTGGTACTAGCAGTGGAGATGCTACTA
CTGCTTATGCAACAGTGTTTTCAACATAATACAAGCCACATCTGCTAATGTTGCGCGTC
TTTTGAGTGTATAACGCGTGATATTGTATATGATGACATTAAGAGCTTGCAGTATGAAT
TGTACCAGCAGGTTTATAGGCGAGTCAATTTTGACCCAGCATTGTTGAAAAGTTTTATT
CTTATTTGTGTAAGAATTTCTCATTGATGATCTTGTCTGACGACGGTGTGTTTGTGTA
ACAACACATTAGCCAAACAAGGCTTGTAGCAGATATTTCTGGTTTTAGAGAAGTTCTCT
ACTATCAGAACATGTTTTTATGGCTGATTCTAAATGTTGGGTTGAACCAGATTAGAAA
AAGGCCACATGAATTTTGTTTACAGCACACAATGTTAGTGGAGGTTGATGGTGAGCCTA
GATACTTGCCATATCCAGACCCATCACGTATTTTGTGTGATGTGTTTTGTAGATGATT
TGGATAAGACAGAATCTGTGGCTGTTATGGAGCGTTATATCGCTCTTGCCATAGATGCGT
ACCCACTAGTACATCATGAAATGAGGAGTACAAGAAGGTATTCTTTGTGCTTCTTTCAT
ACATCAGAAAACCTCTATCAAGAGCTTTCTCAGAATATGCTTATGGACTACTCTTTGTAA
TGGATATAGATAAGGGTAGTAAATTTTGGGAACAGGAGTTCTATGAAAATATGTATAGAG
CCCCTACAACATTACAGTGTGTTGGCGTTTGTGTAGTGTGTAATAGTCAAACCTATATTGC
GCTGTGGTAATTGTATTGCGAAACCATTTTGTGTTGTAAGTGTGCTATGACCATGTCA
TGCACACAGACCACAAAAATGTTTTGTCTATAAATCCTTACATTGCTCAGAGCCAGGTT
GTGGTGAAGCAGATGTTACTAAATGTACCTCGGAGGTATGTCATACTTCTGCGTAATC
ATAAACCAAAGTTATCAATACCGTTAGTATCTAATGGTACAGTGTGGAATTTACAGGG
CTAATTGTGCAGGTAGCGAAAATGTTGATGATTTTAATCAACTAGCTACTACTAATTGGT
CTACTGTGGAACCTTATATTTTGGCAAATCGTTGTGTAGATTCGTTGAGACGCTTTGCTG
CAGAGACAGTAAAGCTACAGAAGAATTACATAAGCAACAATTTGCTAGTGCAGAAGTGA
GAGAAGTACTCTCAGATCGTGAATTGATTCTGTCTTGGGAGCCAGGTAACCAGGCCTC
CATTGAATAGAAATATGTTTTCACTGGCTTTCACTTTACTAGAACTAGTAAAGTTCAGC
TCGGTGATTTTACATTTGAAAAGGTGAAGGTAAGGACGTTGTCTATTATCGAGCGACGT
CTACTGCTAAATGTCTGTGAGACATTTTGTGTTTAACTCAGCAATGTTGTTTCTC
TTATAGCGCCAACGTTGTGTCCTCAGCAAACCTTTTCTAGGTTTGTGAATTTAAGACCTA
ATGTGATGGTACCTGCGTGTGTTGTAATAACATTCCATTGTACCATTTAGTAGCAAGC
AGAAGCGTACTACAGTACAAGGCCCTCCTGGCAGTGGTAAATCCATTTTGCTATAGGAT

- continued

TGGCGGCTTACTTTAGTAACGCCCGTGTCTGTTTTACTGCATGCTCTCATGCAGCTGTTG
ATGCTTTATGTGAAAAAGCTTTTAAAGTTTCTTAAAGTAGATGATTGCACTCGTATAGTAC
CTCAAAGGACTACTATCGATTGCTTCTCTAAGTTTAAAGGTAATGACACAGGCAAAAAGT
ACATTTTTAGTACTATTAATGCCTTGCCAGAAGTTAGTTGTGACATTCTTTGGTTGACG
AGGTTAGTATGTTGACCAATTACGAATTGTCTTTTATTAATGGTAAGATAAACTATCAAT
ATGTTGTGTATGTAGGTGATCCTGCTCAATTACCGGCGCCTCGTACGTTGCTTAACGGTT
CACTCTCTCCAAAGGATTATAATGTTGTGCACAAACCTTATGGTTTGTGTTAAACCTGACA
TTTTCTTGCAAAGTGTACCGTTGTCTTAAAGAAATTGTAGATACTGTTTCTACTCTTG
TATATGATGGAAAGTTTATTGCAAATAACCCGGAATCACGTCAGTGTTTCAAGGTTATAG
TTAATAATGGTAATTCTGATGTAGGACATGAAAGTGGCTCAGCCTACAACTAACTCAAT
TAGAATTTGTGAAAGATTTTGTCTGTGCAATAAGGAATGGCGGAAGCAACATTCATTT
CACCTTATAATGCTATGAACAGAGAGCCTACCGTATGCTTGGACTTAATGTTGAGACAG
TAGACTCGTCTCAAGGTTCCGAGTATGATTATGTTATCTTTTGTGTTACTGCAGATTCGC
AGCATGCACTGAATATTAAACAGATTCAATGTAGCGCTTACAAGAGCCAAGCGTGGTATAC
TAGTTGTCTATGCGTCAGCGTGATGAACATATTCAGCTCTTAAGTTTATAGAGCTTGATA
GTGTAGCAAGTCTGCAAGGTACAGGCTTGTTTAAATTTGCAACAAAGAGTTTAGTGGTG
TTCACCCAGCTTATGCAGTCACAACTAAGGCTCTTGCTGCAACTTATAAAGTTAATGATG
AACTTGCTGCACCTTGTTAACGTGGAAGCTGGTTCAGAAATAACATATAAACATCTTATTT
CTTTGTTAGGGTTTAAAGATGAGTGTAAATGTTGAAGGCTGCCACAACATGTTTATAACAC
GTGATGAGGCTATCCGCAACGTAAGAGGTTGGGTAGGTTTGTATGTAGAAGCAACACATG
CTTGCGGTACTAACATTGGTACTAACCTGCCTTTCCAAGTAGGTTTCTCTACTGGTGCAG
ACTTTGTAGTTACGCCTGAGGGACTTGTAGATACTTCAATAGGCAATAATTTGAGCCTG
TGAATTTCTAAAGCACCTCCAGGTGAACAATTTAATCACTTGAGAGCGTTATTCAAAGTG
CTAAACCTTGCGATGTTGTAAGGCCAAGGATTGTGCAAAATGTTAGCGGATAACCTGTGCA
ACGTTTCAGATTGTGTAGTGTGTTGTACGTGGTGTCTATGGCCTAGAACTAACCACTTTGC
GCTATTTTGTGTTAAATAGGCAAGGACCAAGTTTGTCTTGCGGTTCTAGAGCAACAACCTT
TTAATTTCTCACTCAGGCTTATGCTTGTGGAAGCATTGCTTGGGTTTGTATTTGTTT
ATAATCCACTCTTAGTGATATTCAACAGTGGGGTTATTCTGGTAACCTACAATTTAACC
ATGATTTGCATTTGTAATGTGCATGGACACGCACATGTAGCTTCTGCGGATGCTATTATGA
CGCGTTGTCTTGCAATTAATAATGCATTTTGTCAAGATGTCAACTGGGATTTAACCTACC
CTCATATAGCAAAATGAGGATGAAGTCAATTCTAGCTGTAGATATTTACAACGCATGTATC
TTAATGCATGTGTTGATGCTCTTAAAGTTAACGTTGTCTATGATATAGGCAACCTAAAG
GTATAAAATGTGTTAGACGTGGAGACTTAAATTTTAGATTCTATGATAAGAATCCAATAG
TACCAATGTCAAGCAGTTTGAGTATGACTATAATCAGCACAAAGATAAGTTTGCTGATG
GTCTTTGTATGTTTGGAAATTGTAATGTGGATTGTTATCCCGACAATTCCTTAGTTTGTG
GGTACGACACACGAAATTTGAGTGTGTTTAACTACCTGCTTGAATGGTGGTAGCTTGT
ATGTTAACAAGCATGCATTCCACACACCTAAATTTGATCGCACTAGCTTTCGTAATTTGA
AAGCTATGCCATTCTTTTCTATGACTCATCGCCTTGCGAGACCATTCAATGGATGGAG
TTGCGCAAGACCTTGTCATTAGCTACGAAAGATTGTATCACAAAATGCAACATAGGCG
GTGCTGTTTGTAAAAAGCACGCAAAATGTATGCAGATTTTGTGACTTCTTATAATGCAG
CTGTACTGCTGGTTTACTTTTTGGGTTACTAATAATTTTAAACCATATAATTTGTGGA

AAAGTTTTTCAGCTCTCCAGTCTATCGACAATATTGCTTATAATATGTATAAGGGTGGTC
ATTATGATGCTATTGCAGGAGAAATGCCCACTATCGTAACTGGAGATAAAGTTTTTGTTA
TAGATCAAGGCGTAGAAAAAGCAGTTTTTTTTTAATCAAACAATTCTGCCTAGATCTGTAG
CGTTTGAGCTGTATGCGAAGAGAAATATTCGCACACTGCCAAACAACCGTATTTTGAAAG
GTTTGGGTGTAGATGTGACTAATGGATTGTAAATTTGGGATTACACGAACCAACACCAC
TATACCGTAATACTGTTAAGGTATGTGCATATACAGACATAGAACCAATGGCCTAATAG
TGCTGTATGATGATAGATATGGTGATTACCAGTCTTTCTAGCTGCTGATAATGCTGTTT
TAGTTTCTACACAGTGTACAAAGCGGTATTCGTATGTAGAAATACCGTCAAACCTGCTTG
TTCAGAACGGTATTCGGTTAAAAGATGGAGCGAACCTGTATGTTTATAAGCGTGTTAATG
GTGCGTTTTGTTACGCTACCTAACACATTAAACACACAGGGTCGCAGTTATGAACTTTTG
AACCTCGTAGTGATGTTGAGCGTGATTTTCTCGACATGTCTGAGGAGAGTTTTGTAGAAA
AGTATGGTAAAGAATTAGGTCTACAGCACATACTGTATGGTGAAGTTGATAAGCCCCAAT
TAGGTGGTTTACACACTGTTATAGGTATGTGCAGACTTTTACGTGCGAATAAGTTGAACG
CAAAGTCTGTTACTAATCTGATTCTGATGTCATGCAAAATTATTTGTATTGGCAGACA
ATGGTTCCTACAGCAAGTGTGTACTGTTGTGGATTGCTGCTTGATGATTCTTAGAAC
TTCCTAGGAACATACTGAAAGAGTATGGTACTAATAAGTCTAAAGTTGAACAGTGTCAA
TTGATTACCATAGCATAAAATTTATGACTTGGTTTGAAGATGGCATTATTAACATGTT
ATCCACAGCTTCAATCAGCATGGACGTGTGGTTATAATATGCCTGAACCTTATAAGTTC
AGAATTGTGTTATGGAACCTTGCAACATTCCTAATTATGGTGTGGAATAGCGTTGCCAA
GTGGTATTATGATGAATGTGGCAAAGTATACACAACCTCTGTCAATACCTTTCGAAAACAA
CAATGTGTGTACCGCATAATATGCGAGTAATGCATTTTGGAGCTGGAAGTGACAAAGGAG
TGGCTCCAGGTAGTACTGTTCTTAAACAATGGCTCCAGAAAGGGACACTCCTTGTCGATA
ATGATAATTGTAGACTATGTGTCTGATGCACATGTTTCTGTGCTTTCAGATTGCAATAAAT
ATAAGACAGAGCACAAGTTTGATCTTGATATCTGATATGTATACAGACAATGATTCAA
AAAGAAAGCATGAAGGCGTGATAGCCAATAATGGCAATGATGACGTTTTTCATATATCTCT
CAAGTTTTCTTCGTAATAATTTGGCTCTAGGTGGTAGTTTTGCTGTAAAAGTGACAGAGA
CAAGTTGGCACGAAGTTTTATATGACATTGCACAGGATTGTGCATGGTGGACAATGTTTT
GTACAGCAGTGAATGCCTCTCTTCAGAAGCATTCTTGGTTGGTGTTAATTATTTGGGTG
CAAGTGAAAAGGTTAAGGTTAGTGAAAAACGCTGCACGCAAATTATATATTTTGAGGA
ATTGTAATTATTTACAAACCTCTGCTTATAGTATATTTGACGTTGCTAAGTTTGATTTGA
GATTGAAAGCAACACCAGTTGTTAATTTGAAAACGAACAAAAGAGAGACTTAGTGTTTA
ATTTAATTAAGTGTGGTAAGTTACTGGTAAGAGATGTTGGTAACACCTCTTTTACTAGTG
TACCAAAGTGCCCTTTAGACCACCTAATGGTTGGCATTACACGGGGGTGCTTATGCGGTG
GTTAATATTTCTAGCGAATCTAATAATGCAGGCTCTTACCTGGGTGATTGTTGGTACT
ATTGATGGTGGTGTGTTGTTAATGCTTCTCTATAGCTATGACGGCACCGTCATCAGGT
ATGGCTTGGTCTAGCAGTCAGTTTTGTACTGCACACTGTAACCTTTTACGATACTACAGTG
TTTGTACACATTGTTATAAATATGATGGGTGCTCTATAACTGGCATGCTTCAAAGAAT
TTTTTACGTGTTTCTGCTATGAAAAATGGCCAGCTTTTCTATAATTTAACAGTTAGTGTA
GCTAAGTACCCTACTTTTTAAATCATTTTCAGTGTGTTAATAATTTAACATCCGTATATTTA
AATGGTGATCTTGTTTACACCTCTAATGAGACCACAGATGTTACATCTGCAGGTGTTTAT

- continued

TTTAAAGCTGGTGGACCTATAACTTATAAAGTTATGAGAGAAGTTAAAGCCCTGGCTTAT
TTTGTTAATGGTACTGCACAAGATGTTATTTTGTGTGATGGATCACCTAGAGGCTTGTTA
GCATGCCAGTATAAATACTGGCAATTTTTCAGATGGCTTTTATCCTTTTATTAATAGTAGT
TTAGTTAAGCAGAAGTTTATTGTCTATCGTGAAAATAGTGTTAATACTACTTTTACGTTA
CACAATTTCACTTTTCATAATGAGACTGGCGCCAACCTAATCCTAGTGGTGTTTCAGAAT
ATTCAAACCTTACCAAACACAACAGCTCAGAGTGGTTATTATAATTTTAATTTTTCCTTT
CTGAGTAGTTTTGTTTATAAGGAGTCTAATTTTATGTATGGATCTTATCACCCAAGTTGT
AATTTTAGACTAGAACTATTAATAATGGCTTGTGGTTAATTCACCTTCAGTTTCAATT
GCTTACGGTCCTCTTCAAGGTGGTTGCAAGCAATCTGTCTTAGTGGTAGAGCAACTTGT
TGTTATGCTTATTCATATGGAGGTCCTTCGCTGTGTAAAGGTGTTTATTACAGTGAGTTA
GATCTTAATTTTGAATGTGGACTGTAGTTTATGTTACTAAGAGCGGTGGCTCTCGTATA
CAAACAGCCACTGAACCGCCAGTTATAACTCGACACAATTATAATAATATTACTTTAAAT
ACTTGTGTTGATTATAATATATATGGCAGAACTGGCCAAGGTTTATTACTAATGTAACC
GACTCAGCTGTTAGTTATAATTATCTAGCAGACGCAGGTTTGGCTATTTTAGATACATCT
GGTTCATAGACATCTTTGTTGTACAAGGTGAATATGGTCTTACTATTATTAGGTTAAC
CCTTGCGAAGATGTCAACCAGCAGTTTGTAGTTTCTGGTGGTAAATTAGTAGGTATTCTT
ACTTCACGTAATGAGACTGGTTCTCAGCTTCTTGAGAACCAGTTTACATTAAATCACT
AATGGAACACGTCGTTTTAGACGTTCTATTACTGAAAATGTTGGAATTTGCCCTTATGTT
AGTTATGGTAAGTTTTGTATAAAACCTGATGGTTCAATTGCCACAATAGTACCAAAACAA
TTGGAACAGTTTGTGGCACCTTTACTTAAATGTTACTGAAAATGTGCTCATACCTAACAGT
TTTAATTTAACTGTTACAGATGAGTACATACAAACGCGTATGGATAAGGTCCAAATTAAT
TGTCTGCAGTATGTTTGTGGCAATTCTCTGGATTGTAGAGATTTGTTTCAACAATATGGG
CCTGTTTGTGACAACATATTGTCTGTAGTAAATAGTATTGGTCAAAAAGAAGATATGGAA
CTTTTGAATTTCTATTCTTCTACTAAACCGCTGGTTTTAATACACCATTTCTTAGTAAT
GTTAGCACTGGTGAGTTTAATATTTCTCTTCTGTTAACAACCTCCTAGTAGTCTTAGAAGG
CGTTCTTTTATTGAAGACCTTCTATTTACAAGCGTTGAATCTGTTGGATTACCAACAGAT
GACGCATACAAAAATTGCACTGCAGGACCTTTAGGTTTTCTTAAGGACCTTGCCTGTGCT
CGTGAATATAATGGTTTGCTTGTGTGCCTCCATTATAACAGCAGAAATGCAAATTTTG
TATACTAGTTCTCTAGTAGCTTCTATGGCTTTTGGTGGTATTACTGCAGCTGGTGCTATA
CCTTTTGCCACACAACCTGCAGGCTAGAATTAATCACTTGGGTATTACCCAGTCACTTTTG
TTGAAGAATCAAGAAAAAATGCTGCTTCCTTTAATAAGGCCATTGGTCGTATGCAGGAA
GGTTTTAGAAGTACATCTCTAGCATTACAACAAATTCAAGATGTTGTTAATAAGCAGAGT
GCTATTCTTACTGAGACTATGGCATCACTTAATAAAAAATTTGGTGCTATTCTTCTATG
ATTCAAGAAATCTACCAGCAACTTGACGCCATACAAGCAAATGCTCAAGTGGATCGTCTT
ATAACTGGTAGATTGTCATCACTTTCTGTTTTCAGCATCTGCTAAGCAGCGGAGCATATT
AGAGTGTCACAACAGCGTGAGTTAGCTACTCAGAAAAATTAATGAGTGTGTTAAGTCACAG
TCTATTAGGTACTCCTTTTGTGGTAATGGACGACATGTTCTAACCATACCGCAAAATGCA
CCTAATGGTATAGTGTTTATACACTTTTCTTATACTCCAGATAGTTTTGTTAATGTACT
GCAATAGTGGGTTTTTGTGTAAAGCCAGCTAATGCTAGTCAGTATGCAATAGTACCCGCT
AATGGTAGGGGTATTTTATACAAGTTAATGGTAGTTACTACATCACAGCACGAGATATG
TATATGCCAAGAGCTATTACTGCAGGAGATATAGTTACGCTTACTTCTGTCAAGCAAT

TATGTAAGTGTAATAAGACCGTCATTACTACATTCGTAGACAATGATGATTTTGATTTT
AATGACGAATTGTCAAAATGGTGAATGACACTAAGCATGAGCTACCAGACTTTGACAAA
TTCAATTACACAGTACCTATACTTGACATTGATAGTGAAATTGATCGTATTCAGGCGTT
ATACAGGGTCTTAATGACTCTTTAATAGACCTTGAAAACTTCAATACTCAAACTTAT
ATTAAGTGGCCTTGGTATGTGTGGTTAGCCATAGCTTTTGCCACTATTATCTTCATCTTA
ATACTAGGATGGGTTTTCTTCATGACTGGATGTTGTGGTTGTTGTGTGGATGCTTTGGC
ATTATGCCTCTAATGAGTAAGTGTGGTAAGAAATCTTCTATTACACGACTTTTGATAAC
GATGTGGTAACCTAACAATACAGACCTAAAAAGTCTGTTTAATGATTCAAAGTCCCACGT
CCTTCCTAATAGTATTAATTTTTCTTTGGTGTAACCTGTACTAAGTTGTTTTAGAGAGT
TTATTATAGCGCTCCAACAATAATACAAGTTTTACTCCAAATATCAATAGTAACCTAC
AGCCTAGACTGACCCTTTGTCCAGTCTAGACTAATGTTAACTTAGAAGCAATTATTGA
AACTGGTGAGCAAGTATTCAAAAAATCAGTTTCAATTACAGCATATTTCAAGTGATT
AAACACAGAAGTATTTGACCCCTTGACTATTGTTATTACAGAGGAGTAATTTTGGGA
AATAGAGTCAGCTGAAGATTGTTCAGGTGATGATGAATTTATTGAATAAGTCGCTAGAGG
AAAATGGAAGTTTTCTAACAGCGCTTTATATATTTGTAGGATTTTAGCACTTTATCTTC
TAGGTAGAGCACTTCAAGCATTGTACAGGCTGCTGATGCTGTTGTTTATTTTGGTATA
CATGGGTAGTAATTCAGGAGCTAAGGGTACAGCCTTTGTATATAAGTATACATATGGTA
GAAAACTTAACAATCGGAATTAGAAGCAGTTATTGTCAACGAGTTTCCTAAGAACGGTT
GGAATAATAAAAAATCCAGCAAAATTTCAAGATGTCCAACGAGACAAATGTACTCTTGAC
TTTGAACAGTCAGTTGAGCTTTTAAAGAGTATAATTTATTTATAACTGCATTCTTGTTG
TTCTTAACCATAATACTTCAGTATGGCTATGCAACAAGAAGTAAGTTTATTTATATACTG
AAAATGATAGTGTTATGTGTCTTTTGGCCCTTAACATTGCAGTAGGTGAATTCATGT
ATATACCCACCAACACAGGAGGTCTTGTCGACGATAATACTTACAGTGTGTTGCGTGT
CTGTCTTTTGTAGGTTATTGGATCCAGAGTATTAGACTCTTTAAGCGGTGTAGGTCATGG
TGGTCATTTAACCAGAATCTAATGCCGTAGGTTCAATACTCCTAATAAGGTCAACAA
TGTAATTTTGCTATAGAGAGTGTGCCAATGGTGCTTTCTCCAATTATAAAGAATGGTGTT
CTTTATTGTGAGGGTCAGTGGCTTGCTAAGTGTGAACCAGACCACTTGCCATAAGATATA
TTTGTGTTGACACCGGATAGACGTAATATCTACCGTATGGTGAGAAATATACTGGTGAC
CAAAGCGGAAATAAGAAACGGTTTGCTACGTTTGCTATGCAAAGCAGTCAGTAGATACT
GGCGAGCTAGAAAGTGTAGCAACAGGAGGAGTAGTCTTTACACCTAAATGTGTGTGTGT
AGAGAGTATTTAAAATTATTCTTTAATAGTGCCTCTATTTAAGAGCGCATAATAGTATT
ATTTTGGAGGATATTAATATAAATCCTCTCTGTTTTATACTCTCTTTCAAGAGCTATTA
TTTAAAAACAGTTTTTCCACTCTTTTGTGCCAAAACTATTGTTGTTAATGGTGTAACC
TTTCAAGTAGATAATGGAAGTCTACTACGAAGGAAACCAATTTTTCAGAAAGGTTGT
TGTAAGTTGTGGTTGAGTTATAAAAAAGATTAACTACCTACTACACTTATTTTATAAG
AGGCGTTTTATCTTACAAGCGCTTAATAAATACGGACGATGAAATGGCTGACTAGTTTTG
TAAGGGCAGTTATTTTCATGTTATAAACCCCTATTATTAACCTAATTAAGAGTATTAGATA
GGTTAATCTTAGATCATGGACCAAAACACATCTTAACGTGTGTTAGGTGCGTGATTTTGT
TTCAATTAGATTTAGTTTATAGGTTGGCGTATACGCCTACTCAATCGTGATGAATAA
TAGTAAAGATAATCCTTTTGCAGGCAATAGCAAGAAAGCGCAATTTATCTGAGAGA

- continued

AGGATTAGATTGTGTTTACTTTCTTAACAAAGCAGGACAAGCAGAGTCTTGTCCTCCGCGTG
TACCTCTCTAGTATTCCAGGGGAAAACCTTGTGAGGAACACAAATATAATAATCTTTT
GTCATGGCAAGCGGTAAAGGCAACTGGAAAGACAGATGCCCGAGCTCCAGTCATCAAACATA
GGAGGACCAAAGCCACCTAAAGTTGGTTCTTCTGAAATGTATCTTGGTTTCAAGCAATA
AAAGCCAAGAAGTTAAATTACCTCCGCCTAAGTTTGAAGGTAGCGGTGTTCTTGATAAT
GAAAATCTAAAACCAAGTCAGCAGCATGGATATTGGAGACGCCAAGCTAGGTTTAAAGCCA
GGTAAAGGTGGAAGAAAACAGTCCCAGATGCTTGGTATTTTGTATAGTACTGGAACAGGA
CCAGCCGCTAACCTGAATTGGGGTGATGCCAAGATGGTATAGTGTGGGTGCTGGTAAAG
GGTGTGATAGTAAATTTAGATCTAATCAGGGTACTCGTGACTCTGACAAGTTTGACCAA
TATCCGCTACGGTTTTTTCAGACGGAGGACCTGATGGTAATTTCCGTTGGGATTTTATTCTCT
CTGAATCGTGGCAGGAGTGGGAGATCAACAGCAGCTTCATCAGCAGCATCTAGTAGAGCA
CCATCACGTGAAGTTTCGCGTGGTCGCAGGAGTGGTTCTGAAGATGATCTTATTGCTCGT
GCAGCAAGGATAATTCAGGATCAGCAGAAGAAGGGTTCTCGCATTACAAAGGCTAAGGCT
GATGAAATGGCTCACGCCGGTATTGCAAGCGCAGTATCCACCTAATTATAAGGTTGAT
CAAGTGTTTGGTCCCCGTAATAAGGTAAGGAGGAAATTTGGTGATGACAAGATGAAT
GAGGAAGGTATTAAGGATGGGCGCGTTACAGCAATGCTCAACCTAGTTTCTAGCAGCCAT
GCTTGTCTTTTCGGAAGTAGAGTGACGCCAGACTTCAACCAGATGGGCTGCACCTTGAAA
TTTGAATTTACTACTGTGGTCCACGTGATGATCCGCAGTTTGATAATTATGTAATAATTT
TGTGATCAGTGTGTTGATGGTGTAGGAACACGTCCAAAAGATGATGAACCAAGACCAAAG
TCACGCTCAAGTTCAAGACCTGCAACAAGAGGAAATTTCCAGCGCCAAGACAGCAGCGC
CCTAAGAAGGAGAAAAAGCCAAAGAAGCAGGATGATGAAGTGGATAAAGCATTGACCTCA
GATGAGGAGAGGAACAATGCACAGCTGGAATTTGATGATGAACCAAGGTAATTAAGTGG
GGGGATTACGCGCTAGGAGAGAATGAACCTTTGAGTAAATTTGAATAGTAAGAGTTAAGGA
AGATAGGCATGTAGCTTGATTACCTACATGTCTATCGCCAGGGAATGTCTAATTTGTCT
ACTTAGTAGCCTGGAACGAACGGTAGACCCTTAGATTTTAAATTTAGTTTAAATTTTAGT
TTAGTTTAAAGTTAGTTTAGAGTAGGTATAAAGATGCCAGTGGCGGGGCCACGCGGAGTAC
GACCGAGGGTACAGCACTAGGACGCCCATTAGGGGAAGAGCTAAATTTTAGTTTAAAGTTA
AGTTTAAATGGCTATGTATAGTTAAATTTATAGGCTAGTATAGAGTTAGAGCAAAAAAA
AAAAA

Replicase

In addition to the structural and accessory genes, two-thirds of a coronavirus genome comprises the replicase gene (at the 5' end of the genome), which is expressed as two polyproteins, pp1a and pp1ab, in which pp1ab is an extension product of pp1a as a result of a -1 ribosomal shift mechanism. The two polyproteins are cleaved by two types of virus-encoded proteinases usually resulting in 16 non-structural proteins (Nsp1-16); IBV lacks Nsp1 thereby encoding Nsp2-16.

Thus Gene 1 in IBV encodes 15 (16 in other coronaviruses) non-structural proteins (nsp2-16), which are associated with RNA replication and transcription.

The term 'replicase protein' is used herein to refer to the pp1a and pp1ab polyproteins or individual nsp subunits.

The term 'replicase gene' is used herein to refer to a nucleic acid sequence which encodes for replicase proteins.

A summary of the functions of coronavirus nsp proteins is provided in Table 1.

TABLE 1

Nsp Protein	Key features
1	Conserved within but not between coronavirus genetic groups; potential regulatory functions in the host cell.
2	Dispensable for MHV and SARS-CoV replication in tissue culture
3	Acidic domain; macro domain with ADPR and poly (ADP-ribose)-binding activities; one or two ZBD-containing papain-like proteases; Y domain
4	Transmembrane domain
5	3C-like main protease, homodimer
6	Transmembrane domain
7	Interacts with nsp8 to form a hexadecamer complex
8	Noncanonical RNA polymerase; interacts with nsp7 to form a hexadecameric complex
9	ssRNA-binding protein, dimer
10	RNA-binding protein, homododecamer, zinc-binding domain, known to interact with nsp14 and nsp16

TABLE 1-continued

Nsp Protein	Key features
11	Unknown
12	RNA-dependent RNA polymerase
13	Zinc-binding domain, NTPase, dNTPase, 5'-to-3' RNA and DNA helicase, RNA 5'-triphosphate
14	3'-to 5' exoribonuclease, zinc-binding domain and N7-methyltransferase
15	Uridylate-specific endoribonuclease, homohexamer
16	Putative ribose-2'-O-methyltransferase

The variant replicase gene encoded by the coronavirus of the present invention comprises a mutation in one or more of the sections of sequence encoding nsp-10, nsp-14, nsp-15 or nsp-16.

Nsp10 has RNA-binding activity and appears to be involved in homo and/or heterotypic interactions within other nsps from the pp1a/pp1ab region. It adopts an α/β fold comprised of five α -helices, one 3_{10} -helix and three β -strands. Two zinc-binding sites have been identified that are formed by conserved cysteine residues and one histidine residue (Cys-74/Cys-77/His-83/Cys-90; Cys-117/Cys-120/Cys-128/Cys-130). The protein has been confirmed to bind single-stranded and double-stranded RNA and DNA without obvious specificity. Nsp-10 can be cross-linked with nsp-9, suggesting the existing of a complex network of protein-protein interactions involving nsp-7, -8, -9 and -10. In addition, nsp-10 is known to interact with nsp-14 and nsp-16.

Nsp-14 comprises a 3'-to-5' exoribonuclease (ExoN) active domain in the amino-terminal region. SARS-CoV ExoN has been demonstrated to have metal ion-dependent 3'-to-5' exoribonuclease activity that acts on both single-stranded and double-stranded RNA, but not on DNA. Nsp-14 has been shown to have proof-reading activity. This nsp has also been shown to have N7-methyltransferase (MT) activity in the carboxyl-terminal region.

Nsp-15 associated NendoU (nidoviral endoribonuclease, specific for U) RNase activity has been reported for a number of coronaviruses, including SARS-CoV, MHV and IBV. The activities were consistently reported to be significantly enhanced by Mn^{2+} ions and there was little activity in the presence of Mg^{2+} and Ca^{2+} . NendoU cleaves at the 3' side of uridylate residues in both single-stranded and double-stranded RNA. The biologically relevant substrate(s) of coronavirus NendoUs remains to be identified.

Nsp-16 has been predicted to mediate ribose-2'-O-methyltransferase (2'-O-MTase) activity and reverse-genetics experiments have shown that the 2'-O-MTase domain is essential for viral RNA synthesis in HCoV-229E and SARS-CoV. The enzyme may be involved in the production of the cap 1 structures of coronavirus RNAs and it may also cooperate with NendoU and ExoN in other RNA processing pathways. 2'-O-MTase might also methylate specific RNAs to protect them from NendoU-mediated cleavage.

The genomic and protein sequences for nsp-10, -14, -15 and -16 are provided as SEQ ID NO: 2-5 and 6-9, respectively.

(nsp-10 nucleotide sequence- nucleotides 11884-12318 of SEQ ID NO: 1)
SEQ ID NO: 2

TCTAAGGTCATGAGACAGAGGAAGTGGATGCTGTAGGCATTCTCTCACTTTGTTCTTTTCAGTA
GATCCTGCGGATACATATTGTAAATATGTGGCAGCAGGTAATCAACCTTTAGGTAACGTGTGTTAAA
ATGTTGACAGTACATAATGGTAGTGGTTTTGCAATAACATCAAGCCAAAGTCCAACTCCGGATCAG
GATTCTTATGGAGGAGCTTCTGTGTGCTTTATTGTAGAGCACATATAGCACCTTGGCGGAGCA
GGAAATTTAGATGGACGCTGTCAATTTAAAGGTTCTTTTGTGCAAATACCTACTACGGAGAAAGAT
CCTGTTGGATTCTGTCTACGTAACAAGGTTTGCAGTGTGTGTCAGTGTGGATTGGTTATGGATGT
CAGTGTGATTCACTTAGACAACCTAAACCTTCTGTTTCAG

(nsp-14 nucleotide sequence- nucleotides 16938-18500 of SEQ ID NO: 1)
SEQ ID NO: 3

GGTACAGGCTTGTTTAAATTTGCAACAAAGAGTTTAGTGGTGTCCACCGAGCTTATGCAGTCACA
ACTAAGGCTCTGTGCAACTTATAAAGTTAATGATGAAGTGTGTCAGTGTGTAACGTGGAAGCT
GGTTCAGAAATAACATATAACATCTTATTTCTTTGTTAGGGTTTAAGATGAGTGTAAATGTTGAA
GGCTGCCACAACATGTTTATAACACGTGATGAGGCTATCCGCAACGTAAGAGGTGGGTAGGTTTT
GATGTAGAAGCAACATGCTTGCAGTACTAACATGGTACTAACCTGCCTTTCCAAGTAGGTTTT
TCTACTGGTGACACTTTGTAGTTACGCCTGAGGGACTTGTAGATACTTCAATAGGCAATAATTTT
GAGCCTGTGAATTCTAAAGCACCTCCAGGTGAACAATTAATCACTTGAGAGCGTTATTCAAAGT
GCTAAACCTTGGCATGTTGTAAAGGCCAAGGATTGTGCAAATGTTAGCGGATAACCTGTGCAACGTT
TCAGATTGTGTAGTGTGTGTACGTGGTGTATGGCCTAGAACTAACCACTTTGCGCTATTTGTT
AAAATAGGCAAGGACCAAGTTTGTCTTTCGGGTTCTAGAGCAACAACCTTTAATCTCATACTCAG
GCTTATGCTTGTGGAAGCATTGCTTGGGTTTTGATTTGTTTATAATCCACTCTTAGTGGATATT
CAACAGTGGGTTATTCTGGTAACCTACAATTTAACCATGATTGTCATTGTAATGTGCATGGACAC
GCACATGTAGCTTCTCGGATGCTATTATGACGCGTTGTCTGCAATTAATAATGCATTTTGTCAA

-continued

GATGTCAACTGGGATTAACTTACCTCATATAGCAAATGAGGATGAAGTCAATCTAGCTGTAGA
TATTTACAACGCATGTATCTTAATGCATGTGTTGATGCTCTTAAAGTTAACGTTGTCTATGATATA
GGCAACCCCTAAAGGTATTAATGTGTTAGACGTGGAGACTTAAATTTTAGATTCTATGATAAGAAT
CCAAAGTAGTACCAATGTCAAGCAGTTTGAGTATGACTATAATCAGCACAAAGATAAGTTTGCTGAT
GGTCTTTGTATGTTTTGGAATTGTAATGTGGATTGTTATCCCGACAATTCCTTACTTTGTAGGTAC
GACACACGAAATTTGAGTGTGTTTAACTACCTGGTTGTAATGGTGGTAGCTTGTATGTTAACAAG
CATGCATTCCACACACCTAAATTTGATCGCACTAGCTTTCGTAATTTGAAAGCTATGCCATTCTTT
TTCTATGACTCATCGCCTTGCAGAGACCATTCAATTGGATGGAGTTGCGCAAGACCTTGTGTCATTA
GCTACGAAAGATTGTATCAGAAATGCAACATAGGCGGTGCTGTTTGTAAAAAGCACGCACAAATG
TATGCAGATTTTGTGACTTCTTATAATGCAGCTGTTACTGCTGGTTTTACTTTTGGGTTACTAAT
AATTTTAACCCATATAATTTGTGGAAAAGTTTTTCAGCTCTCCAG

(nsp-15 nucleotide sequence- nucleotides 18501-19514 of SEQ ID NO: 1)
SEQ ID NO: 4
TCTATCGACAATATGCTTATAATATGTATAAGGGTGGTCATTATGATGCTATTGCAGGAGAAATG
CCCCTATCGTAACCTGGAGATAAAGTTTTTGTATAGATCAAGGCGTAGAAAAAGCAGTTTTTTTT
AATCAAACAATTTGCCTACATCTGTAGCGTTTGAGCTGTATGCGAAGAGAAATATTGCACACTG
CCAAACAACCGTATTTTGAAGGTTTGGGTGTAGATGTGACTAATGGATTTGTAATTTGGGATTAC
ACGAACCAAACCACTATACCGTAATACTGTTAAGGTATGTGCATATACAGACATAGAACCAAAT
GGCCTAATAGTCTGTATGATGATAGATATGGTGATTACCAGTCTTTTCTAGCTGCTGATAATGCT
GTTTTAGTTTCTACACAGTGTTACAAGCGGTATTGCTATGTAGAAATACCGTCAAACCTGCTTGT
CAGAACGGTATTCGGTAAAAGATGGAGCGAACCTGTATGTTTATAAGCGTGTAAATGGTGCGTTT
GTTACGCTACCTAACACAATAAACACACAGGGTCGAAGTTATGAACTTTTGAACCTCGTAGTGAT
GTTGAGCGTGATTTTCTCGACATGTCTGAGGAGAGTTTGTAGAAAAGTATGGTAAAGAATTAGGT
CTACAGCACATACTGTATGGTGAAGTTGATAAGCCCAATTAGGTGGTTTCCACACTGTTATAGGT
ATGTGCAGACTTTTACGTGCGAATAAGTTGAACGCAAAGTCTGTTACTAATCTGATTCTGATGTC
ATGCAAAATTATTTGTATTGGCAGACAATGGTTCTTACAAGCAAGTGTGACTGTTGTGGATTG
CTGCTTGATGATTTCTTAGAACTTCTTAGGAACATACTGAAAGAGTATGGTACTAATAAGTCTAAA
GTTGTAACAGTGTCAATTGATTACCATAGCATAAATTTATGACTTGGTTTGAAGATGGCATTATT
AAAACATGTTATCCACAGCTTCAA

(nsp-16 nucleotide sequence- nucleotides 19515-20423 of SEQ ID NO: 1)
SEQ ID NO: 5
TCAGCATGGACGTGTGGTTATAATATGCCTGAACTTTATAAAGTTCAGAATGTGTTATGGAACCT
TGCAACATTCTTAATTATGGTGTGGAATAGCGTTGCCAAGTGGTATTATGATGAATGTGGCAAAG
TATACACAACCTCTGTCAATACCTTTGAAAACAACAATGTGTGTACCGCATAATATGCGAGTAATG
CATTTTGGAGCTGGAAGTGACAAAGGAGTGGTGCCAGGTAGTACTGTTCTTAAACAATGGCTCCCA
GAAGGGACACTCCTTGTGATAATGATATTGTAGACTATGTGTCTGATGCACATGTTCTGTGCTT
TCAGATTGCAATAAATATAAGACAGAGCACAAAGTTTGATCTTGTGATATCTGATATGTATACAGAC
AATGATTCAAAAAGAAAGCATGAAGGCGTGATAGCCAATAATGGCAATGATGACGTTTTTCATATAT
CTCTCAAGTTTTCTTCGTAATAATTTGGCTCTAGGTGGTAGTTTTGCTGTAAAAGTGACAGAGACA
AGTTGGCACGAAGTTTATATGACATTGCACAGGATTGTGCATGGTGGACAATGTTTTGTACAGCA
GTGAATGCCTCTTCTTCAAGCATTCTTGATTGGTGTAAATTATTTGGGTGCAAGTGAAAAGGTT
AAGGTTAGTGAAAAACGCTGCACGCAAATTATATATTTTGGAGGAATTGTAATTATTTACAAACC

-continued

TCTGCTTATAGTATATTTGACGTTGCTAAGTTTGATTTGAGATTGAAAGCAACGCCAGTTGTTAAT
 TTGAAACTGAACAAAAGACAGACTTAGTCTTTAATTTAATTAAGTGTGGTAAGTTACTGGTAAGA
 GATGTTGGTAACACCTCTTTTACTAGTGACTCTTTTGTGTGTACTATGTAG

(nsp-10 amino acid sequence)

SEQ ID NO: 6

SKGHETEEVDVAVGILSLCSFAVDPADTYCKYVAAGNQPLGNCVKMLTVKNGSGFAITSKPSPTPDQ
 DSYGGASVCLYCRAHIAHPGGAGNLDGRCQPKGSFVQIPTTEKDPVGFCLRNKVCTVCQCWIGYGC
 QCDSLRLQPKPSVQ

(nsp-14 amino acid sequence)

SEQ ID NO: 7

GTGLFKICNKEFSGVHPAYAVTTKALAATYKVNDELAALVNVEAGSEITYKHLISLLGFKMSVNVN
 GCHNMFITRDEAIRNVRGWVGFDEATHACGTNIGTNLPPQVGFSTGADFVVTPEGLVDTSIGNNF
 EPVNSKAPPGEQFNHLRALFKSAKPWHVVRPRIVQMLADNLCNVSDCVFVFWCHGLELTLTRYFV
 KIGKDQVCSGSRATTFNSHTQAYACWKHCLGDFVYNPLLVDIQQWGYSGNLQFNHDLHCNVHGH
 AHVASADAIMTRCLAINNAFCQDVNWDLTYPHIANEDEVNSSCRYLQRMVNLNACVDALKVNVVYDI
 GNPKGIKCVRGDLNFRFYDKNPVIVPNVKQFEYDYNQHKDKFADGLCMFWNCNVDCYPDNLVCRY
 DTRNLSVFNLPNCNGSLYVKNHAFHTPKFDRTSFRNLKAMPPFFYDSSPCETIQLDGVAQDLVSL
 ATKDCITKCNICGAVCKKKAQMYADFVTSYNAAVTAGFTFWVTNNFNPYNLWKSFSALQ

(nsp-15 amino acid sequence)

SEQ ID NO: 8

SIDNIAYNMYKGGHYDAIAGEMPTIVTGDVVFVIDQGVKAVFFNQITLPTSVAFELYAKRNIRTL
 PNNRILKGLGVDVTNGFVIWDTYNQTPLYRNTVKVCAYTDIEPNGLIVLYDDRYGDYQSFLAADNA
 VLVSTQCYKRYSYVEIPSNLLVQNGIPLKDGANLYVYKRVNGAFVTLPTNTLTQGRSYETFEPRSD
 VERDFLDMSEESFVEKYGKELGLQHILYGEVDKPKQLGGLHTVIGMCRLLRANKLNAKSVTNSDSV
 MQNYFVLADNGSYKQVCTVVDLLDDFLELLRNILKEYGTNKSQVTVSIDYHSINFMTWFEDGII
 KTCYPQLQ

(nsp-16 amino acid sequence)

SEQ ID NO: 9

SAWTCGYNMPELYKVNQNCVMEPCNIPNYGVGIALPSGIMMNVAKYTQLCQYLSKTTMCVPHNMRVM
 HFGAGSDKGAVPAGSTVLKQWLPEGTLLVDNDIVDYVSDAHVSVLSDCNKYKTEHKFDLVISDMYTD
 NDSKRKHEGVIANNGNDVFIYLSFSLRNALGGSFAVKVTETSWHEVLYDIAQDCAWWTMFCFA
 VNASSEAFVLGVNVLGASEKVIWSGKTLHANYIFWRNCNYLQTSAYSIFDVAKFDLRLKATPVVN
 LKTEQKTDLVFNLIKCGKLLVRDVGNTSFTSDSFVCTM

Reduced Pathogenicity

The live, attenuated coronavirus of the present invention comprises a variant replicase gene which causes the virus to have reduced pathogenicity compared to a coronavirus expressing the corresponding wild-type gene.

The term “attenuated” as used herein, refers to a virus that exhibits said reduced pathogenicity and may be classified as non-virulent. A live, attenuated virus is a weakened replicating virus still capable of stimulating an immune response and producing immunity but not causing the actual illness.

The term “pathogenicity” is used herein according to its normal meaning to refer to the potential of the virus to cause disease in a subject. Typically the pathogenicity of a coronavirus is determined by assaying disease associated symptoms, for example sneezing, snicking and reduction in tracheal ciliary activity.

The term “reduced pathogenicity” is used to describe that the level of pathogenicity of a coronavirus is decreased, lessened or diminished compared to a corresponding, wild-type coronavirus.

In one embodiment, the coronavirus of the present invention has a reduced pathogenicity compared to the parental M41-CK virus from which it was derived or a control coronavirus. The control coronavirus may be a coronavirus with a known pathogenicity, for example a coronavirus expressing the wild-type replicase protein.

The pathogenicity of a coronavirus may be assessed utilising methods well-known in the art. Typically, pathogenicity is assessed by assaying clinical symptoms in a subject challenged with the virus, for example a chicken.

As an illustration, the chicken may be challenged at 8-24 days old by nasal or ocular inoculation. Clinical symptoms, associated with IBV infection, may be assessed 3-10 days post-infection. Clinical symptoms commonly assessed to

determine the pathogenicity of a coronavirus, for example an IBV, include gasping, coughing, sneezing, snicking, depression, ruffled feathers and loss of tracheal ciliary activity.

The variant replicase of the present invention, when expressed in a coronavirus, may cause a reduced level of clinical symptoms compared to a coronavirus expressing a wild-type replicase.

For example a coronavirus expressing the variant replicase may cause a number of snicks per bird per minute which is less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20% or less than 10% of the number of snicks caused by a virus expressing the wild type replicase.

A coronavirus expressing a variant replicase according to the present invention may cause wheezing in less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20% or less than 10% of the number of birds in a flock infected with the a virus expressing the wild type replicase.

A coronavirus expressing a variant replicase according to the present invention may result in tracheal ciliary activity which is at least 60%, at least 70%, at least 80%, at least 90% or at least 95% of the level of tracheal ciliary activity in uninfected birds.

A coronavirus expressing a variant replicase according to the present invention may cause clinical symptoms, as defined in Table 2, at a lower level than a coronavirus expressing the wild type replicase.

TABLE 2

IBV severity limits based on clinical signs:

Snicking (sneezing)	}	IBV specific: Mild (N.B. Respiratory signs become apparent from 2-3 dpi if they are going to occur and can continue for up to 7d).
Nasal exudate		
Watery eyes		
Swollen infraorbital sinuses		
Rales (vibration in trachea or bronchi region)		
Hunched posture/depressed	}	Mild, if exceed 2d increase to moderate
Fluffed up feathers		
Eating and drinking less		
Drinking in excess: evident by fluid filled crop or measured water intake	—	IBV specific: Mild, if exceed 24h increase to moderate for a max of 2d. If still drinking in excess then kill by schedule 1 method.
Less active but still evade capture	}	Mild, if exceed 1d increase to moderate.
Weight loss		
Not eating or drinking		
Birds sit alone and does not evade capture	}	Moderate: birds at end point. Kill by schedule 1 method.
Severe respiratory distress: e.g. excessive gasping		
Snicking and/or rales for 7d in total		
Found dead	—	Severe: report to project license holder. Full post-mortem to be performed.

The variant replicase of the present invention, when expressed in a coronavirus, may cause the virus to replicate at non-pathogenic levels in ovo.

While developing vaccines to be administered in ovo to chicken embryos, attention must be paid to two points: the effect of maternal antibodies on the vaccines and the effect of the vaccines on the embryo. Maternal antibodies are known to interfere with active immunization. For example, vaccines with mild strains do not induce protective antibody

levels when administered to broiler chickens with maternal antibodies as these strains are neutralized by the maternal antibody pool.

Thus a viral particle must be sufficiently efficient at replicating and propagating to ensure that it is not neutralized by the maternally-derived antibodies against the virus. Maternally-derived antibodies are a finite pool of effective antibodies, which decrease as the chicken ages, and neutralization of the virus in this manner does not equate to the establishment of long-term immunity for the embryo/chick. In order to develop long-term immunity against the virus, the embryo and hatched chicken must develop an appropriate protective immune response which is distinct to the effect of the maternally-derived antibodies.

To be useful for in ovo vaccination, the virus must also not replicate and propagate at a level which causes it to be pathogenic to the embryo.

Reduced pathogenicity in terms of the embryo may mean that the coronavirus causes less reduction in hatchability compared to a corresponding, wild-type control coronavirus. Thus the term “without being pathogenic to the embryo” in the context of the present invention may mean “without causing reduced hatchability” when compared to a control coronavirus.

A suitable variant replicase may be identified using methods which are known in the art. For example comparative challenge experiments following in ovo vaccination of

embryos with or without maternally-derived antibodies may be performed (i.e. wherein the layer has or has not been vaccinated against IBV).

If the variant replicase enables the virus to propagate at a level which is too high, the embryo will not hatch or will not be viable following hatching (i.e. the virus is pathogenic to the embryo). A virus which is pathogenic to the embryo may kill the embryo.

If the variant replicase causes a reduction in viral replication and propagation which is too great, the virus will be

neutralised by the maternally-derived antibodies. Subsequent challenge of the chick with IBV will therefore result in the development of clinical symptoms (for example wheezing, snickering, loss of ciliary activity) and the onset of disease in the challenged chick; as it will have failed to develop effective immunity against the virus.

Variant

As used herein, the term 'variant' is synonymous with 'mutant' and refers to a nucleic acid or amino acid sequence which differs in comparison to the corresponding wild-type sequence.

A variant/mutant sequence may arise naturally, or may be created artificially (for example by site-directed mutagenesis). The mutant may have at least 70, 80, 90, 95, 98 or 99% sequence identity with the corresponding portion of the wild type sequence. The mutant may have less than 20, 10, 5, 4, 3, 2 or 1 mutation(s) over the corresponding portion of the wild-type sequence.

The term "wild type" is used to mean a gene or protein having a nucleotide or amino acid sequence which is identical with the native gene or protein respectively (i.e. the viral gene or protein).

Identity comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate % identity between two or more sequences. A suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (University of Wisconsin, U.S.A.; Devereux et al., 1984, Nucleic Acids Research 12:387). Examples of other software that can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al., 1999 *ibid*—Chapter 18), FASTA (Atschul et al., 1990, J. Mol. Biol., 403-410) and the GENWORKS suite of comparison tools, ClustalX (see Larkin et al. (2007) Clustal W and Clustal X version 2.0. Bioinformatics, 23:2947-2948). Both BLAST and FASTA are available for offline and online searching (see Ausubel et al., 1999 *ibid*, pages 7-58 to 7-60). However, for some applications, it is preferred to use the GCG Bestfit program. A new tool, called BLAST 2 Sequences is also available for comparing protein and nucleotide sequence (see FEMS Microbiol Lett 1999 174(2): 247-50; FEMS Microbiol Lett 1999 177(1): 187-8 and tatiana@ncbi.nlm.nih.gov).

The sequence may have one or more deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent molecule. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the activity is retained. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine, serine, threonine, phenylalanine, and tyrosine.

Conservative substitutions may be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

ALIPHATIC	Non-polar	G A P I L V
	Polar- uncharged	C S T M N Q

-continued

Polar- charged	D E K R
AROMATIC	H F W Y

The coronavirus of the present invention may comprise a variant replicase gene which encodes a protein which comprises a mutation compared to any one of SEQ ID NO: 6, 7, 8 or 9 which, when expressed in a coronavirus, causes the virus to have reduced pathogenicity compared to a coronavirus expressing the corresponding wild-type replicase.

The variant replicase gene may encode a protein which comprises at least one or more amino acid mutations in any combination of nsp-10, nsp-14, nsp-15 and nsp-16.

The variant replicase gene of the coronavirus of the present invention may encode a protein comprising a mutation as defined in the M41 mod sequences presented in FIG. 10.

The variant replicase gene of the coronavirus of the present invention may encode a protein which comprises one or more amino acid mutations selected from the list of:

- Pro to Leu at position 85 of SEQ ID NO: 6;
- Val to Leu at position 393 of SEQ ID NO: 7;
- Leu to Ile at position 183 of SEQ ID NO: 8;
- Val to Ile at position 209 of SEQ ID NO: 9.

The variant replicase gene of the coronavirus of the present invention may encode a protein which does not comprise a mutation in nsp-2, nsp-3, nsp-6 or nsp-13.

The variant replicase gene of the coronavirus of the present invention may encode a protein which does not comprise a mutation in nsp10 which corresponds to the threonine to isoleucine mutation caused by a mutation at nucleotide position 12,008 in the gene reported by Ammayappan et al. (Arch Virol (2009) 154:495-499).

Ammayappan et al (as above) reports the identification of sequence changes responsible for the attenuation of IBV strain Arkansas DPI. The study identified 17 amino acid changes in a variety of IBV proteins following multiple passages, approx. 100, of the virus in embryonated eggs. It was not investigated whether the attenuated virus (Ark DPI 101) is capable of replicating in the presence of maternally-derived antibodies against the virus in ovo, without being pathogenic to the embryo. Given that this virus was produced by multiple passage in SPF embryonated eggs, similar methodology for classical IBV vaccines, it is likely that this virus is pathogenic for embryos. The virus may also be sensitive to maternally-derived antibodies if the hens were vaccinated with a similar serotype.

The variant replicase gene of the coronavirus of the present invention may encode a protein which comprises any combination of one or more amino acid mutations provided in the list above.

The variant replicase gene may encode a protein which comprises the amino acid mutation Pro to Leu at position 85 of SEQ ID NO: 6.

The variant replicase gene may encode a protein which comprises the amino acid mutation Val to Leu at position 393 of SEQ ID NO: 7.

The variant replicase gene may encode a protein which comprises the amino acid mutation Leu to Ile at position 183 of SEQ ID NO: 8.

The variant replicase gene may encode a protein which comprises the amino acid mutation Val to Ile at position 209 of SEQ ID NO: 9.

41

The variant replicase gene may encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6, and Val to Leu at position 393 of SEQ ID NO: 7.

The variant replicase gene may encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6 and Val to Ile at position 183 of SEQ ID NO: 8.

The variant replicase gene may encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6 and Val to Ile at position 209 of SEQ ID NO: 9.

The variant replicase gene may encode a protein which comprises the amino acid mutations Val to Leu at position 393 of SEQ ID NO: 7 and Leu to Ile at position 183 of SEQ ID NO: 8.

The variant replicase gene may encode a protein which comprises the amino acid mutations Val to Leu at position 393 of SEQ ID NO: 7 and Val to Ile at position 209 of SEQ ID NO: 9.

The variant replicase gene may encode a protein which comprises the amino acid mutations Leu to Ile at position 183 of SEQ ID NO: 8 and Val to Ile at position 209 of SEQ ID NO: 9.

The variant replicase gene may encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6, Val to Leu at position 393 of SEQ ID NO: 7 and Val to Ile at position 183 of SEQ ID NO: 8.

The variant replicase gene may encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6 and Val to Ile at position 209 of SEQ ID NO: 9.

The variant replicase gene may encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6, Val to Leu at position 393 of SEQ ID NO: 7 and Val to Ile at position 209 of SEQ ID NO: 9.

The variant replicase gene may encode a protein which comprises the amino acid mutations Val to Leu at position 393 of SEQ ID NO: 7, Leu to Ile at position 183 of SEQ ID NO: 8 and Val to Ile at position 209 of SEQ ID NO: 9.

The variant replicase gene may encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6, Val to Leu at position 393 of SEQ ID NO: 7, Leu to Ile at position 183 of SEQ ID NO: 8 and Val to Ile at position 209 of SEQ ID NO: 9.

The variant replicase gene may also be defined at the nucleotide level.

For example the nucleotide sequence of the variant replicase gene of the coronavirus of the present invention may comprise one or more nucleotide substitutions within the regions selected from the list of: 11884-12318, 16938-18500, 18501-19514 and 19515-20423 of SEQ ID NO:1.

For example the nucleotide sequence of the variant replicase gene of the coronavirus of the present invention may comprise one or more nucleotide substitutions selected from the list of:

C to Tat nucleotide position 12137;
G to C at nucleotide position 18114;
T to A at nucleotide position 19047; and
G to A at nucleotide position 20139;
compared to the sequence shown as SEQ ID NO: 1.

As used herein, the term "substitution" is synonymous with the term mutation and means that the nucleotide at the identified position differs to that of the wild-type nucleotide sequence.

The nucleotide sequence may comprise any combination of the nucleotide substitutions selected from the list of:

42

C to Tat nucleotide position 12137;
G to Cat nucleotide position 18114;
T to A at nucleotide position 19047; and
G to A at nucleotide position 20139;

5 compared to the sequence shown as SEQ ID NO: 1.

The nucleotide sequence may comprise the substitution C12137T.

The nucleotide sequence may comprise substitution G18114C.

10 The nucleotide sequence may comprise the substitution T19047A.

The nucleotide sequence may comprise the substitution G20139A.

The nucleotide sequence may comprise the substitutions C12137T and G18114C.

15 The nucleotide sequence may comprise the substitutions C12137T and T19047A.

The nucleotide sequence may comprise the substitutions C12137T and G20139A.

20 The nucleotide sequence may comprise the substitutions G18114C and T19047A.

The nucleotide sequence may comprise the substitutions G18114C and G20139A.

The nucleotide sequence may comprise the substitutions T19047A and G20139A.

25 The nucleotide sequence may comprise the substitutions C12137T, G18114C and T19047A.

The nucleotide sequence may comprise the substitutions C12137T, T19047A and G20139A.

30 The nucleotide sequence may comprise the substitutions C12137T, G18114C and G20139A.

The nucleotide sequence may comprise the substitutions G18114C, T19047A and G20139A.

35 The nucleotide sequence may comprise the substitutions C12137T, G18114C, T19047A and G20139A.

The nucleotide sequence may not comprise a substitution which corresponds to the C12008T substitution reported by Ammayappan et al. (as above).

40 The nucleotide sequence may be natural, synthetic or recombinant. It may be double or single stranded, it may be DNA or RNA or combinations thereof. It may, for example, be cDNA, PCR product, genomic sequence or mRNA.

The nucleotide sequence may be codon optimised for production in the host/host cell of choice.

45 It may be isolated, or as part of a plasmid, virus or host cell.

Plasmid

A plasmid is an extra-chromosomal DNA molecule separate from the chromosomal DNA which is capable of replicating independently of the chromosomal DNA. They are usually circular and double-stranded.

Plasmids, or vectors (as they are sometimes known), may be used to express a protein in a host cell. For example a bacterial host cell may be transfected with a plasmid capable of encoding a particular protein, in order to express that protein. The term also includes yeast artificial chromosomes and bacterial artificial chromosomes which are capable of accommodating longer portions of DNA.

60 The plasmid of the present invention comprises a nucleotide sequence capable of encoding a defined region of the replicase protein. It may also comprise one or more additional coronavirus nucleotide sequence(s), or nucleotide sequence(s) capable of encoding one or more other coronavirus proteins such as the S gene and/or gene 3.

65 The plasmid may also comprise a resistance marker, such as the guanine xanthine phosphoribosyltransferase gene (gpt) from *Escherichia coli*, which confers resistance to

mycophenolic acid (MPA) in the presence of xanthine and hypoxanthine and is controlled by the vaccinia virus P7.5 early/late promoter.

Recombinant Vaccinia Virus

The present invention also relates to a recombinant vaccinia virus (rVV) comprising a variant replicase gene as defined herein.

The recombinant vaccinia virus (rVV) may be made using a vaccinia-virus based reverse genetics system.

In this respect, the present invention also provides a method for making a viral particle by:

- (i) transfecting a plasmid as described in the previous section into a host cell;
- (ii) infecting the host cell with a recombining virus comprising the genome of a coronavirus strain with a replicase gene;
- (iii) allowing homologous recombination to occur between the replicase gene sequences in the plasmid and the corresponding sequences in the recombining virus genome to produce a modified replicase gene;
- (iv) selecting for recombining virus comprising the modified replicase gene.

The term 'modified replicase gene' refers to a replicase gene which comprises a variant replicase gene as described in connection with the first aspect of the present invention. Specifically, the term refers to a gene which is derived from a wild-type replicase gene but comprises a nucleotide sequence which causes it to encode a variant replicase protein as defined herein.

The recombination may involve all or part of the replicase gene. For example the recombination may involve a nucleotide sequence encoding for any combination of nsp-10, nsp-14, nsp-15 and/or nsp-16. The recombination may involve a nucleotide sequence which encodes for an amino acid mutation or comprises a nucleotide substitution as defined above.

The genome of the coronavirus strain may lack the part of the replicase protein corresponding to the part provided by the plasmid, so that a modified protein is formed through insertion of the nucleotide sequence provided by the plasmid.

The recombining virus is one suitable to allow homologous recombination between its genome and the plasmid. The vaccinia virus is particularly suitable as homologous recombination is routinely used to insert and delete sequences for the vaccinia virus genome.

The above method optionally includes the step:

- (v) recovery of recombinant coronavirus comprising the modified replicase gene from the DNA from the recombining virus from step (iv).

Methods for recovering recombinant coronavirus, such as recombinant IBV, are known in the art (See Britton et al (2005) see page 24; and PCT/GB2010/001293).

For example, the DNA from the recombining virus from step (iv) may be inserted into a plasmid and used to transfect cells which express cytoplasmic T7 RNA polymerase. The cells may, for example be pre-infected with a fowlpox virus expressing T7 RNA polymerase. Recombinant coronavirus may then be isolated, for example, from the growth medium.

When the plasmid is inserted into the vaccinia virus genome, an unstable intermediate is formed. Recombinants comprising the plasmid may be selected for e.g. using a resistance marker on the plasmid.

Positive recombinants may then be verified to contain the modified replicase gene by, for example, PCR and sequencing.

Large stocks of the recombining virus including the modified replicase gene (e.g. recombinant vaccinia virus, (rVV) may be grown up and the DNA extracted in order to carry out step (v)).

Suitable reverse genetics systems are known in the art (Casais et al (2001) J. Virol 75:12359-12369; Casais et al (2003) J. Virol. 77:9084-9089; Britton et al (2005) J. Virological Methods 123:203-211; Armesto et al (2008) Methods in Molecular Biology 454:255-273).

Cell

The coronavirus may be used to infect a cell.

Coronavirus particles may be harvested, for example from the supernatant, by methods known in the art, and optionally purified.

The cell may be used to produce the coronavirus particle. Thus the present invention also provides a method for producing a coronavirus which comprises the following steps:

- (i) infection of a cell with a coronavirus according to the invention;
- (ii) allowing the virus to replicate in the cell; and
- (iii) harvesting the progeny virus.

The present invention also provides a cell capable of producing a coronavirus according to the invention using a reverse genetics system. For example, the cell may comprise a recombining virus genome comprising a nucleotide sequence capable of encoding the replicase gene of the present invention.

The cell may be able to produce recombinant recombining virus (e.g. vaccinia virus) containing the replicase gene.

Alternatively the cell may be capable of producing recombinant coronavirus by a reverse genetics system. The cell may express or be induced to express T7 polymerase in order to rescue the recombinant viral particle.

Vaccine

The coronavirus may be used to produce a vaccine. The vaccine may be a live attenuated form of the coronavirus of the present invention and may further comprise a pharmaceutically acceptable carrier. As defined herein, "pharmaceutically acceptable carriers" suitable for use in the invention are well known to those of skill in the art. Such carriers include, without limitation, water, saline, buffered saline, phosphate buffer, alcohol/aqueous solutions, emulsions or suspensions. Other conventionally employed diluents and excipients may be added in accordance with conventional techniques. Such carriers can include ethanol, polyols, and suitable mixtures thereof, vegetable oils, and injectable organic esters. Buffers and pH adjusting agents may also be employed. Buffers include, without limitation, salts prepared from an organic acid or base. Representative buffers include, without limitation, organic acid salts, such as salts of citric acid, e.g., citrates, ascorbic acid, gluconic acid, histidine-Hel, carbonic acid, tartaric acid, succinic acid, acetic acid, or phthalic acid, Iris, trimethanmine hydrochloride, or phosphate buffers. Parenteral carriers can include sodium chloride solution, Ringer's dextrose, dextrose, trehalose, sucrose, and sodium chloride, lactated Ringer's or fixed oils. Intravenous carriers can include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose and the like. Preservatives and other additives such as, for example, antimicrobials, antioxidants, chelating agents (e.g., EDTA), inert gases and the like may also be provided in the pharmaceutical carriers. The present invention is not limited by the selection of the carrier. The preparation of these pharmaceutically acceptable compositions, from the above-described components, having appropriate pH isotonicity, stability and other conventional char-

acteristics is within the skill of the art. See, e.g., texts such as Remington: The Science and Practice of Pharmacy, 20th ed, Lippincott Williams & Wilkins, pub!., 2000; and The Handbook of Pharmaceutical Excipients, 4.sup.th edit., eds. R. C. Rowe et al, APhA Publications, 2003.

The vaccine of the invention will be administered in a “therapeutically effective amount”, which refers to an amount of an active ingredient, e.g., an agent according to the invention, sufficient to effect beneficial or desired results when administered to a subject or patient. An effective amount can be administered in one or more administrations, applications or dosages. A therapeutically effective amount of a composition according to the invention may be readily determined by one of ordinary skill in the art. In the context of this invention, a “therapeutically effective amount” is one that produces an objectively measured change in one or more parameters associated Infectious Bronchitis condition sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations. For purposes of this invention, an effective amount of drug, compound, or pharmaceutical composition is an amount sufficient to reduce the incidence of Infectious Bronchitis. As used herein, the term “therapeutic” encompasses the full spectrum of treatments for a disease, condition or disorder. A “therapeutic” agent of the invention may act in a manner that is prophylactic or preventive, including those that incorporate procedures designed to target animals that can be identified as being at risk (pharmacogenetics); or in a manner that is ameliorative or curative in nature; or may act to slow the rate or extent of the progression of at least one symptom of a disease or disorder being treated.

The present invention also relates to a method for producing such a vaccine which comprises the step of infecting cells, for example Vero cells, with a viral particle comprising a replicase protein as defined in connection with the first aspect of the invention.

Vaccination Method

The coronavirus of the present invention may be used to treat and/or prevent a disease.

To “treat” means to administer the vaccine to a subject having an existing disease in order to lessen, reduce or improve at least one symptom associated with the disease and/or to slow down, reduce or block the progression of the disease.

To “prevent” means to administer the vaccine to a subject who has not yet contracted the disease and/or who is not showing any symptoms of the disease to prevent or impair the cause of the disease (e.g. infection) or to reduce or prevent development of at least one symptom associated with the disease.

The disease may be any disease caused by a coronavirus, such as a respiratory disease and and/or gastroenteritis in humans and hepatitis, gastroenteritis, encephalitis, or a respiratory disease in other animals.

The disease may be infectious bronchitis (IB); Porcine epidemic diarrhoea; Transmissible gastroenteritis; Mouse hepatitis virus; Porcine haemagglutinating encephalomyelitis; Severe acute respiratory syndrome (SARS); or Bluecomb disease.

The disease may be infectious bronchitis.

The vaccine may be administered to hatched chicks or chickens, for example by eye drop or intranasal administration. Although accurate, these methods can be expensive e.g. for large broiler flocks. Alternatives include spray inoculation of administration to drinking water but it can be difficult to ensure uniform vaccine application using such methods.

The vaccine may be provided in a form suitable for its administration, such as an eye-dropper for intra-ocular use.

The vaccine may be administered by in ovo inoculation, for example by injection of embryonated eggs. In ovo vaccination has the advantage that it provides an early stage resistance to the disease. It also facilitates the administration of a uniform dose per subject, unlike spray inoculation and administration via drinking water.

The vaccine may be administered to any suitable compartment of the egg, including allantoic fluid, yolk sac, amnion, air cell or embryo. It may be administered below the shell (aircell) membrane and chorioallantoic membrane.

Usually the vaccine is injected into embryonated eggs during late stages of embryonic development, generally during the final quarter of the incubation period, such as 3-4 days prior to hatch. In chickens, the vaccine may be administered between day 15-19 of the 21-day incubation period, for example at day 17 or 18.

The process can be automated using a robotic injection process, such as those described in WO 2004/078203.

The vaccine may be administered together with one or more other vaccines, for example, vaccines for other diseases, such as Newcastle disease virus (NDV). The present invention also provides a vaccine composition comprising a vaccine according to the invention together with one or more other vaccine(s). The present invention also provides a kit comprising a vaccine according to the invention together with one or more other vaccine(s) for separate, sequential or simultaneous administration.

The vaccine or vaccine composition of the invention may be used to treat a human, animal or avian subject. For example, the subject may be a chick, chicken or mouse (such as a laboratory mouse, e.g. transgenic mouse).

Typically, a physician or veterinarian will determine the actual dosage which will be most suitable for an individual subject or group of subjects and it will vary with the age, weight and response of the particular subject(s).

The composition may optionally comprise a pharmaceutically acceptable carrier, diluent, excipient or adjuvant. The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise as (or in addition to) the carrier, excipient or diluent, any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s), and other carrier agents that may aid or increase the delivery or immunogenicity of the virus.

The invention will now be further described by way of Examples, which are meant to serve to assist one of ordinary skill in the art in carrying out the invention and are not intended in any way to limit the scope of the invention.

EXAMPLES

Example 1—Generation of an IBV Reverse Genetics System Based on M41-CK

A M41-CK full-length cDNA was produced by replacement of the Beaudette cDNA in the Vaccinia virus reverse genetics system previously described in PCT/GB2010/001293 (herein incorporated by reference) with synthetic cDNA derived from the M41 consensus sequence.

The IBV cDNA within recombinant Vaccinia virus (rVV) rVV-BeauR-Rep-M41 structure described in Armesto, Cavanagh and Britton (2009). PLoS ONE 4(10): e7384. doi:10.1371/journal.pone.0007384, which consisted of the replicase derived from IBV Beaudette strain and the struc-

tural and accessory genes and 3' UTR from IBV M41-CK, was further modified by replacement of the Beaudette 5' UTR-Nsp2-Nsp3 sequence with the corresponding sequence from IBV M41-CK. The resulting IBV cDNA consisted of 5' UTR-Nsp2-Nsp3 from M41, Nsp4-Nsp16 from Beaudette and the structural and accessory genes and 3' UTR from M41. This cDNA was further modified by the deletion of the Beaudette Nsp4-Nsp16 sequence. The resulting cDNA, lacking Nsp4-16, was modified in four further steps in which the deleted Nsps were sequentially replaced with the corresponding sequences from M41-CK, the replacement cDNAs represented M41-CK Nsp4-8, Nsp9-12, Nsp12-14 and finally Nsp15-16. Each replacement cDNA contained approx. 500 nucleotides at the 5' end corresponding to the 3' most M41 sequence previously inserted and approx. 500 nucleotides at the 3' end corresponding to the M41 S gene sequence. This allowed insertion of the M41 cDNA sequence by homologous recombination and sequential addition of contiguous M41 replicase gene sequence. The synthetic cDNAs containing the M41-derived Nsp sequences were added by homologous recombination utilising the inventor's previous described transient dominant selection (IDS) system (see PCT/GB2010/001293). The M41-derived cDNAs containing sequence corresponding to the M41 Nsps-10, -14, -15 and -16 contained the modified amino acids at positions 85, 393, 183 and 209, respectively, as indicated in FIG. 10.

A full-length cDNA representing the genome of M41-CK was generated in Vaccinia virus representing the synthetic sequences. Two rIBVs, M41-R-6 and M41-R-12, were rescued and shown to grow in a similar manner as M41-CK (FIG. 1).

Example 2—Determining the Pathogenicity of Rescued M41 Viruses

The viruses rescued in Example 1 were used to infect 8-day-old specific pathogen free (SPF) chicks by ocular and nasal inoculation to test them for pathogenicity, as observed by clinical signs on a daily basis 3-7 days post-infection and for ciliary activity days 4 and 6 post-infection. Loss of ciliary activity is a well-established method for determining the pathogenicity of IBV. The two M41-R viruses were found to be apathogenic when compared to M41-CK though they did show some clinical signs in comparison to uninfected control chicks (FIG. 2) and some but inconsistent loss in ciliary activity (FIG. 3).

Thus, the M41-R molecular clones of M41-CK were not pathogenic when compared to the parental virus M41-CK.

The inventors identified several nucleotide differences in the M41-R compared to the M41-CK sequences. The majority of these were synonymous mutations, as the nucleotide change did not affect the amino acid sequence of the protein associated with the sequence. However, four non-synonymous mutations were identified in the IBV replicase gene specific to Nsp-10, Nsp-14, Nsp-15 and Nsp-16 components of the replicase gene, these mutations resulted in amino acid changes (Table 3).

TABLE 3

Non-Synonymous mutations identified in the Nsps of M41-R full-length genome			
Region of Replicase	Nucleotide position	Nucleotide Mutation	Amino Acid Change
Nsp10	12137	C→T	Pro→Leu
Nsp14	18114	G→C	Val→Leu

TABLE 3-continued

Non-Synonymous mutations identified in the Nsps of M41-R full-length genome			
Region of Replicase	Nucleotide position	Nucleotide Mutation	Amino Acid Change
Nsp15	19047	T→A	Leu→Ile
Nsp16	20139	G→A	Val→Ile

Example 3—Repair of M41-R rIBVs

In order to determine whether the identified mutations were responsible for the loss of pathogenicity associated with M41-R, the Nsp10 mutation was repaired and the mutations in Nsp-14, -15 & -16 were repaired and shown to grow in a similar manner as M41-CK (FIG. 9). The inventors thus generated the rIBVs, M41R-nsp10rep and M41R-nsp14, 15, 16rep, using synthetic cDNAs containing the correct nucleotides utilising the inventor's previous described (TDS) system (see PCT/GB2010/001293).

The rIBVs were assessed for pathogenicity in chicks as described previously. Both rIBVs showed increased pathogenicity when compared to M41-R but not to the level observed with M41-CK (FIGS. 4 and 5). M41R-nsp14, 15, 16rep gave more clinical signs and more reduction in ciliary activity than M41R-nsp10rep, overall these results indicated that the changes associated with the four Nsps appear to affect pathogenicity.

To determine the roles of the Nsps in pathogenicity the full-length cDNA corresponding to M41R-nsp10rep was used to repair the mutations in Nsps14, 15 & 16 using a synthetic cDNA containing the correct nucleotides utilising the TDS system.

The following rIBVs were produced:

M41R-nsp10, 15rep—M41-R with the mutations in Nsp-10 and Nsp-15 repaired

M41R-nsp10, 14, 15rep—M41-R with mutations in Nsp-10, -14 and -15 repaired

M41R-nsp10, 14, 16rep—M41-R with mutations in Nsp-10, -14 and -16 repaired

M41R-nsp10, 15, 16rep—M41-R with mutations in Nsp-10, -15 and -16 repaired

M41-K—All four mutations, Nsp-10, -14, -15 & -16 repaired in M41-R

The rIBVs were shown to grow in a similar manner as M41-CK (FIG. 9) and assessed for pathogenicity as described previously. M41-K (in which all four mutations had been repaired) resulted in clinical signs and 100% loss of ciliary activity (complete ciliostasis) by 4 days post-infection (FIGS. 6, 7 & 8). The other rIBVs demonstrated varying levels of pathogenicity, apart from M41R-nsp10, 15, 16rep, which was essentially apathogenic. These results confirmed that repair of all four Nsps restored pathogenicity to M41-R; again supporting the previous evidence that the mutations described in the four Nsps are implicated in attenuating M41-CK.

The inventors also generated rIBV M41R-nsp 10, 14 rep (nsp 10 and 14 are repaired, nsp 15 and 16 contain mutations) and rIBV M41R-nsp 10, 16 rep (nsp 10 and 16 are repaired, nsp 14 and 15 contain mutations) and assessed the pathogenicity of these viruses.

rIBV M41R-nsp 10, 14 rep less pathogenic than M41-K but caused around 50% ciliostasis on days 4-6 post-infection. rIBV M41R-nsp 10, 16 rep was almost apathogenic and caused no ciliostasis (see FIG. 11a-c).

Thus the genome associated with M41-R is a potential backbone genome for a rationally attenuated IBV.

Example 4—Vaccination/Challenge Study with M41-R

Candidate vaccine viruses were tested in studies in which fertilized chicken eggs were vaccinated in ovo at 18 days embryonation and in which the hatchability of the inoculated eggs was determined. The clinical health of the chickens was investigated and the chickens were challenged at 21 days of age with a virulent IB M41 challenge virus at $10^{3.65}$ EID₅₀ per dose.

Clinical signs were investigated after challenge protection by the vaccine and a ciliostasis test was performed at 5 days after challenge to investigate the effect of the challenge viruses on movement of the cilia and protection by the vaccine against ciliostasis (inhibition of cilia movement).

In Ovo Vaccination in Commercial Broiler Eggs

The design of the experiment is given in Table 4 and the clinical results are given in Table 5. Hatchability of the eggs inoculated with IB M41-R was good and chickens were healthy. IB M41-R protected against clinical signs after challenge in the broilers (placebo: 19/19 affected, IB M41-R: 3/18 affected and 1 dead). The results of the ciliostasis test are given in Table 6. IB M41-R generated protection against ciliostasis.

TABLE 4

Design of a hatchability, safety, efficacy study in commercial eggs							
Treatment	Description	EID ₅₀ ¹ per dose	Route of Admin	Day(s) of Admin	Day(s) of Challenge ²	End of Study	Nr. of eggs per treatment
T01	None	NA	NA	NA	NA	NA	30
T02	IB M41-R	10^4	In ovo	18 days	At 21 days	At 26	30
NTX	Saline	NA	In ovo	embryo- nation	of age, 20 chickens per group	days of age	30

¹Dose volume 0.1 ml, NA, not applicable.

² $10^{3.65}$ EID₅₀ per dose.

TABLE 5

Hatch percentages and clinical data before and after challenge in commercial chickens, for design see Table 1.						
Treatment	Hatch/ total	Vital/ total	Before challenge		After challenge	
			Deaths/ total	Symptoms/ total	Deaths/ total	Symptoms/ total
None	28/30	Euthanized directly after hatch for blood collection				
IB M41-R	28/30	28/28	1/20	0/19	1/19	3/18 ^{1, 7}
Saline	29/30	29/29	1/20	0/19	0/19	19/19 ^{1, 2, 3, 4, 5, 6, 7}

¹Disturbed respiratory system

²Whizzing

³Change of voice

⁴Breathing difficult

⁵Swollen intra-orbital sinuses

⁶Uneven growth

⁷Weak

TABLE 6

Results of the ciliostasis test after challenge, for design see Table 1.		
Treatment	Protected/total	Percentage protection
Saline	0/19	0%
IB M41R	5/18	28%

In Ovo Vaccination in Specific Pathogen-Free (SPF) Eggs

The design of the study in SPF eggs is given in Table 7 and is similar with the design of the studies with commercial broilers, but the vaccination dose for IB M41-R was higher, (10^5 EID₅₀ per dose).

The results (Table 8) show that the hatch percentage for IB M41-R hatch was low, and 19 of 40 hatched and the chicks were weak. Eight chicks died. The remaining 11 chickens were challenged and 11 of the chicks hatched from the eggs which had been inoculated with saline were challenged.

In the ciliostasis test after challenge it appeared that all chickens vaccinated in ovo with IB M41-R were protected, whereas none of the controls was protected, see Table 9.

TABLE 7

Design of a hatchability, safety, efficacy study in SPF eggs							
Treatment	Treatment Description	EID ₅₀ ¹ per dose	Route of Admin	Day of Admin	Day of Challenge ²	End of Study	Nr. of eggs per treatment
T01	IB M41-R	10 ⁵	In ovo	18 days embryo-nation	At 21 days of age	At 26 days of age	40
T04	Saline	NA	In ovo				40
NTX	NA	NA	NA		NA		10

¹Dose volume 0.1 ml, NA, not applicable.²Challenge dose 10^{3.3} EID₅₀ in 0.2 ml.

TABLE 8

Hatch percentages and clinical data before and after challenge in SPF chickens, for design see Table 7.						
Treatment	Hatch/total	Vital/total	Before challenge		After challenge	
			Deaths/total	Symptoms/total	Deaths/total	Symptoms/total
IB M41-R	19/40	11/40	8/40	weak	0	0
Saline	30/40	30/40	0	—	0	0
NA	9/10	9/10	0	—	—	—

TABLE 9

Results of the ciliostasis test after challenge, for design see Table 7.		
Treatment	Protected/total	Percentage protection
Saline	0/11	0%
IB M41R	11/11	100%

In conclusion, IB M41-R was safe in commercial eggs, generated protection against clinical signs and to an extent against ciliostasis.

In SPF eggs vaccinated with IB M41 R a relatively low number of chickens hatched. This may be due to the 10⁵ EID₅₀ per egg of IB M41-R used. This was 10-fold higher than the dose used in earlier studies in which there was a higher level of hatchability. The lower hatch percentages may also be caused by a particularly high susceptibility of

the batch of SPF eggs for viruses, as in other studies the level of embryo mortality was also higher that had previously been observed.

After challenge all surviving chickens after hatch were completely protected against ciliostasis. It is concluded that IB M41-R has great potential as vaccine to be administered in ovo.

All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology, virology or related fields are intended to be within the scope of the following claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 13

<210> SEQ ID NO 1

<211> LENGTH: 27500

<212> TYPE: DNA

<213> ORGANISM: Infectious bronchitis virus

<400> SEQUENCE: 1

```

acttaagata gatattaata tataatctatc acactagcct tgcgctagat ttccaactta      60
acaaaacgga cttaaataacc tacagctggg cctcataggt gttccattgc agtgcacttt      120
agtgccttgg atggcacctg gccacctgtc aggtttttgt tattaaaatc ttattgttgc      180
tggtatcact gcttgttttg ccgtgtctca cttatacat cgttgcttg ggctacctag      240
tatccagcgt cctaagggcg ccgtggctgg ttcgagtgcg aagaacctct gggtcatcta      300

```

-continued

gcggtaggcg ggtgtgtgga agtagcactt cagacgtacc ggttctgttg tgtgaaatac	360
ggggtcacct cccccacat acctctaagg gcttttgagc ctagcgttgg gctacgttct	420
cgcataaggt cggctatacg acgtttgtag ggggtagtgc caaacaaccc ctgaggtgac	480
aggttcttgt ggtgtttagt gagcagacat acaatagaca gtgacaacat ggcttcaagc	540
ctaaaacagg gagtatctcc caaactaagg gatgtcattc ttgtatccaa agacattcct	600
gaacaacttt gtgacgcttt gtttttctat acgtcacaca accctaagga ttacgtgat	660
gcttttgagc ttaggcagaa gtttgatcgt aatctgcaga ctgggaaaca gttcaaattt	720
gaaactgtgt gtggtctctt cctcttgaag ggagttgaca aaataacacc tggcgtecca	780
gcaaaagtct taaaagccac ttctaagttg gcagatttag aagacatctt tgggtgtctt	840
ccctttgcaa gaaaatatcg tgaacttttg aagacagcat gccagtggc tcttactgta	900
gaaacactgg atgctcgtgc acaactctt gatgaaattt ttgaccctac tgaaatactt	960
tggcttcagg tggcagcaaa aatccaagtt tcggctatgg cgatgcgcag gcttgttggg	1020
gaagtaactg caaaagtcac ggatgctttg ggctcaaata tgagtgtctt ttccagatt	1080
tttaacaac aaatagtcag aatttttcaa aaagcgctgg ctatttttga gaatgtgagt	1140
gaattaccac agcgtattgc agcacttaag atggcttttg ctaagtgtgc caagtccatt	1200
actgttgtgg ttatggagag gactctagtt gttagagagt tcgcaggaac ttgtcttgca	1260
agcattaatg gtgctgttgc aaaattcttt gaagaactcc caaatggttt catgggtgct	1320
aaaattttca ctacacttgc cttctttagg gaggtgcag tgaaaattgt ggataacata	1380
ccaaatgcac cgagaggcac taaagggttt gaagtcgttg gtaatgcca aggtacacaa	1440
gttgttgtgc gtggcatgcg aaatgactta acaactgctt accaaaaagc tgaaattcct	1500
gtggagtcag aaggttggtc tgcaattttg ggtggacatc tttgctatgt ctttaagagt	1560
ggtgatcgtc ttacgcggc acctctttca ggaaattttg cattgcatga tgtgcattgt	1620
tgtgagcgtg ttgtctgtct ttctgatggt gtaacaccgg agataaatga tggacttatt	1680
cttgacgcaa tctactcttc ttttagtgtc gcagaacttg tggcagccat taaaaggggt	1740
gaaccattta agtttctggg tcataaattt gtgtatgcaa aggatgcagc agtttctttt	1800
acattagcga aggtctgtac tattgcagat gttttgaagc tgtttcaatc agcgcgtgtg	1860
aaagtagaag atgtttggtc ttcacttact gaaaagtctt ttgaattctg gaggcttgca	1920
tatggaaaag tgcgtaatct cgaagaattt gtttaagactt gttttgttaa ggctcaaatg	1980
gcgatttgta ttttagcgac agtgcttgga gagggcattt ggcatcttgt ttcgcaagtc	2040
atctataaag tagtggtgtc ttttactaaa gttgttgact tttgtgaaaa atattggaaa	2100
ggtttttgtg cacagttgaa aagagctaag ctcattgtca ctgaaaccct ctgtgttttg	2160
aaaggagttg cacagcattg ttttcaacta ttgctggatg caatacagtt tatgtataaa	2220
agttttaaga agtgtgcact tggtagaatc catggagact tgctcttctg gaaaggagggt	2280
gtgcacaaaa ttattcaaga gggcgatgaa atttggtttg acgccattga tagtattgat	2340
gttgaagatc tgggtgttgt tcaagaaaaa ttgattgatt ttgatgtttg tgataatgtg	2400
acacttcag agaaccaacc cggtcatatg gttcaaactc aggatgacgg aaagaactac	2460
atgttcttcc gcttcaaaaa ggatgagaac atttattata caccaatgtc acagcttggt	2520
gctattaatg tggtttgcaa agcaggcggg aaaactgtca cctttggaga aactactgtg	2580
caagaaatac caccacctga tgttgtgtt attaaggtta gcattgagtg ttgtggtgaa	2640
ccatggaata caatcttcaa aaaggcttat aaggagccca ttgaagtaga gacagacctc	2700

-continued

acagttgaac aattgctctc tgtggtctat gagaaaatgt gtgatgatct caagctgttt	2760
cggaggctc cagaaccacc accatttgag aatgtcacac ttgttgataa gaatggtaaa	2820
gatttggatt gcataaaatc atgccatctg atctatcgtg attatgagag cgatgatgac	2880
atcgaggaag aagatgcaga agaattgac acggattcag gtgatgctga ggagtgtgac	2940
actaattcag aatgtgaaga agaagatgag gatactaaag tgttggctct tatacaagac	3000
cgggcaagta acaaatatcc tctgcctctt gatgatgatt atagcgtcta caatggatgt	3060
attgttcata aggacgctct cgatgttggt aatttaccat ctggtgaaga aaccttgtt	3120
gtcaataact gcttgaagg ggctgttaaa gctcttccgc agaaagttat tgatgttcta	3180
ggtgactggg gtgaggctgt tgatgcgcaa gaacaattgt gtcaacaaga atcaactcgg	3240
gtcatatctg agaaatcagt tgagggtttt actggtagtt gtgatgcaat ggctgaacaa	3300
gctattgttg aagagcagga aatagtagct gttgttgaac aaagtcagga ttagttgtt	3360
tttacacctg cagacctaga agttgttaaa gaaacagcag aagaggttga tgagtttatt	3420
ctcatctctg ctgtccctaa agaagaagt gtgtctcagg agaaagagga gccacagggt	3480
gagcaagagc ctaccctagt tgttaaagca caacgtgaga agaaggctaa aaagttcaaa	3540
gttaaaccag ctacatgtga aaaacccaaa ttttggagt acaaacatg tgtgggtgat	3600
ttggtgttg taattgccaa agcattggat gagtttaaag agttctgcat tgtaaacgct	3660
gcaaatgagc acatgtcgca tgggtgtggc gttgcaaagg caattgcaga cttttgtgga	3720
cgggactttg ttgaatatg cgcggactat gttaagaaac atgggtccaca gcaaaaactt	3780
gtcacacctt catttggtta aggcatccta tgtgtgaata atgtttagg acctcgccat	3840
ggagacagca acttgcgtga gaagcttgtt gctgcttaca agagtgttct ttaggtgga	3900
gtggttaact atgttgtgcc agttctctca tcagggtatt ttggtgtaga ttttaaaata	3960
tcaatagatg ctatgcgoga agcttttaaa ggttgtgcca tacgcgttct tttattttct	4020
ctgagtcaag aacacatoga ttatttogat gcaacttgta agcagaagac aatttatctt	4080
acggaggatg gtgttaaaata ccgctctgtt gttttaaac ctggtgatc tttgggtcaa	4140
tttgacagg tttttgcaag aaataaggta gtcttttcgg ctgatgatgt tgaggataaa	4200
gaaatcctct ttataccac aactgacaag actattcttg aatattatgg ttagatgcg	4260
caaaagtatg taacatatat gcaaacgctt gcgcagaaat gggatgttca atatagagac	4320
aattttgtta tattagatg gcgtgacgga aattgctgga ttagttcagc aatagttctc	4380
cttcaagctg ctaaaattag atttaaagg tttcttgacag aagcatgggc taaactgttg	4440
ggtggagatc ctacagactt tgttgcttgg tgttatgcaa gttgcaatgc taaagtaggt	4500
gatttttcag atgctaattg gcttttgcc aatttagcag aacattttga cgcagattac	4560
acaaatgcac ttcttaagaa gtgtgtgtcg tgcaattgtg gtgttaagag ttatgaactt	4620
aggggtcttg aagcctgtat tcagccagtt cgagcaccta atcttctaca ttttaaacg	4680
caatattcaa attgcccaac ctgtggtgca agtagtacgg atgaagtaat agaagcttca	4740
ttacggtact tattgctttt tgcactgat ggtcctgcta cagttgattg tgatgaaaat	4800
gctgtaggga ctgtgtttt cattggtct actaatagtg gccattgtta tacacaagcc	4860
gatgtaagg cttttgacaa tcttgctaag gatagaaaat ttggaaggaa gtcgccttac	4920
attacagcaa tgtatacacg tttttctctt aggagtgaat atccctact tgttgttgaa	4980
catagtaagg gtaaaagctaa agtagtaaaa gaagatgttt ctaacctgc tactagtctt	5040

-continued

aaagccagtt ttgacgatct tactgacttt gaacagtggg atgatagcaa catctatgag	5100
agtcttaaag tgcaggagac acctgataat cttgatgaat atgtgtcatt tacgacaaag	5160
gaagattcta agttgccact gacacttaaa gttagaggta tcaaatcagt tgttgacttt	5220
aggctaaagg atggtttttac ttataagtta acacctgata ctgatgaaaa ttcaaaaaca	5280
ccagtctact acccagtcctt ggattctatt agtcttaggg caatatgggt tgaaggcagt	5340
gctaattttg ttgttgggca tccaaattat tatagtaagt ctctccgaat tcccacgttt	5400
tgggaaaatg ccgagagcctt tgttaaaatg ggttataaaa ttgatgggtg aactatgggc	5460
ctttggcgtg cagaacacct taataaacct aatttgaga gaatttttaa cattgctaag	5520
aaagtatttg ttggatctag tgtgtttact acgcagtgtg gtaaaatact agttaagca	5580
gtacatacgt ttgccgataa agtaggtgat ggtgtagttc gcaatattac agatagaatt	5640
aagggctctt gtggattcac acgtggccat ttgaaaaga aaatgtccct acaatttcta	5700
aagacacttg tgttcttttt cttttatttc ttaaaggcta gtgctaagag tttagtctt	5760
agctataaga ttgtgttatg taagggtgtg ttgtctacct tacttatagt gtggtttata	5820
tacacaagta atccagtagt gtttactgga atacgtgtgc tagacttccct atttgaagg	5880
tctttatgtg gtccttataa tgactacgtt aaagattctt ttgatgtgtt acgctattgt	5940
gcaggtgatt ttacttgtcg tgtgtgttta catgatagag attcacttca tctgtacaaa	6000
catgcttata gcgtagaaca aatttataag gatgcagctt ctggcattaa ctttaattgg	6060
aattggcttt atttggctct tctaataatta ttgtttaagc cagtggcagg ttttgttatt	6120
atttgttatt gtgttaagta ttgtgtattg agttcaactg tgttgcaaac tgggttaggt	6180
tttctagatt gggtttgtaa aacagttttt acccatttta attttatggg agcgggattt	6240
tatttctggc tcttttataa gatatacgtt caagtgcac atatatgtta ctgtaaggat	6300
gtaacatgtg aagtgtgcaa gagagttgca cgcagcaaca ggcaagagg tagcgttgta	6360
gttggtagac gcaagcaaat agtgcagtgt tacactaatt ctggctataa cttttgtaag	6420
agacataatt ggtattgtag aaattgtgat gattatggtc accaaaatac atttatgtcc	6480
cctgaagttg ctggcgagct ttctgaaaag cttaagcgcc atgttaaacc tacagcatat	6540
gcttaccacg ttgtgtatga ggcattgctg gttgatgatt ttgttaattt aaaatataag	6600
gctgcaattc ctggttaagga taatgcatct tctgctgtta agtgtttcag tgttacagat	6660
tttttaaga aagctgtttt tcttaaggag gcattgaaat gtgaacaaat atctaagat	6720
ggttttatag tgtgtaatac acagagtgcg catgcactag aggaagcaaa gaatgcagcc	6780
gtctattatg cgcaatatct gtgtaagcca atacttatac ttgaccaggc actttatgag	6840
caattaatag tagagcctgt gtctaagagt gttatagata aagtgtgtag cattttgtct	6900
aatataatat ctgtagatac tgcagcttta aattataagg caggcacact tcgtgatgct	6960
ctgctttcta ttactaaaga cgaagaagcc gtagatatgg ctatcttctg ccacaatcat	7020
gaagtggaat aactgtgtga cggttttact aatgtgatac cgtcatatgg tatggacact	7080
gataagttga cacctcgtga tagagggttt ttgataaatg cagatgcttc tattgctaat	7140
ttaagagtca aaaatgctcc tccggtagta tggaagtttt ctgatcttat taaattgtct	7200
gacagttgcc ttaaatattt aatttcagct actgtcaagt caggagggtc tttctttata	7260
acaaagtctg gtgctaaaca agttattttct tgtcataccc agaaactgtt ggtagagaaa	7320
aaggcaggtg gtgttattaa taacactttt aaatgggtta tgagttgttt taaatggctt	7380
tttgtctttt atatactttt tacagcatgt tgtttgggtt actactatat ggagatgaat	7440

-continued

aaaagttttg	ttcaccccat	gtatgatgta	aactccacac	tgcattgtga	agggttcaaa	7500
gttatagaca	aaggtgttat	tagagagatt	gtgtcagaag	ataattgttt	ctctaataag	7560
tttgtaatt	ttgacgcctt	ttggggtaaa	tcatatgaaa	ataataaaaa	ctgtccaatt	7620
gttacagttg	ttatagatgg	tgacgggaca	gtagctgttg	gtgttcctgg	ttttgtatca	7680
tgggttatgg	atggtgttat	gtttgtgcat	atgacacaga	ctgatcgtag	accttggtac	7740
attcctacct	ggtttaatat	agaaattgtt	ggttacactc	aggattcaat	tatcactgag	7800
ggtagttttt	atacatctat	agcattattt	tctgctagat	gtttatat	aacagccagc	7860
aatacacctc	aattgtattg	ttttaatggc	gacaatgatg	cacctggagc	cttaccattt	7920
ggtagtatta	ttcctcatag	agtatacttc	caacctaagt	gtgttaggct	tatagttcca	7980
caacaaatag	tgcatacacc	ctacatagtg	aagtttgttt	cagacagcta	ttgtagaggt	8040
agtgtatgtg	agtatactaa	accaggttac	tgtgtgtcac	tagactccca	atgggttttg	8100
tttaatgatg	aatacattag	taaacctggc	gttttctgtg	gttctactgt	tagagaactt	8160
atgtttaata	tggttagtac	attccttact	ggtgtcaacc	ctaataatta	tattcagcta	8220
gcaactatgt	ttttaatact	agttgttatt	gtgttaattt	ttgcaatggg	tataaagttt	8280
caagtggttt	ttaaagctta	tgcgaccatt	gtgtttacaa	taatgttagt	ttgggttatt	8340
aatgcatttg	ttttgtgtgt	acatagttat	aatagtgttt	tagctgttat	attattagta	8400
ctctattgct	atgcacattt	ggttacaagt	cgcaatactg	ctataataat	gcattgttgg	8460
cttggtttta	cctttgggtt	aatagtacct	acatgggttg	cttggtgcta	tctgggattt	8520
attctttata	tgtacacacc	gttggttttc	tggtgttacg	gtactactaa	aaatactcgt	8580
aagttgtatg	atggcaacga	gtttgttggt	aattatgacc	ttgctgcgaa	gagcactttt	8640
gttattcgtg	gtactgaatt	tgtaagctt	acgaatgaga	taggtgataa	atttgaagcc	8700
tatctttctg	cgtatgctag	acttaataac	tattcaggca	ctggtagtga	gcaagattac	8760
ttgcaagctt	gtcgtgcatg	gttagcttat	gctttggacc	aatatagaaa	tagtggtgtt	8820
gaggttggtt	ataccccacc	gcgttactct	attggtgtta	gtagactaca	cgctgggttt	8880
aaaaaactag	tttctcctag	tagtgctgtt	gagaagtgca	ttgttagtgt	ctcttataga	8940
ggcaataatc	ttaatggact	gtggctgggt	gattctattt	actgccacg	ccatgtgtta	9000
ggtaagttta	gtggtgacca	gtgggtgac	gtactaaacc	ttgctaataa	tcatgagttt	9060
gaagttgtaa	ctcaaatagg	tgttactttg	aatgttgtca	gcaggcggct	taaaggagca	9120
gttttaattt	tacaaactgc	agttgccaat	gctgaaactc	ctaagtataa	gtttgttaaa	9180
gctaattgtg	gtgatagttt	cactatagct	tggtcttatg	gtggtacagt	tataggactt	9240
tacctgtgca	ctatgcgttc	taatggtagt	attagagcat	ctttctagc	aggagcctgt	9300
ggctcagttg	gttttaatat	agaaaagggt	gtagttaatt	tcttttatat	gcaccatctt	9360
gagttaccta	atgcattaca	cactggaact	gacctaatgg	gtgagtttta	tggtggttat	9420
gtagtgaag	aggttgcgca	aagagtgcc	ccagataatc	tagttactaa	caatattgta	9480
gcattggctc	atgcggcaat	tattagtgtt	aaagaaagta	gtttttcaca	acctaaatgg	9540
ttggagagta	ctactgtttc	tattgaagat	tacaataggt	gggctagtga	taatggtttt	9600
actccatttt	ccactagtac	tgtattact	aaattaagtg	ctataactgg	ggttgatgtt	9660
tgtaaaactc	ttcgacttat	tatggtaaaa	agtgctcaat	ggggtagtga	tcccatttta	9720
ggacaatata	attttgaaga	cgaattgaca	ccagaatctg	tatttaataa	agttggtggt	9780

-continued

gtaggttac	agtcttcttt	tgtaagaaaa	gctacatctt	ggttttggag	tagatgtgta	9840
ttagcttgct	tcttgtttgt	gttggtgct	attgtcttat	ttacggcagt	gccacttaag	9900
ttttatgtac	atgcagctgt	tattttgttg	atggctgtgc	tctttatttc	ttttactgtt	9960
aaacatgtta	tggcatacat	ggacactttc	ctattgccta	cattgattac	agttattatt	10020
ggagtttggtg	ctgaagtcct	tttcatatac	aatactctaa	ttagtcaagt	tgttattttc	10080
ttaagccaat	ggtagatcc	tgtagtcttt	gatactatgg	taccatggat	gttattgcca	10140
ttagtggtgt	acactgcttt	taagtgtgta	caaggctgct	atatgaattc	tttcaatact	10200
tctttgttaa	tgctgtatca	gtttatgaag	ttaggttttg	ttattttcac	ctcttcaaac	10260
actcttactg	catatacaga	aggtaattgg	gagttattct	ttgagttggg	tcacactatt	10320
gtgttggtgta	atgtagtag	taattcctta	attggtttta	ttgtttttta	gtgtgctaag	10380
tggattttat	attattgcaa	tgcaacatac	tttaataatt	atgtgttaat	ggcagtcagt	10440
gttaatggca	taggctggct	ttgcacctgt	tactttggat	tgtattgggtg	ggtaataaaa	10500
gtttttggtt	taaccttagg	taaatacaat	tttaaagttt	cagtagatca	atataggtat	10560
atgtgtttgc	ataaggtaaa	tccacctaaa	actgtgtggg	aggtctttac	tacaaatata	10620
cttatacaag	gaattggagg	cgatcgtgtg	ttgcctatag	ctacagtgca	atctaaattg	10680
agtgatgtaa	agtgatcaac	tgtgttttta	atgcagcttt	tgactaagct	taatgttgaa	10740
gcaaattcaa	aaatgcctgc	ttatcttggt	gagttacaca	ataaaatcct	cgcactctgat	10800
gatgttggtg	agtgcatgga	taattttattg	ggtatgctta	taacactatt	ttgtatagat	10860
tctactattg	atttgggtga	gtattgtgat	gatatactta	agaggtcaac	tgtattacaa	10920
tcggttactc	aagagttttc	gcacataccc	tcgtatgctg	aatatgaaag	agctaagagt	10980
atttatgaaa	aggttttagc	cgattctaaa	aatggtgggtg	taacacagca	agagcttgct	11040
gcataatcgt	aagctgcaa	tattgcaaag	tcagtttttg	atagagactt	ggctgttcaa	11100
aagaagttag	atagcatggc	agaacgtgct	atgacaacaa	tgtataaaga	ggcgcgtgta	11160
actgatagaa	gagcaaaatt	agtttcatca	ttacatgcac	tacttttttc	aatgcttaag	11220
aaaatagatt	ctgagaagct	taatgtctta	tttgaccagg	cgaatagtgg	tgttgtacct	11280
ctagcaactg	ttccaattgt	ttgtagtaat	aagcttacct	ttgttatacc	agaccagag	11340
acgtgggtca	agtggtgga	gggtgtgcat	gttacatatt	caacagttgt	ttggaatata	11400
gactgtgtta	ctgatgcga	tggcacagag	ttacacccca	cttctacagg	tagtggttg	11460
acttactgta	taagtgtgta	taatatagca	tggcctttta	aggtaactt	gactaggaat	11520
gggcataata	aggttgatgt	tgccttgcaa	aataatgagc	ttatgcctca	cgggtgtaaag	11580
acaaaggctt	gcgtagcagg	tgtagatcaa	gcacattgta	gcgttgagtc	taaatgttat	11640
tatacaagta	ttagtggtg	ttcagttgta	gctgctatta	cctcttcaaa	tcctaactctg	11700
aaagtagcct	cttttttgaa	tgaggcagg	aatcagattt	atgtagactt	agaccacca	11760
tgtaaatttg	gtatgaaagt	gggtgataag	gttgaagttg	ttacctgta	ttttataaaa	11820
aatacaggtg	ctattgtgaa	aggtatggta	cttggtgcta	tatctaattg	tgttggtgta	11880
caatctaaag	gtcatgagac	agaggaagtg	gatgctgtag	gcattctctc	actttgttct	11940
tttgagtag	atcctgcgga	tacatattgt	aaatatgtgg	cagcaggtaa	tcaaccttta	12000
ggtaactgtg	ttaaaatgtt	gacagtacat	aatggtagtg	gttttgcaat	aacatcaaa	12060
ccaagtccaa	ctccggatca	ggattcttat	ggaggagctt	ctgtgtgtct	ttattgtaga	12120
gcacatatag	cacacctg	cggagcagga	aatttagatg	gacgtgtca	atttaaagg	12180

-continued

```

tcttttgtgc aaatacctac tacggagaaa gatcctgttg gattctgtct acgtaacaag 12240
gtttgcactg tttgtcagtg ttggattggg tatggatgtc agtgtgattc acttagacaa 12300
cctaaacctt ctgttcagtc agttgtctgtt gcctctggtt ttgataagaa ttattttaa 12360
gggtacgggg tagcagtgag gctcggctga taccctagc taatggatgt gaccccgatg 12420
ttgtaaagcg agcctttgat gtttgaata aggaatcagc cggatgtttt caaaatttga 12480
agcgtaaactg tgcacgattc caagaagtac gtgatactga agatggaaat cttgagtatt 12540
gtgattctta ttttgtgggt aaacaaacca ctccctagtaa ttatgaacat gagaaagctt 12600
gttatgaaga cttaaagtca gaagtaacag ctgatcatga tttctttgtg ttcaataaga 12660
acatttataa tatttagtagg cagaggctta ctaagtatac tatgatggat ttttgctatg 12720
ctttgcggca ctttgaccca aaggattgag aagttcttaa agaaatactt gtcacttatg 12780
gttgatataga agattatcac cctaagtggg ttgaagagaa taaggattgg tacgacccaa 12840
tagaaaaacc taaatattat gccatgttgg ctaaaatggg acctattgta cgacgtgctt 12900
tattgaatgc tattgagttc ggaacacctca tgggtgaaaa aggttatgtt ggtgttatta 12960
cacttgataa ccaagatctt aatggcaaat tttatgattt tgggtgattt cagaagacag 13020
cgcctggtgc tgggtgtcct gtttttgata cgtattatct ttacatgatg cccatcatag 13080
ccatgactga tgcgttgcca cctgagaggt attttgaata tgatgtgcat aagggttata 13140
aatcttatga tctcctcaag tatgattata ctgaggagaa acaagatttg ttcagaagt 13200
actttaagta ttgggatcaa gagtatcacc ctaactgtcg cgactgtagt gatgacaggt 13260
gtttgatata ttgtgcaaac ttcaacatct tgttttctac acttgtagcg cagacttctt 13320
tcggtaattt gtgtagaaag gtttttgttg atggtgtacc atttatagct acttgtggct 13380
atcattctaa ggaacttggg gttattatga atcaagataa caccatgtca ttttcaaaaa 13440
tgggttttag tcaactcatg cagtttgttg gagatcctgc cttgttagtg gggacatcca 13500
ataaattagt ggatcttaga acgtcttggt ttagtgtttg tgcttttagcg tctggtatta 13560
ctcatcaaac ggtaaaacca ggtcacttta acaaggattt ctacgatttt gcagagaagg 13620
ctggtagtgt taaggaaggg tctctatac cacttaaaaa tttctctac ccacagactg 13680
gtaatgctgc tataaacgat tatgattatt atcggtataa caggcctacc atgtttgata 13740
tacgtcaact tttattttgt ttagaagtga cttctaaata ttttgaatgt tatgaaggcg 13800
gctgtatacc agcaagccaa gttgtagtta acaatttaga taagagtga gggtatccgt 13860
tcaataagtt tggaaaggcc cgtctctatt atgaaatgag tctagaggag caggaccaac 13920
tctttgagag tacaagaag aacgtcctgc ctactataac tcagatgaat ttaaaatatg 13980
ccatattcgc gaaaaataga gcgcgtacag tggcaggtgt gtctatcctt tctactatga 14040
ctaataggca gtttcatcag aagattctta agtctatagt caacactaga aacgtcctg 14100
tagttattgg aacaaccaag ttttatggcg gttgggataa catgttgaga aaccttattc 14160
aggggtgtga agaccgatt cttatgggtt gggattatcc aaagtgtgat agagcaatgc 14220
ctaatttgtt gcgtatagca gcactcttag tactcgctcg taaacacact aattgttgta 14280
cttggtctga acgcgtttat aggttggtata atgaatgcgc tcagggttta tctgaaactg 14340
tcttagctac aggtgggtata tatgtgaaac ctggtggtac tagcagtgga gatgctacta 14400
ctgcttatgc aaacagtgtt ttcaacataa tacaagccac atctgcta atgttgccgctc 14460
ttttgagtgt tataacgcgt gatattgtat atgatgacat taagagcttg cagtatgaat 14520

```

-continued

tgtaccagca	ggtttatagg	cgagtcgaatt	ttgacccagc	atttgttgaa	aagttttatt	14580
cttatttgtg	taagaatttc	tcattgatga	tcttgtctga	cgacgggtgt	gtttgttata	14640
acaacacatt	agccaaacaa	ggctctgtag	cagatatttc	tggttttaga	gaagttctct	14700
actatcagaa	caatgttttt	atggctgatt	ctaaatgttg	ggttgaacca	gatttagaaa	14760
aaggccca	tgaattttgt	tcacagcaca	caatgttagt	ggaggttgat	ggtgagccta	14820
gatacttgcc	atatccagac	ccatcacgta	ttttgtgtgc	atgtgttttt	gtagatgatt	14880
tggataagac	agaatctgtg	gctgttatgg	agcgttatat	cgctcttgcc	atagatgcgt	14940
accactagt	acatcatgaa	aatgaggagt	acaagaaggt	attctttgtg	cttctttcat	15000
acatcagaaa	actctatcaa	gagctttctc	agaatatgct	tatggactac	tcttttgtaa	15060
tggatataga	taagggtagt	aaattttggg	aacaggagtt	ctatgaaaat	atgtatagag	15120
cccctacaac	attacagtct	tgtggcggtt	gtgtagtgtg	taatagtc	actatattgc	15180
gctgtggtaa	ttgtattcgc	aaaccatttt	tgtgttgtaa	gtgttgc	gtatgaccat	15240
tgcacacaga	ccacaaaaat	gttttgtcta	taaatcctta	catttgc	gcagccaggt	15300
gtggtgaagc	agatgttact	aaattgtacc	tcggaggtat	gtcactctc	tgccggaatc	15360
ataaacacaa	gttatcaata	cgttagtat	ctaattgtac	agtggttgga	atttacaggg	15420
ctaattgtgc	aggtagcgaa	aattgtgatg	attttaatca	actagctact	actaattggt	15480
ctactgtgga	accttatatt	ttggcaaatc	gttgtgtaga	ttcgttgaga	cgctttgctg	15540
cagagacagt	aaaagctaca	gaagaattac	ataagcaaca	atttgc	gtacagaggt	15600
gagaagtact	ctcagatcgt	gaattgattc	tgtcttgga	gccaggtaaa	accaggccctc	15660
cattgaatag	aaattatggt	ttcactggct	ttcactttac	tagaactagt	aaagttcagc	15720
tcggtgattt	tacatttgaa	aaagggtgaag	gtaaggacgt	tgtctattat	cgagcgacgt	15780
ctactgctaa	attgtctggt	ggagacattt	ttgttttaac	ctcacacaat	gttgtttctc	15840
ttatagcgcc	aacgttgtgt	cctcagcaaa	ccttttctag	gtttgtgaat	ttaagacct	15900
atgtgatggt	acctgcgtgt	tttgtaaaata	acattccatt	gtaccattta	gtaggcaagc	15960
agaagcgtac	tacagtacaa	ggccctcctg	gcagtggtaa	atcccatttt	gctataggat	16020
tggcggttta	cttttagtaac	gcccggtgctg	tttttactgc	atgctctcat	gcagctggtg	16080
atgctttatg	tgaaaaagct	tttaagtctc	ttaaagtaga	tgattgcact	cgtatagtag	16140
ctcaaaggac	tactatcgat	tgcttctcta	agtttaagc	taatgacaca	ggcaaaaagt	16200
acatttttag	tactattaat	gccttgccag	aagtttagttg	tgacattctt	ttgggtgacg	16260
aggttagtat	gttgaccaat	tacgaattgt	cttttattaa	tggttaagata	aactatcaat	16320
atgttgtgta	tgtagggtgat	cctgctcaat	taccggcgcc	tcgtacgttg	cttaacgggt	16380
cactctctcc	aaaggattat	aatgttgtca	caaaccttat	ggtttgtgtt	aaacctgaca	16440
ttttccttgc	aaagtgttac	cgttgtccta	aagaaattgt	agatactgtt	tctactcttg	16500
tatatgatgg	aaagtattat	gcaaataacc	cggaaatcacg	tcagtgtttc	aaggttatag	16560
ttaataatgg	taattctgat	gtaggacatg	aaagtggctc	agcctacaac	ataactcaat	16620
tagaatttgt	gaaagatttt	gtctgtcgca	ataaggaatg	gcgggaagca	acattcattt	16680
caccttataa	tgctatgaac	cagagagcct	accgtatgct	tggaactaat	gttcagacag	16740
tagactcgctc	tcaaggttcg	gagtatgatt	atgttatctt	ttgtgttact	gcagattcgc	16800
agcatgcact	gaatattaac	agattcaatg	tagcgtctac	aagagccaag	cgtggtatac	16860
tagttgtcat	gcgtcagcgt	gatgaactat	attcagctct	taagtttata	gagcttgata	16920

-continued

gtgtagcaag	tctgcaaggt	acaggcttgt	ttaaaatttg	caacaaagag	tttagtggtg	16980
ttcaccacagc	ttatgcagtc	acaactaagg	ctcttgctgc	aacttataaa	gttaatgatg	17040
aacttgctgc	acttgtaaac	gtggaagctg	gttcagaaat	aacatataaa	catcttattt	17100
ctttgttagg	gtttaagatg	agtgttaatg	ttgaaggctg	ccacaacatg	tttataaacac	17160
gtgatgaggc	tatccgcaac	gtaagagggt	gggtagggtt	tgatgtagaa	gcaacacatg	17220
cttgcggtac	taacattggg	actaacctgc	ctttccaagt	aggtttctct	actgggtgcag	17280
actttgtagt	tacgcctgag	ggacttgtag	atacttcaat	aggcaataat	tttgagcctg	17340
tgaattctaa	agcacctcca	ggggaacaat	ttaatcactt	gagagcggtta	ttcaaaagtg	17400
ctaaaccttg	gcattgttga	aggccaagga	ttgtgcaaat	gttagcggat	aacctgtgca	17460
acgtttcaga	ttgtgtagt	ttgtcacgt	gggtgcatgg	cctagaacta	accactttgc	17520
gctattttgt	taaaataggc	aaggaccaag	ttgttcttg	cggttctaga	gcaacaactt	17580
ttaattctca	tactcaggt	tatgcttgtt	ggaagcattg	cttgggtttt	gattttgttt	17640
ataatccact	cttagtggt	attcaacagt	gggtttatct	tggtaaccta	caatttaacc	17700
atgatttgca	ttgtaatgtg	catggacacg	cacatgtagc	ttctgcggat	gctattatga	17760
cgcgttgtct	tgcaattaat	aatgcatttt	gtcaagatgt	caactgggat	ttaacttacc	17820
ctcatatagc	aaatgaggat	gaagtcaatt	ctagctgtag	atattttaca	cgcatgtatc	17880
ttaatgcatg	tgttgatgct	cttaaagtta	acgttgctta	tgatataggc	aaccttaaag	17940
gtataaaatg	tgtagacgt	ggagacttaa	atttttagatt	ctatgataag	aatccaatag	18000
taccaaatgt	caagcagttt	gagtatgact	ataatcagca	caaagataag	ttgtctgatg	18060
gtctttgtat	gttttggaat	tgtaatgtgg	attgttatcc	cgacaattcc	ttagtttgta	18120
ggtagcacac	acgaaatttg	agtgtgttta	acctacctgg	ttgtaatggt	ggtagcttgt	18180
atgttaacaa	gcattgcattc	cacacacctc	aatttgatcg	cactagcttt	cgtaatttga	18240
aagctatgcc	attctttttc	tatgactcat	cgccttgcca	gaccattcaa	ttggatggag	18300
ttgcgcaaga	ccttggtgca	ttagctacga	aagattgtat	cacaaaatgc	aacataggcg	18360
gtgctgtttg	taaaaagcac	gcacaaatgt	atgcagattt	tgtgacttct	tataatgcag	18420
ctgttactgc	tggttttact	ttttgggtta	ctaataattt	taaccatata	aatttggtga	18480
aaagtttttc	agctctccag	tctatcgaca	atattgctta	taatatgtat	aagggtgggtc	18540
attatgatgc	tattgcagga	gaaatgccca	ctatcgtaac	tgagagataa	gtttttgtta	18600
tagatcaagg	cgtagaaaaa	gcagtttttt	ttaatcaaac	aattctgcct	acatctgtag	18660
cgtttgagct	gtatgcgaag	agaaatattc	gcacactgcc	aaacaaccgt	attttgaaag	18720
gtttgggtgt	agatgtgact	aatggatttg	taatttgga	ttacacgaac	caaaccaccac	18780
tataccgtaa	tactgttaag	gtatgtgcat	atacagacat	agaaccaa	ggcctaatag	18840
tgctgtatga	tgatagatat	gggtgattacc	agtcttttct	agctgctgat	aatgctgttt	18900
tagtttctac	acagtgttac	aagcgggtatt	cgtatgtaga	aataccgtca	aacctgcttg	18960
ttcagaacgg	tattccgtta	aaagatggag	cgaacctgta	tgttttataag	cgtgttaatg	19020
gtgcgtttgt	tacgtacct	aacacattaa	acacacaggg	tcgcagttat	gaaacttttg	19080
aacctcgtag	tgatgttgag	cgtgattttc	tcgacatgct	tgaggagagt	ttttagaaa	19140
agtatggtaa	agaattaggt	ctacagcaca	tactgtatgg	tgaagttgat	aagccccaat	19200
taggtgggtt	acacactggt	ataggatatgt	gcagactttt	acgtgcgaat	aagttgaacg	19260

-continued

caaagtctgt	tactaattct	gattctgatg	tcatgcaaaa	ttattttgta	tggcagaca	19320
atggttccta	caagcaagtg	tgtactgttg	tggatttgct	gcttgatgat	ttcttagaac	19380
ttcttaggaa	catactgaaa	gagtatggta	ctaataagtc	taaagttgta	acagtgtaa	19440
ttgattacca	tagcataaat	tttatgactt	ggtttgaaga	tggcattatt	aaaacatgtt	19500
atccacagct	tcaatcagca	tggacgtgtg	gttataatat	gcctgaactt	tataaagttc	19560
agaattgtgt	tatggaacct	tgcaacattc	ctaattatgg	tgttgaata	gcgttgccaa	19620
gtggtattat	gatgaatgtg	gcaaagtata	cacaactctg	tcaatacctt	tcgaaaacaa	19680
caatgtgtgt	accgcataat	atgcgagtaa	tgcatttttg	agctggaagt	gacaaaggag	19740
tggctccagg	tagtactgtt	cttaaacaa	ggctcccaga	agggacactc	ctgtcgata	19800
atgatattgt	agactatgtg	tctgatgcac	atgtttctgt	gctttcagat	tgcaataaat	19860
ataagacaga	gcacaagttt	gatcttgtga	tatctgatat	gtatacagac	aatgattcaa	19920
aaagaaagca	tgaaggcgtg	atagccaata	atggcaatga	tgacgttttc	atatatctct	19980
caagttttct	tcgtaataat	ttggctctag	gtggtagttt	tgctgtaaaa	gtgacagaga	20040
caagttggca	cgaagtttta	tatgacattg	cacaggattg	tgcattggtg	acaatgtttt	20100
gtacagcagt	gaatgcctct	tcttcagaag	cattcttggt	tggtgttaat	tatttgggtg	20160
caagtgtaaa	ggtaaggtt	agtggaaaa	cgctgcacgc	aaattatata	tttggagga	20220
attgtaatta	tttacaacc	tctgcttata	gtatatttga	cggtgctaag	tttgatttga	20280
gattgaaagc	aacaccagtt	gttaatttga	aaactgaaca	aaagacagac	ttagtcttta	20340
atttaattaa	gtgtggttaag	ttactggtaa	gagatgttgg	taacacctct	tttactagt	20400
actcttttgt	gtgtactatg	tagtgctgct	ttgtatgaca	gtagttctta	cgtttactac	20460
taccaaaagt	ccttttagacc	acctaattgt	tggcatttac	acgggggtgc	ttatgcggta	20520
gttaaatatt	ctagcgaatc	taataatgca	ggctcttcac	ctgggtgtat	tgttggtact	20580
attcatgggt	gtcgtgttgt	taatgcttct	tctatagcta	tgacggcacc	gtcatcaggt	20640
atggcttggt	ctagcagtea	gttttgtact	gcacactgta	acttttcaga	tactacagt	20700
tttgttacac	attgttataa	atatgatggg	tgctctataa	ctggcatgct	tcaaaagaat	20760
tttttacgtg	tttctgctat	gaaaaatggc	cagcttttct	ataatttaac	agttagtgt	20820
gctaagtacc	ctacttttaa	atcatttcag	tgtgttaata	atttaacatc	cgtatattta	20880
aatggtgatc	ttgtttacac	ctctaagag	accacagatg	ttacatctgc	aggtgtttat	20940
tttaaagctg	gtggacatat	aacttataaa	gttatgagag	aagttaaagc	cctggcttat	21000
tttgttaatg	gtactgcaca	agatgttatt	ttgtgtgatg	gatcacctag	aggcttggt	21060
gcatgccagt	ataaactgtg	caatttttca	gatggctttt	atccttttat	taatagtagt	21120
ttagttaaag	agaagtttat	tgtctatcgt	gaaaatagtg	ttaatactac	ttttacgtta	21180
cacaatttca	cttttcataa	tgagactggc	gcccaacccta	atcctagtg	tgttcagaat	21240
attcaaaact	accaaacaca	aacagctcag	agtgtgttatt	ataattttaa	tttttccttt	21300
ctgagtagtt	ttgtttataa	ggagtcta	tttatgtatg	gatcttatca	cccaagttgt	21360
aatttttagac	tagaaactat	taataatggc	ttgtgggtta	attcactttc	agtttcaatt	21420
gcttacggtc	ctcttcaagg	tgggtgcaag	caatctgtct	ttagtggtag	agcaacttgt	21480
tgttatgctt	attcatatgg	aggctcttcg	ctgtgtaaag	gtgtttatc	aggtgagtta	21540
gatcttaatt	ttgaatgtgg	actgttagtt	tatgttacta	agagcgggtg	ctctcgata	21600
caaacagcca	ctgaaccgcc	agttataact	cgacacaatt	ataataatat	tacttttaatt	21660

-continued

```

acttgtgttg attataatat atatggcaga actggccaag gttttattac taatgtaacc 21720
gactcagctg ttagttataa ttacttagca gacgcaggtt tggctatttt agatacatct 21780
ggttccatag acatctttgt tgtacaaggt gaatatggtc ttacttatta taaggttaac 21840
ccttgccaag atgtcaacca gcagtttgta gtttctggtg gtaaattagt aggtattcct 21900
acttcacgta atgagactgg ttctcagctt cttgagaacc agttttacat taaaatcact 21960
aatggaacac gtcgttttag acgttctatt actgaaaatg ttgcaaattg cccttatgtt 22020
agtatatgga agttttgtat aaaacctgat ggttcaattg ccacaatagt accaaaaaca 22080
ttggaacagt ttgtggcacc ttacttaat gttactgaaa atgtgctcat acctaacagt 22140
tttaatttaa ctgttacaga tgagtacata caaacgcgta tggataaggt ccaaattaat 22200
tgtctgcagt atgtttgttg caattctctg gattgtagag atttgtttca acaatatggg 22260
cctgtttgtg acaacatatt gtctgtagta aatagtattg gtcaaaaaga agatatggaa 22320
cttttgaatt tctattcttc tactaaaccg gctggtttta atacaccatt tcttagtaat 22380
gttagcactg gtgagtttaa tatttctctt ctgttaacaa ctctagtag tctagaagg 22440
cgttctttta ttgaagacct tctatttaca agcgttgaat ctgttgatt accaacagat 22500
gacgcataca aaaattgcac tgcaggacct ttaggttttc ttaaggacct tgcgtgtgct 22560
cgtgaatata atggtttgct tgtgttgctt cccattataa cagcagaaat gcaaattttg 22620
tatactagtt ctctagtagc ttctatggct ttggttggtta ttactgcagc tgggtgctata 22680
ccttttgcca cacaactgca ggctagaatt aatcacttgg gtattacca gtcacttttg 22740
ttgaagaatc aagaaaaaat tgetgcttcc tttaataagg ccattggtcg tatgcaggaa 22800
ggttttagaa gtacatctct agcattacaa caaattcaag atgttgtaa taagcagagt 22860
gctattctta ctgagactat ggcactcatt aataaaaaat ttggtgctat ttcttctatg 22920
attcaagaaa tctaccagca acttgacgcc atacaagcaa atgctcaagt ggatcgtctt 22980
ataactggta gattgtcatc actttctggt ttagcatctg ctaagcaggc ggagcatatt 23040
agagtgtcac aacagcgtga gttagctact cagaaaatta atgagtgtgt taagtcacag 23100
tctattaggt actccttttg tggtaatgga cgacatgttc taaccatacc gcaaatgca 23160
cctaattgga tagtgtttat acacttttct tatactccag atagttttgt taatgttact 23220
gcaatagtgg gtttttgtgt aaagccagct aatgctatgc agtatgcaat agtaccgct 23280
aatggtaggg gtatttttat acaagttaat ggtagtact acatcacagc acgagatatg 23340
tatatgcaa gagctattac tgcaggagat atagttacgc ttacttcttg tcaagcaaat 23400
tatgtaagtg taaataagac cgtcattact acattcgtag acaatgatga ttttgatgtt 23460
aatgacgaat tgtcaaaatg gtggaatgac actaagcatg agctaccaga ctttgacaaa 23520
ttcaattaca cagtacctat acttgacatt gatagtgaat ttgatcgtat tcaaggcgtt 23580
atacagggtc ttaatgactc tttaatagac cttgaaaaac tttcaatact caaaacttat 23640
attaagtggc cttggtatgt gtggttagcc atagcttttg ccaactattat ctcatctta 23700
atactaggat gggttttctt catgactgga tgttggtggt gttgttggtg atgctttggc 23760
attatgcctc taatgagtaa gtgtggttaag aaatcttctt attacacgac ttttgataac 23820
gatgtggtaa cttaacaata cagacctaaa aagtctgttt aatgattcaa agtcccacgt 23880
ccttcctaata agtattaatt tttctttggt gttaaactgt actaagttgt tttagagagt 23940
ttattatagc gctccaacaa ctaatacaag ttttactcca aattatcaat agtaacttac 24000

```

-continued

agcctagact	gaccctttgt	cacagctctag	actaatgtta	aacttagaag	caattattga	24060
aactggtgag	caagtgtatc	aaaaaatcag	tttcaattta	cagcatattt	caagtgtatt	24120
aaacacagaa	gtatttgacc	cctttgacta	ttgttattac	agaggaggta	atttttggga	24180
aatagagtca	gctgaagatt	gttcagggtga	tgatgaattt	attgaataag	tcgctagagg	24240
aaaatggaag	ttttctaaca	gcgcctttata	tattttagg	attttttagca	ctttatcttc	24300
taggtagagc	acttcaagca	ttgttacagg	ctgctgatgc	ttgttgttta	ttttggtata	24360
catgggtagt	aattccagga	gctaagggtga	cagcctttgt	atataagtat	acatatggta	24420
gaaaacttaa	caatccggaa	ttagaagcag	ttattgtcaa	cgagtcttct	aagaacgggt	24480
ggaataataa	aaatccagca	aattttcaag	atgtccaacg	agacaaattg	tactcttgac	24540
tttgaacagt	cagttgagct	ttttaagag	tataatttat	ttataactgc	attcttggtg	24600
ttcttaacca	taatacttca	gtatggctat	gcaacaagaa	gtaagtttat	ttatatactg	24660
aaaatgatag	tgttatgggtg	cttttggccc	cttaacattg	cagtaggtgt	aatttcatgt	24720
atatacccac	caaacacagg	aggtcttgtc	gcagcgataa	tacttacagt	gtttgcgtgt	24780
ctgtcttttg	taggttattg	gatccagagt	attagactct	ttaagcgggtg	taggtcatgg	24840
tggtcattta	accagaatc	taatgccgta	ggttcaatac	tcctaactaa	tggtcaacaa	24900
tgtaattttg	ctatagagag	tggtccaatg	gtgctttctc	caattataaa	gaatggtgtt	24960
ctttattgtg	agggtcagtg	gcttgctaag	tgtgaaccag	accacttgcc	taaagatata	25020
tttgtttgta	caccggatag	acgtaatatc	taccgtatgg	tcagaaata	tactggtgac	25080
caaagcggaa	ataagaaacg	gtttgctacg	tttgtctatg	caaagcagtc	agtagatact	25140
ggcgagctag	aaagtgtagc	aacaggagggtg	agtagtcttt	acacctaaat	gtgtgtgtgt	25200
agagagtatt	taaaattatt	ctttaatagt	gcctctattt	taagagcgca	taatagtatt	25260
atttttgagg	atattaatat	aaatcctctc	tgttttatatac	tctcttttca	agagctatta	25320
tttaaaaaac	agtttttcca	ctctttttgtg	ccaaaaacta	ttgttggttaa	tggtgtaacc	25380
tttcaagtag	ataatggaaa	agtcctactac	gaaggaaaac	caatttttca	gaaaggttgt	25440
tgtagggtgt	ggttgagtta	taaaaaagat	taaactacct	actacactta	tttttataag	25500
aggcggtttta	tcttacaagc	gcttaataaa	tacggacgat	gaaatggctg	actagttttg	25560
taagggcagt	tatttcatgt	tataaaccct	tattattaac	tcaattaaga	gtattagata	25620
ggttaatctt	agatcatgga	ccaaaacaca	tcttaacgtg	tgttaggtgc	gtgattttgt	25680
ttcaattaga	tttagtttat	aggttggcgt	atacgctac	tcaatcgctg	gtatgaataa	25740
tagtaaatag	aatccttttt	gcggagcaat	agcaagaaaa	gcgcgaattt	atctgagaga	25800
aggattagat	tgtgtttact	ttcttaacaa	agcaggacaa	gcagagtctt	gtcccgcgtg	25860
tacctctcta	gtattccagg	ggaaaacttg	tgaggaacac	aaatataata	ataatctttt	25920
gtcatggcaa	gcggtaaagg	aactggaaaag	acagatgccc	cagctccagt	catcaaaacta	25980
ggaggaccaa	agccacctaa	agttggttct	tctggaaatg	tatcttggtt	tcaagcaata	26040
aaagccaaga	agttaaatc	acctccgcct	aagtttgaag	gtagcggtgt	tcctgataat	26100
gaaaatctaa	aaccaagtca	gcagcatgga	tattggagac	gccaagctag	gtttaagcca	26160
ggtaaagggtg	gaagaaaacc	agtcacagat	gcttggtatt	tttactatac	tggaacagga	26220
ccagccgcta	acctgaattg	gggtgatagc	caagatggta	tagtgggtg	tgctggttaag	26280
ggtgctgata	ctaaatttag	atctaatacag	ggtactcgtg	actctgacaa	gtttgaccaa	26340
tatccgctac	ggttttcaga	cggaggacct	gatggtaatt	tccgttggtga	tttcattcct	26400

-continued

```

ctgaatcgtg gcaggagtgg gagatcaaca gcagcttcat cagcagcatc tagtagagca 26460
ccatcacgtg aagtttcgcg tggtcgcagg agtggttctg aagatgatct tattgctcgt 26520
gcagcaagga taattcagga tcagcagaag aagggttctc gcattacaaa ggctaaggct 26580
gatgaaatgg ctcaccgccc gtattgcaag cgcactattc cacctaatta taaggttgat 26640
caagtgtttg gtccccgtac taaaggtgaag gagggaaatt ttggtgatga caagatgaat 26700
gaggaaggta ttaaggatgg gcgcgttaca gcaatgctca acctagtccc tagcagccat 26760
gcttgctctt tcggaagtag agtgacgccc agacttcaac cagatgggct gcactgaaa 26820
tttgaattta ctactgtggt cccacgtgat gatccgcagt ttgataatta tgtaaaaatt 26880
tgtgatcagt gtgttgatgg ttaggaaca cgtccaaaag atgatgaacc aagaccaaa 26940
tcacgctcaa gttcaagacc tgcaacaaga ggaaattctc cagcgccaag acagcagcgc 27000
cctaagaagg agaaaaagcc aaagaagcag gatgatgaag tggataaagc attgacctca 27060
gatgaggaga ggaacaatgc acagctggaa ttgatgatg aaccaagggt aattaactgg 27120
ggggattcag ccctaggaga gaatgaactt tgagtaaat tcaatagtaa gagttaagga 27180
agataggcat gtagcttgat tacctacatg tctatcgcca gggaaatgct taatttgtct 27240
acttagtagc ctggaaaacga acggtagacc cttagatttt aatttagttt aatttttagt 27300
ttagtttaag ttagtttaga gtaggtataa agatgccagt gccggggcca cgcggagtac 27360
gaccgagggg acagcactag gacgcccatt aggggaagag ctaaatttta gtttaagtta 27420
agtttaattg gctatgtata gttaaaattt ataggctagt atagagttag agcaaaaaaa 27480
aaaaaaaaaa aaaaaaaaaa 27500

```

```

<210> SEQ ID NO 2
<211> LENGTH: 435
<212> TYPE: DNA
<213> ORGANISM: Infectious bronchitis virus

```

```

<400> SEQUENCE: 2

```

```

tctaaaggtc atgagacaga ggaagtggat gctgtaggca ttctctcact ttgttctttt 60
gcagtagatc ctgcggatag atattgtaaa tatgtggcag caggtaatca accttttagt 120
aactgtgtta aaatgttgac agtacataat ggtagtggtt ttgcaataac atcaaagcca 180
agtccaactc cggatcagga ttcttatgga ggagcttctg tgtgtcttta ttgtagagca 240
catatagcac accttgccgg agcaggaaat ttagatggac gctgtcaatt taaaggttct 300
tttgtgcaaa tacctactac ggagaaagat cctgttggtt tctgtctacg taacaagggt 360
tgcaactgtt gtcagtgttg gatttggtat ggatgtcagt gtgattcact tagacaacct 420
aaaccttctg ttcag 435

```

```

<210> SEQ ID NO 3
<211> LENGTH: 1563
<212> TYPE: DNA
<213> ORGANISM: Infectious bronchitis virus

```

```

<400> SEQUENCE: 3

```

```

ggtacaggct tgtttaaaat ttgcaacaaa gagtttagtg gtgttcaccc agcttatgca 60
gtcacaacta aggcctcttc tgcaacttat aaagttaatg atgaacttgc tgcacttgtt 120
aacgtggaag ctgggtcaga aataacatat aaacatctta tttctttggt aggggttaag 180
atgagtgtta atgttgaagg ctgccacaac atgtttataa cagtgatga ggctatccgc 240

```

-continued

aacgtaagag gttgggtagg ttttgatgta gaagcaacac atgcttgccg tactaacatt	300
ggtactaacc tgcctttcca agtaggtttc tctactggtg cagactttgt agttacgcct	360
gagggacttg tagatacttc aataggaat aattttgagc ctgtgaattc taaagcacct	420
ccaggtgaac aatttaata cttgagagcg ttattcaaaa gtgctaaacc ttggcatgtt	480
gtaaggccaa ggattgtgca aatggttagcg gataacctgt gcaacgttc agattgtgta	540
gtgtttgtca cgtgggtgca tggcctagaa ctaaccactt tgcgctattt tgttaaaata	600
ggcaaggacc aagtttggtc ttgcggttct agagcaacaa cttttaattc tcatactcag	660
gcttatgctt gttggaagca ttgcttgggt ttgatttttg tttataatcc actcttagtg	720
gatattcaac agtgggggta ttctggtaac ctacaattta accatgattt gcattgtaat	780
gtgcatggac acgcacatgt agcttctgcg gatgctatta tgacgcgttg tcttgcaatt	840
aataatgcat tttgtcaaga tgtcaactgg gatttaactt accctcatat agcaaatgag	900
gatgaagtc attctagctg tagatattta caacgcgtgt atcttaatgc atgtgttgat	960
gctcttaaag ttaacgttgt ctatgatata ggcaacccta aaggtattaa atgtgttaga	1020
cgtggagact taaatttttag attctatgat aagaatccaa tagtaccxaa tgtcaagcag	1080
tttgagtatg actataatca gcacaaagat aagtttgctg atggtctttg tatgttttgg	1140
aattgtaatg tggattgtta tcccgacaat tccttacttt gtaggtacga cacacgaaat	1200
ttgagtgtgt ttaacctacc tgggttgaat ggtggtagct tgtatgttaa caagcatgca	1260
ttccacacac ctaaatttga tcgcactagc ttctgtaatt tgaaagctat gccattcttt	1320
ttctatgact catgccttg cgagaccatt caattggatg gagttgcga agacctgtg	1380
tcattagcta cgaaagattg tatcacaaaa tgcaacatag gcggtgctgt ttgtaaaaag	1440
cacgcacaaa tgtatgcaga ttttgtagt tcttataatg cagctgttac tgcgtgtttt	1500
actttttggg ttactaataa ttttaacca tataatttgt ggaaaagttt ttcagctctc	1560
cag	1563

<210> SEQ ID NO 4

<211> LENGTH: 1014

<212> TYPE: DNA

<213> ORGANISM: Infectious bronchitis virus

<400> SEQUENCE: 4

tctatcgaca atattgctta taatatgtat aagggtggtc attatgatgc tattgcagga	60
gaaatgccca ctatcgtaac tggagataaa gtttttgta tagatcaagg cgtagaaaaa	120
gcagtttttt ttaatcaaac aattctgcct acatctgtag cgtttgagct gtatgcgaag	180
agaaatattc gcacactgcc aaacaaccgt attttgaaag gtttgggtgt agatgtgact	240
aatggatttg taattttgga ttacacgaac caaacaccac tataccgtaa tactgttaag	300
gtatgtgcat atacagacat agaaccatag ggcctaatag tgctgtatga tgatagatat	360
ggtgattacc agtcttttct agctgctgat aatgctgttt tagtttctac acagtgttac	420
aagcgggtatt cgtatgtaga aataccgtca aacctgcttg ttcagaacgg tattccgtta	480
aaagatggag cgaacctgta tgtttataag cgtgttaatg gtgcgtttgt tacgctacct	540
aacacaataa acacacaggg tcgaagttat gaaacttttg aacctcgtag tgatgttgag	600
cgtgattttc tcgacatgac tgaggagagt tttgtagaaa agtatggtaa agaattaggt	660
ctacagcaca tactgtatgg tgaagttgat aagccccaat tagtggtttt ccacactgtt	720
ataggtatgt gcagactttt acgtgcgaat aagttgaacg caaagtctgt tactaattct	780

-continued

115					120					125					
Gly	Tyr	Gly	Cys	Gln	Cys	Asp	Ser	Leu	Arg	Gln	Pro	Lys	Pro	Ser	Val
130					135					140					
Gln															
145															
<210> SEQ ID NO 7															
<211> LENGTH: 521															
<212> TYPE: PRT															
<213> ORGANISM: Infectious bronchitis virus															
<400> SEQUENCE: 7															
Gly	Thr	Gly	Leu	Phe	Lys	Ile	Cys	Asn	Lys	Glu	Phe	Ser	Gly	Val	His
1				5					10					15	
Pro	Ala	Tyr	Ala	Val	Thr	Thr	Lys	Ala	Leu	Ala	Ala	Thr	Tyr	Lys	Val
	20							25					30		
Asn	Asp	Glu	Leu	Ala	Ala	Leu	Val	Asn	Val	Glu	Ala	Gly	Ser	Glu	Ile
	35						40					45			
Thr	Tyr	Lys	His	Leu	Ile	Ser	Leu	Leu	Gly	Phe	Lys	Met	Ser	Val	Asn
	50					55					60				
Val	Glu	Gly	Cys	His	Asn	Met	Phe	Ile	Thr	Arg	Asp	Glu	Ala	Ile	Arg
65					70					75				80	
Asn	Val	Arg	Gly	Trp	Val	Gly	Phe	Asp	Val	Glu	Ala	Thr	His	Ala	Cys
			85					90						95	
Gly	Thr	Asn	Ile	Gly	Thr	Asn	Leu	Pro	Phe	Gln	Val	Gly	Phe	Ser	Thr
		100					105						110		
Gly	Ala	Asp	Phe	Val	Val	Thr	Pro	Glu	Gly	Leu	Val	Asp	Thr	Ser	Ile
	115						120					125			
Gly	Asn	Asn	Phe	Glu	Pro	Val	Asn	Ser	Lys	Ala	Pro	Pro	Gly	Glu	Gln
	130					135					140				
Phe	Asn	His	Leu	Arg	Ala	Leu	Phe	Lys	Ser	Ala	Lys	Pro	Trp	His	Val
145					150					155				160	
Val	Arg	Pro	Arg	Ile	Val	Gln	Met	Leu	Ala	Asp	Asn	Leu	Cys	Asn	Val
			165					170					175		
Ser	Asp	Cys	Val	Val	Phe	Val	Thr	Trp	Cys	His	Gly	Leu	Glu	Leu	Thr
	180							185					190		
Thr	Leu	Arg	Tyr	Phe	Val	Lys	Ile	Gly	Lys	Asp	Gln	Val	Cys	Ser	Cys
	195					200					205				
Gly	Ser	Arg	Ala	Thr	Thr	Phe	Asn	Ser	His	Thr	Gln	Ala	Tyr	Ala	Cys
	210					215					220				
Trp	Lys	His	Cys	Leu	Gly	Phe	Asp	Phe	Val	Tyr	Asn	Pro	Leu	Leu	Val
225				230						235				240	
Asp	Ile	Gln	Gln	Trp	Gly	Tyr	Ser	Gly	Asn	Leu	Gln	Phe	Asn	His	Asp
		245						250					255		
Leu	His	Cys	Asn	Val	His	Gly	His	Ala	His	Val	Ala	Ser	Ala	Asp	Ala
		260						265					270		
Ile	Met	Thr	Arg	Cys	Leu	Ala	Ile	Asn	Asn	Ala	Phe	Cys	Gln	Asp	Val
	275						280					285			
Asn	Trp	Asp	Leu	Thr	Tyr	Pro	His	Ile	Ala	Asn	Glu	Asp	Glu	Val	Asn
	290					295					300				
Ser	Ser	Cys	Arg	Tyr	Leu	Gln	Arg	Met	Tyr	Leu	Asn	Ala	Cys	Val	Asp
305					310					315				320	
Ala	Leu	Lys	Val	Asn	Val	Val	Tyr	Asp	Ile	Gly	Asn	Pro	Lys	Gly	Ile
			325					330						335	

-continued

Lys Cys Val Arg Arg Gly Asp Leu Asn Phe Arg Phe Tyr Asp Lys Asn
 340 345 350
 Pro Ile Val Pro Asn Val Lys Gln Phe Glu Tyr Asp Tyr Asn Gln His
 355 360 365
 Lys Asp Lys Phe Ala Asp Gly Leu Cys Met Phe Trp Asn Cys Asn Val
 370 375 380
 Asp Cys Tyr Pro Asp Asn Ser Leu Val Cys Arg Tyr Asp Thr Arg Asn
 385 390 395 400
 Leu Ser Val Phe Asn Leu Pro Gly Cys Asn Gly Gly Ser Leu Tyr Val
 405 410 415
 Asn Lys His Ala Phe His Thr Pro Lys Phe Asp Arg Thr Ser Phe Arg
 420 425 430
 Asn Leu Lys Ala Met Pro Phe Phe Phe Tyr Asp Ser Ser Pro Cys Glu
 435 440 445
 Thr Ile Gln Leu Asp Gly Val Ala Gln Asp Leu Val Ser Leu Ala Thr
 450 455 460
 Lys Asp Cys Ile Thr Lys Cys Asn Ile Gly Gly Ala Val Cys Lys Lys
 465 470 475 480
 His Ala Gln Met Tyr Ala Asp Phe Val Thr Ser Tyr Asn Ala Ala Val
 485 490 495
 Thr Ala Gly Phe Thr Phe Trp Val Thr Asn Asn Phe Asn Pro Tyr Asn
 500 505 510
 Leu Trp Lys Ser Phe Ser Ala Leu Gln
 515 520

<210> SEQ ID NO 8

<211> LENGTH: 338

<212> TYPE: PRT

<213> ORGANISM: Infectious bronchitis virus

<400> SEQUENCE: 8

Ser Ile Asp Asn Ile Ala Tyr Asn Met Tyr Lys Gly Gly His Tyr Asp
 1 5 10 15
 Ala Ile Ala Gly Glu Met Pro Thr Ile Val Thr Gly Asp Lys Val Phe
 20 25 30
 Val Ile Asp Gln Gly Val Glu Lys Ala Val Phe Phe Asn Gln Thr Ile
 35 40 45
 Leu Pro Thr Ser Val Ala Phe Glu Leu Tyr Ala Lys Arg Asn Ile Arg
 50 55 60
 Thr Leu Pro Asn Asn Arg Ile Leu Lys Gly Leu Gly Val Asp Val Thr
 65 70 75 80
 Asn Gly Phe Val Ile Trp Asp Tyr Thr Asn Gln Thr Pro Leu Tyr Arg
 85 90 95
 Asn Thr Val Lys Val Cys Ala Tyr Thr Asp Ile Glu Pro Asn Gly Leu
 100 105 110
 Ile Val Leu Tyr Asp Asp Arg Tyr Gly Asp Tyr Gln Ser Phe Leu Ala
 115 120 125
 Ala Asp Asn Ala Val Leu Val Ser Thr Gln Cys Tyr Lys Arg Tyr Ser
 130 135 140
 Tyr Val Glu Ile Pro Ser Asn Leu Leu Val Gln Asn Gly Ile Pro Leu
 145 150 155 160
 Lys Asp Gly Ala Asn Leu Tyr Val Tyr Lys Arg Val Asn Gly Ala Phe
 165 170 175
 Val Thr Leu Pro Asn Thr Leu Asn Thr Gln Gly Arg Ser Tyr Glu Thr
 180 185 190

-continued

Lys Thr Leu His Ala Asn Tyr Ile Phe Trp Arg Asn Cys Asn Tyr Leu
 225 230 235 240

Gln Thr Ser Ala Tyr Ser Ile Phe Asp Val Ala Lys Phe Asp Leu Arg
 245 250 255

Leu Lys Ala Thr Pro Val Val Asn Leu Lys Thr Glu Gln Lys Thr Asp
 260 265 270

Leu Val Phe Asn Leu Ile Lys Cys Gly Lys Leu Leu Val Arg Asp Val
 275 280 285

Gly Asn Thr Ser Phe Thr Ser Asp Ser Phe Val Cys Thr Met
 290 295 300

<210> SEQ ID NO 10
 <211> LENGTH: 145
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Mutated Nsp10 sequence

<400> SEQUENCE: 10

Ser Lys Gly His Glu Thr Glu Glu Val Asp Ala Val Gly Ile Leu Ser
 1 5 10 15

Leu Cys Ser Phe Ala Val Asp Pro Ala Asp Thr Tyr Cys Lys Tyr Val
 20 25 30

Ala Ala Gly Asn Gln Pro Leu Gly Asn Cys Val Lys Met Leu Thr Val
 35 40 45

His Asn Gly Ser Gly Phe Ala Ile Thr Ser Lys Pro Ser Pro Thr Pro
 50 55 60

Asp Gln Asp Ser Tyr Gly Gly Ala Ser Val Cys Leu Tyr Cys Arg Ala
 65 70 75 80

His Ile Ala His Leu Gly Gly Ala Gly Asn Leu Asp Gly Arg Cys Gln
 85 90 95

Phe Lys Gly Ser Phe Val Gln Ile Pro Thr Thr Glu Lys Asp Pro Val
 100 105 110

Gly Phe Cys Leu Arg Asn Lys Val Cys Thr Val Cys Gln Cys Trp Ile
 115 120 125

Gly Tyr Gly Cys Gln Cys Asp Ser Leu Arg Gln Pro Lys Pro Ser Val
 130 135 140

Gln
 145

<210> SEQ ID NO 11
 <211> LENGTH: 521
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Mutated Nsp14 sequence

<400> SEQUENCE: 11

Gly Thr Gly Leu Phe Lys Ile Cys Asn Lys Glu Phe Ser Gly Val His
 1 5 10 15

Pro Ala Tyr Ala Val Thr Thr Lys Ala Leu Ala Ala Thr Tyr Lys Val
 20 25 30

Asn Asp Glu Leu Ala Ala Leu Val Asn Val Glu Ala Gly Ser Glu Ile
 35 40 45

Thr Tyr Lys His Leu Ile Ser Leu Leu Gly Phe Lys Met Ser Val Asn
 50 55 60

Val Glu Gly Cys His Asn Met Phe Ile Thr Arg Asp Glu Ala Ile Arg

-continued

65					70						75					80
Asn	Val	Arg	Gly	Trp	Val	Gly	Phe	Asp	Val	Glu	Ala	Thr	His	Ala	Cys	
				85					90					95		
Gly	Thr	Asn	Ile	Gly	Thr	Asn	Leu	Pro	Phe	Gln	Val	Gly	Phe	Ser	Thr	
		100						105					110			
Gly	Ala	Asp	Phe	Val	Val	Thr	Pro	Glu	Gly	Leu	Val	Asp	Thr	Ser	Ile	
		115					120					125				
Gly	Asn	Asn	Phe	Glu	Pro	Val	Asn	Ser	Lys	Ala	Pro	Pro	Gly	Glu	Gln	
	130						135				140					
Phe	Asn	His	Leu	Arg	Ala	Leu	Phe	Lys	Ser	Ala	Lys	Pro	Trp	His	Val	
145					150					155					160	
Val	Arg	Pro	Arg	Ile	Val	Gln	Met	Leu	Ala	Asp	Asn	Leu	Cys	Asn	Val	
				165					170					175		
Ser	Asp	Cys	Val	Val	Phe	Val	Thr	Trp	Cys	His	Gly	Leu	Glu	Leu	Thr	
			180					185					190			
Thr	Leu	Arg	Tyr	Phe	Val	Lys	Ile	Gly	Lys	Asp	Gln	Val	Cys	Ser	Cys	
	195						200					205				
Gly	Ser	Arg	Ala	Thr	Thr	Phe	Asn	Ser	His	Thr	Gln	Ala	Tyr	Ala	Cys	
	210					215					220					
Trp	Lys	His	Cys	Leu	Gly	Phe	Asp	Phe	Val	Tyr	Asn	Pro	Leu	Leu	Val	
225				230						235					240	
Asp	Ile	Gln	Gln	Trp	Gly	Tyr	Ser	Gly	Asn	Leu	Gln	Phe	Asn	His	Asp	
				245					250					255		
Leu	His	Cys	Asn	Val	His	Gly	His	Ala	His	Val	Ala	Ser	Ala	Asp	Ala	
			260					265					270			
Ile	Met	Thr	Arg	Cys	Leu	Ala	Ile	Asn	Asn	Ala	Phe	Cys	Gln	Asp	Val	
	275						280					285				
Asn	Trp	Asp	Leu	Thr	Tyr	Pro	His	Ile	Ala	Asn	Glu	Asp	Glu	Val	Asn	
	290					295					300					
Ser	Ser	Cys	Arg	Tyr	Leu	Gln	Arg	Met	Tyr	Leu	Asn	Ala	Cys	Val	Asp	
305					310					315					320	
Ala	Leu	Lys	Val	Asn	Val	Val	Tyr	Asp	Ile	Gly	Asn	Pro	Lys	Gly	Ile	
				325					330					335		
Lys	Cys	Val	Arg	Arg	Gly	Asp	Leu	Asn	Phe	Arg	Phe	Tyr	Asp	Lys	Asn	
			340					345					350			
Pro	Ile	Val	Pro	Asn	Val	Lys	Gln	Phe	Glu	Tyr	Asp	Tyr	Asn	Gln	His	
	355						360					365				
Lys	Asp	Lys	Phe	Ala	Asp	Gly	Leu	Cys	Met	Phe	Trp	Asn	Cys	Asn	Val	
	370					375					380					
Asp	Cys	Tyr	Pro	Asp	Asn	Ser	Leu	Leu	Cys	Arg	Tyr	Asp	Thr	Arg	Asn	
385					390					395					400	
Leu	Ser	Val	Phe	Asn	Leu	Pro	Gly	Cys	Asn	Gly	Gly	Ser	Leu	Tyr	Val	
				405					410					415		
Asn	Lys	His	Ala	Phe	His	Thr	Pro	Lys	Phe	Asp	Arg	Thr	Ser	Phe	Arg	
				420					425				430			
Asn	Leu	Lys	Ala	Met	Pro	Phe	Phe	Phe	Tyr	Asp	Ser	Ser	Pro	Cys	Glu	
	435						440					445				
Thr	Ile	Gln	Leu	Asp	Gly	Val	Ala	Gln	Asp	Leu	Val	Ser	Leu	Ala	Thr	
	450					455					460					
Lys	Asp	Cys	Ile	Thr	Lys	Cys	Asn	Ile	Gly	Gly	Ala	Val	Cys	Lys	Lys	
465					470					475				480		
His	Ala	Gln	Met	Tyr	Ala	Asp	Phe	Val	Thr	Ser	Tyr	Asn	Ala	Ala	Val	
				485					490					495		

-continued

Thr Ala Gly Phe Thr Phe Trp Val Thr Asn Asn Phe Asn Pro Tyr Asn
 500 505 510

Leu Trp Lys Ser Phe Ser Ala Leu Gln
 515 520

<210> SEQ ID NO 12

<211> LENGTH: 338

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Mutated Nsp15 sequence

<400> SEQUENCE: 12

Ser Ile Asp Asn Ile Ala Tyr Asn Met Tyr Lys Gly Gly His Tyr Asp
 1 5 10 15

Ala Ile Ala Gly Glu Met Pro Thr Ile Val Thr Gly Asp Lys Val Phe
 20 25 30

Val Ile Asp Gln Gly Val Glu Lys Ala Val Phe Phe Asn Gln Thr Ile
 35 40 45

Leu Pro Thr Ser Val Ala Phe Glu Leu Tyr Ala Lys Arg Asn Ile Arg
 50 55 60

Thr Leu Pro Asn Asn Arg Ile Leu Lys Gly Leu Gly Val Asp Val Thr
 65 70 75 80

Asn Gly Phe Val Ile Trp Asp Tyr Thr Asn Gln Thr Pro Leu Tyr Arg
 85 90 95

Asn Thr Val Lys Val Cys Ala Tyr Thr Asp Ile Glu Pro Asn Gly Leu
 100 105 110

Ile Val Leu Tyr Asp Asp Arg Tyr Gly Asp Tyr Gln Ser Phe Leu Ala
 115 120 125

Ala Asp Asn Ala Val Leu Val Ser Thr Gln Cys Tyr Lys Arg Tyr Ser
 130 135 140

Tyr Val Glu Ile Pro Ser Asn Leu Leu Val Gln Asn Gly Ile Pro Leu
 145 150 155 160

Lys Asp Gly Ala Asn Leu Tyr Val Tyr Lys Arg Val Asn Gly Ala Phe
 165 170 175

Val Thr Leu Pro Asn Thr Ile Asn Thr Gln Gly Arg Ser Tyr Glu Thr
 180 185 190

Phe Glu Pro Arg Ser Asp Val Glu Arg Asp Phe Leu Asp Met Ser Glu
 195 200 205

Glu Ser Phe Val Glu Lys Tyr Gly Lys Glu Leu Gly Leu Gln His Ile
 210 215 220

Leu Tyr Gly Glu Val Asp Lys Pro Gln Leu Gly Gly Leu His Thr Val
 225 230 235 240

Ile Gly Met Cys Arg Leu Leu Arg Ala Asn Lys Leu Asn Ala Lys Ser
 245 250 255

Val Thr Asn Ser Asp Ser Asp Val Met Gln Asn Tyr Phe Val Leu Ala
 260 265 270

Asp Asn Gly Ser Tyr Lys Gln Val Cys Thr Val Val Asp Leu Leu Leu
 275 280 285

Asp Asp Phe Leu Glu Leu Leu Arg Asn Ile Leu Lys Glu Tyr Gly Thr
 290 295 300

Asn Lys Ser Lys Val Val Thr Val Ser Ile Asp Tyr His Ser Ile Asn
 305 310 315 320

Phe Met Thr Trp Phe Glu Asp Gly Ile Ile Lys Thr Cys Tyr Pro Gln
 325 330 335

-continued

Leu Gln

```

<210> SEQ ID NO 13
<211> LENGTH: 302
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Mutated Nsp16 sequence

<400> SEQUENCE: 13

Ser Ala Trp Thr Cys Gly Tyr Asn Met Pro Glu Leu Tyr Lys Val Gln
1          5          10          15

Asn Cys Val Met Glu Pro Cys Asn Ile Pro Asn Tyr Gly Val Gly Ile
20          25          30

Ala Leu Pro Ser Gly Ile Met Met Asn Val Ala Lys Tyr Thr Gln Leu
35          40          45

Cys Gln Tyr Leu Ser Lys Thr Thr Met Cys Val Pro His Asn Met Arg
50          55          60

Val Met His Phe Gly Ala Gly Ser Asp Lys Gly Val Ala Pro Gly Ser
65          70          75          80

Thr Val Leu Lys Gln Trp Leu Pro Glu Gly Thr Leu Leu Val Asp Asn
85          90          95

Asp Ile Val Asp Tyr Val Ser Asp Ala His Val Ser Val Leu Ser Asp
100         105         110

Cys Asn Lys Tyr Lys Thr Glu His Lys Phe Asp Leu Val Ile Ser Asp
115         120         125

Met Tyr Thr Asp Asn Asp Ser Lys Arg Lys His Glu Gly Val Ile Ala
130         135         140

Asn Asn Gly Asn Asp Asp Val Phe Ile Tyr Leu Ser Ser Phe Leu Arg
145         150         155         160

Asn Asn Leu Ala Leu Gly Gly Ser Phe Ala Val Lys Val Thr Glu Thr
165         170         175

Ser Trp His Glu Val Leu Tyr Asp Ile Ala Gln Asp Cys Ala Trp Trp
180         185         190

Thr Met Phe Cys Thr Ala Val Asn Ala Ser Ser Ser Glu Ala Phe Leu
195         200         205

Ile Gly Val Asn Tyr Leu Gly Ala Ser Glu Lys Val Lys Val Ser Gly
210         215         220

Lys Thr Leu His Ala Asn Tyr Ile Phe Trp Arg Asn Cys Asn Tyr Leu
225         230         235         240

Gln Thr Ser Ala Tyr Ser Ile Phe Asp Val Ala Lys Phe Asp Leu Arg
245         250         255

Leu Lys Ala Thr Pro Val Val Asn Leu Lys Thr Glu Gln Lys Thr Asp
260         265         270

Leu Val Phe Asn Leu Ile Lys Cys Gly Lys Leu Leu Val Arg Asp Val
275         280         285

Gly Asn Thr Ser Phe Thr Ser Asp Ser Phe Val Cys Thr Met
290         295         300

```

The invention claimed is:

1. A live, attenuated coronavirus comprising a variant replicase gene encoding polypeptides comprising a mutation in one or both of non-structural protein(s) nsp-10 and nsp-14, wherein the variant replicase gene encodes a protein comprising an amino acid mutation of Pro to Leu at the position corresponding to position 85 of SEQ ID NO: 6, and/or wherein the variant replicase gene encodes a protein

60 comprising an amino acid mutation of Val to Leu at the position corresponding to position 393 of SEQ ID NO: 7.

2. The coronavirus according to claim 1 wherein the variant replicase gene encodes a protein comprising one or more amino acid mutations selected from:

an amino acid mutation of Leu to Ile at the position corresponding to position 183 of SEQ ID NO: 8; and

95

an amino acid mutation of Val to Ile at the position corresponding to position 209 of SEQ ID NO: 9.

3. The coronavirus according to claim 1 wherein the replicase gene encodes a protein comprising the amino acid mutations Val to Leu at the position corresponding to position 393 of SEQ ID NO: 7; Leu to Ile at the position corresponding to position 183 of SEQ ID NO: 8; and Val to Ile at the position corresponding to position 209 of SEQ ID NO: 9.

4. The coronavirus according to claim 1 wherein the replicase gene encodes a protein comprising the amino acid mutations Pro to Leu at the position corresponding to position 85 of SEQ ID NO: 6; Val to Leu at the position corresponding to position 393 of SEQ ID NO: 7; Leu to Ile at the position corresponding to position 183 of SEQ ID NO: 8; and Val to Ile at the position corresponding to position 209 of SEQ ID NO: 9.

5. The coronavirus according to claim 1 wherein the replicase gene comprises at least one nucleotide substitutions selected from:

C to Tat nucleotide position 12137; and

G to C at nucleotide position 18114;

compared to the sequence shown as SEQ ID NO: 1;

and optionally, comprises one or more nucleotide substitutions selected from T to A at nucleotide position 19047; and

G to A at nucleotide position 20139;

compared to the sequence shown as SEQ ID NO: 1.

6. The coronavirus according to claim 1 which is an infectious bronchitis virus (IBV).

7. The coronavirus according to claim 1 which is IBV M41.

8. The coronavirus according to claim 7, which comprises an S protein at least, part of which is from an IBV serotype other than M41.

9. The coronavirus according to claim 8, wherein the S1 subunit is from an IBV serotype other than M41.

10. The coronavirus according to claim 8, wherein the S protein is from an IBV serotype other than M41.

11. The coronavirus according to claim 1 which has reduced pathogenicity compared to a coronavirus expressing a corresponding wild-type replicase, wherein the virus is capable of replicating without being pathogenic to the embryo when administered to an embryonated egg.

96

12. A variant replicase gene as defined in claim 1.

13. A protein encoded by a variant coronavirus replicase gene according to claim 12.

14. A plasmid comprising a replicase gene according to claim 12.

15. A method for making the coronavirus according to claim 1 which comprises the following steps:

(i) transfecting a plasmid according to claim 14 into a host cell;

(ii) infecting the host cell with a recombining virus comprising the genome of a coronavirus strain with a replicase gene;

(iii) allowing homologous recombination to occur between the replicase gene sequences in the plasmid and the corresponding sequences in the recombining virus genome to produce a modified replicase gene; and

(iv) selecting for recombining virus comprising the modified replicase gene.

16. The method according to claim 15, wherein the recombining virus is a vaccinia virus.

17. The method according to claim 15 which also includes the step:

(v) recovering recombinant coronavirus comprising the modified replicase gene from the DNA from the recombining virus from step (iv).

18. A cell capable of producing a coronavirus according to claim 1.

19. A vaccine comprising a coronavirus according to claim 1 and a pharmaceutically acceptable carrier.

20. A method for treating and/or preventing a disease in a subject which comprises the step of administering a vaccine according to claim 19 to the subject.

21. The method of claim 20, wherein the disease is infectious bronchitis (IB).

22. The method according to claim 20 wherein the method of administration is selected from the group consisting of; eye drop administration, intranasal administration, drinking water administration, post-hatch injection and in ovo injection.

23. The method according to claim 21 wherein the administration is in ovo vaccination.

24. A method for producing a vaccine according to claim 19, which comprises the step of infecting a cell according to claim 18 with a coronavirus according to claim 1.

25. The coronavirus according to claim 1, further comprising a mutation in one or both of nsp-15 and nsp-16.

* * * * *